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SUMMARY xi 
Summary 
With more than 9 million new cases and nearly 2 million deaths per year, Tuberculosis still 
remains a major global burden. The causative agent of the disease, Mycobacterium 
tuberculosis, belongs to the group of slow growing, GC-rich Gram-positive bacteria. 
Mycobacteria in general are characterized by a unique cell envelope, which forms a barrier for 
uptake of numerous chemical compounds. Therefore, treatment of Tuberculosis is naturally 
lenghty and complex. Recently an increase in drug resistant or multidrug-resistant (MDR) 
Tuberculosis has been observed. MDR is due to acquired mutations in several genes, 
conferring resistance to a wide spectrum of antibiotics. Even though M. tuberculosis has been 
described a century ago, the complete mechanisms of infection and virulence are not yet fully 
understood. Upon inhaling droplets containing M. tuberculosis, the bacterium is able to 
survive in lung alveolar macrophages and to persist in the body for decades. A class of 
secreted proteins, the so called lipoproteins, have been shown to be involved in several 
processes of these host-pathogen interactions. The aims of this study were 1) the 
characterization of the transport of lipoproteins to the cell wall of mycobacteria and 2) the 
evaluation of potential new drug targets to fight Tuberculosis including the enhancement of 
mycobacterial drugs used nowadays. 
In order to investigate the transport of lipoproteins to the cell wall of mycobacteria, several 
lipoproteins of M. tuberculosis have been expressed in Mycobacterium smegmatis, a 
mycobacterial model organism. Using subcellular fractionation techniques, these reporter 
proteins were localized either in the cytoplasmic membrane or in the cell wall. Lipoproteins 
are defined by the so called lipobox at the N-terminus, which contains in its mature form a 
universally conserved and lipidated cysteine. In Escherichia coli, the very well characterized 
Gram-negative bacterium, lipoproteins are transported from the inner membrane to the outer 
membrane by the Lol-system, unless they contain a retention signal located at position +2 
after the cysteine. As mycobacteria miss a transporter similar to the Lol-system, transport and 
signal sequences for transport of lipoproteins to the cell wall remain unclear. By site-directed 
mutagenesis, several hybrid lipoprotein reporter constructs have been generated, expressed in 
M. smegmatis and subjected to subcellular fractionation. The results of these experiments 
indicate that a region of 10 amino acids subsequent to the cysteine of the lipobox acts as a 
positive signal for the transport to the cell wall. 
The standard treatment to fight Tuberculosis consits of a combination of several first-line 
drugs. With the rise of multidrug-resistant strains of M. tuberculosis (MDR-TB), second-line 
drugs have been brought back into focus. These antibiotics are second choice beause of either 
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a difficult mode of application (injectable drugs) or are more toxic and cause severe side-
effects. One of those second-line drugs is ethionamide (ETH) which is a prodrug and thus has 
to be activated within the bacterium. The activation is performed by the enzyme EthA, which 
is naturally repressed by EthR. By screening of a chemical compound library generated by a 
synthetic mammalian gene circuit, the substance 2-phenylethyl-butyrate (2-PEB) was found 
to release EthR efficiently. This study shows by applying drug susceptibility testing, that the 
combination of 2-PEB and ETH has a synergistic effect on growth of mycobacteria, even on 
MDR-strains. Therefore we could show that ETH can be applied in sub-inhibitory 
concentrations against M. tuberculosis, which in turn could reduce the potential side-effects of 
this important second-line drug. 
The last part of this work evaluates a new promising class of antibiotics, the NAD-synthetase 
inhibitors. NAD+ is a coenzyme involved in redox reactions in all living cells. In contrast to 
humans, where an NAD-synthetase-independent recycling pathway exists, the biosynthesis of 
NAD+ in M. tuberculosis is absolutely dependent on the activity of NAD-synthetase. 
Screening of compounds with proven inhibition of mycobacterial NAD-synthetase in a 
biochemical assay identified one promising compound inhibiting growth of M. tuberculosis. 
Thus, this new class of antibiotics raises hope for new possibilities to fight Tuberculosis. 
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Zusammenfassung 
Mit mehr als 9 Millionen Neuinfektionen und annähernd 2 Millionen Todesfällen pro Jahr ist 
die Tuberkulose immer noch ein Problem mit globaler Tragweite. Der Erreger der 
Tuberkulose, Mycobacterium tuberculosis, gehört der Gruppe der langsam wachsenden, mit 
einem hohen GC-Anteil versehenen Gram-positiven Bakterien an. Mykobakterien im 
Allgemeinen sind mit einer einzigartigen äusseren Hülle ausgestattet, welche eine natürliche 
Schranke gegen die Aufnahme einer ganzen Reihe von chemischen Substanzen darstellt. Dies 
ist der Grund weshalb die Behandlung der Tuberkulose langwierig und komplex ist. Seit 
einiger Zeit wird ein Anstieg von Infektionen mit resistenten oder gar multiresistenten 
Tuberkulosestämmen beobachtet. Multiresistenz ist auf mehrere erworbene Mutationen in 
unterschiedlichen Genen zurückzuführen. Obwohl der Tuberkuloseerreger bereits vor einem 
Jahrhundert entdeckt und beschrieben wurde, sind wir von einem vollständigen Verständnis 
der Infektion und der Virulenzmechanismen von M. tuberculosis weit entfernt. Nach einer 
Tröpfcheninfektion mit M. tuberculosis gelingt es dem Bakterium in den Makrophagen der 
Lungenalveolen zu überleben und teilweise für Jahrzehnte im Körper zu persistieren. Es 
wurde gezeigt, dass eine spezielle Klasse von Proteinen, die Lipoproteine; in verschiedenen 
Prozessen der Wirt-Pathogen Interaktionen beteiligt sind. Das Ziel dieser Studie ist 1) die 
Untersuchung des Transports von Lipoproteinen zur mykobakteriellen Zellwand sowie die 
Charakterisierung spezifischer Lipoproteine auf molekularer Ebene und 2) die Evaluation 
neuer antibiotischer Zielstrukturen und neuer Antibiotika sowie die Verstärkung der Wirkung 
bestehender Antibiotika. 
Zur Untersuchung des Transports von Lipoproteinen zur Zellwand von Mykobakterien, 
wurden verschiedene Lipoproteine von M. tuberculosis in M. smegmatis, einem 
mykobakteriellen Modell-Organismus, exprimiert. Mit der Hilfe von subzellulären 
Fraktionierungstechniken konnten diese Reporterproteine entweder in der Cytoplas-
mamembran oder in der Zellwand lokalisiert werden. Lipoproteine enthalten in ihrer maturen 
Form ein universell konserviertes und lipidiertes Cystein. In dem sehr gut untersuchten, 
Gram-negativen Bakterium Escherichia coli werden Lipoproteine durch das Lol-System zur 
äusseren Membran transportiert und verankert. Ein Rückhaltesignal, ein Asp an der Position 
+2 nach dem Cystein bewirkt, dass bestimmte Lipoproteine in der Plasmamembran verankert 
bleiben. Da Mykobakterien kein dem Lol-system entsprechendes Transportsystem besitzen, 
ist es wahrscheinlich, dass ihre Lipoproteine auch ein anderes Transportsignal besitzen. In 
dieser Studie wurden durch gezielte Mutationen verschiedene artifizielle Reporterlipoproteine 
generiert, in M. smegmatis exprimiert und ihre Lokalisation mittels Fraktionierung untersucht. 
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Die Resultate dieser Experimente zeigen, dass eine Region von 10 Aminosäuren unmittelbar 
C-terminal des Cysteins der Lipobox als ein positives Transportsignal dient. 
Die aktuelle Standardtherapie zur Behandlung der Tuberkulose besteht aus einer Kombination 
mehrerer Antibiotika der ersten Wahl. Mit dem gehäuften Auftreten mehrfach 
medikamentenresistenter Stämme von M. tuberculosis, rücken die Medikamente der zweiten 
Wahl immer mehr in den Fokus. Aufgrund ihrer zum Teil schwierigeren 
Verabreichungsmethode (Injektion) und ihren grösseren Nebenwirkungen gelten diese 
Medikamente als zweite Wahl. Eines dieser Antibiotika ist Ethionamid. Ethionamid wird als 
ein Vorläufer verabreicht und muss, um seinen antibakteriellen Effekt zu entfalten, im 
Bakterium aktiviert werden. Dieser Vorgang wird von dem mykobakteriellen Enzym EthA 
katalysiert, dessen Expression von seinem natürlichen Repressor EthR vermindert wird. 
Durch systematisches Screening einer Sammlung chemischer Substanzen wurde 2-
Phenylethyl-butyrat (2-PEB) entdeckt, welches die Fähigkeit hat, EthR von dem ethA/ethR-
Operon abzulösen. Die hier vorliegende Studie zeigt mittels Medikamenten-
Suszeptibilitätstests, dass die Kombination von 2-PEB und ETH einen synergistischen 
inhibitorischen Effekt auf das Wachstum von Mykobakterien hat, sogar auf Stämme mit 
Antibiotikaresistenzen. Durch die Zugabe von 2-PEB konnte somit die minimale 
Hemmkonzentration gesenkt werden. 
Der letzte Teil dieser Arbeit widmet sich neuen möglichen Antibiotika zur Behandlung der 
Tuberkulose. Es handelt sich hierbei um eine Klasse von NAD-Synthetase Inhibitoren. NAD+ 
ist ein Coenzym, welches an Redox-Reaktionen in allen lebenden Zellen beteiligt ist. Im 
Gegensatz zu den Menschen, welche einen Recyclingweg für NAD+ besitzen, ist die Synthese 
von NAD+ in Bakterien vollständig von einer funktionellen NAD-Synthetase abhängig. 
Substanzen, welche in einem biochemischen Test die M. tuberculosis-NAD-Synthetase 
inhibierten, wurden bezüglich ihrer Fähigkeit untersucht, das Wachstum von M. tuberculosis 
zu hemmen. Eine der getesteten Substanzen zeigt eine vielversprechende Wirkung gegen 
M. tuberculosis. Diese neue Klasse von Antibiotika gibt Anlass zur Hoffnung im Kampf 
gegen die Tuberkulose. 
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Introduction 
Tuberculosis 
Tuberculosis is a major cause of death around the world, with 9.2 million new cases and 1.7 
million deaths occuring in 2006, which is the highest rate claimed by a single bacterium 
(WHO, 2009). The causative agent of this disease, spreading among infected humans as much 
as one-third of the world’s population, is Mycobacterium tuberculosis, an acid-fast bacillus 
that is transmitted primarly via the respiratory route. Although most organs can be infected 
with M. tuberculosis, the disease usually is manifested in the lungs. In most cases infections 
remain clinically asymptomatic. It is estimated that only 5-10% of persons infected with 
M. tuberculosis present with active disease (Porcelli, 2008). Infected persons who do not 
develop the disease are not contagious, but the infection can reactivate years later, resulting in 
active Tuberculosis. The risk of reactivation is increased in immunocompromised persons, 
including persons co-infected with HIV (Algood et al., 2003). The reasons for the pathogens’ 
extraordinary success are diverse: it evades the immune system by parasitizing the 
macrophages of its host, it has a thick waxy cell wall and therefore is resistant to different 
kinds of mechanical and chemical stress and it is slow-growing which makes antibiotic 
treatment complicated and lengthy. 
The recommended standard treatment for Tuberculosis is a regimen of four out of five first 
line drugs (isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin) for initial two 
months, followed by a four months treatment with isoniazid and rifampicin. During the first 
phase with four different drugs, replicating bacteria are killed, sputum usually becomes sterile 
and patients become non-infectious. The following four months phase with two antibiotics 
eradicates the remaining non-replicating bacteria. Given the length, complexity and adverse 
event profile of this drug treatment, patient adherence can be difficult to maintain (Goodman 
& Lipman, 2008). Inadequate drug therapy selects for M. tuberculosis mutants, leading to 
acquired drug resistance. M. tuberculosis is naturally resistant to several antibiotics, due to the 
presence of hydrolytic and drug-modifying enzymes, drug efflux systems and the highly 
hydrophobic cell wall. Acquired drug resistances led to multidrug- and even extensively drug-
resistant strains of M. tuberculosis during the 1990s (Ducati et al., 2006; Jassal & Bishai, 
2009). Multidrug-resistant strains of M. tuberculosis (MDR-TB) are defined by a resistance to 
the two most efficient drugs isoniazid and rifampicin (Böttger & Springer 2008). The term 
extensively drug-resistant TB (XDR-TB) is defined as MDR-TB further showing resistance to 
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a fluoroquinolone and at least one second-line injectable agent (amikacin, kanamycin and/or 
capreomycin) (WHO, 2007).  
An additional reason for the pathogens spread is the HIV/AIDS epidemic over the past few 
decades. Any condition which perturbs protective host immunity to M. tuberculosis leads to 
an increased risk to develop active disease. The extent to which this occurs depends on the 
degree of disruption of the hosts’ immune system and the number of people affected by such a 
condition. Rates of TB infection are therefore high in those countries in which HIV is 
prevalent, mainly in sub-Saharan Africa and Asia (Goodman & Lipman, 2008). 
The most widely used vaccine throughout the world with an estimated number of more than 3 
billion people being vaccinated is BCG (Bacille Calmette-Guérin) against Tuberculosis. After 
231 passages of Mycobacterium bovis, the causative agent of bovine Tuberculosis, Albert 
Calmette and Camille Guérin observed a reduction in the virulence in animals through this 
period. When infants were given this vaccine, it provided a reduction in mortality by 90% 
(Bloom, 1994). BCG nowadays still is the only vaccine available against Tuberculosis but 
there are serious doubts about its efficacy. It has been shown to be effective against 
disseminated and meningeal Tuberculosis in young children. However, the protective effect 
against adult pulmonary TB varies dramatically from 80 to 0% (Gupta et al., 2007). There 
have been recent advances in development of new vaccines against Tuberculosis: DNA 
vaccines, recombinant BCG vaccines, Sub-unit (protein and peptide) vaccines and living, 
attenuated vaccines. Some of the new approaches already have entered clinical evaluation and 
some of them showed promising results. But nevertheless, a new licensed vaccine might be 
available not before the next decade (Gupta et al., 2007; Lambert et al., 2009). 
Pathogenesis 
Infection with Mycobacterium tuberculosis, the causative agent of Tuberculosis, follows a 
relatively well-defined sequence of events. After being inhaled as droplets from the 
atmosphere, the bacteria are phagocytosed by alveolar macrophages and induce a localized 
proinflammatory response. This immunological reaction entails the recruitment of 
mononuclear cells which are building blocks for granuloma. This lesion, also called tubercle, 
which defines the disease, consists of infected macrophages in the center. They are 
surrounded by foamy giant cells, macrophages and lymphocytes, corresponding to the 
periphery of this structure. The activated macrophages restrict growth of the bacteria and 
therefore end the primary infection, commonly without any symptom presentation (Ducati et 
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al., 2006; Russell, 2001). Typical TB symptoms are weakness, fever, weight loss, night sweat, 
chest pain, respiratory insufficiency and cough. 
In most cases, the bacteria coexist within the host in a dormant form of infection, though still 
representing a large bacterial reservoir among infected individuals. Only 10% of the people 
infected with M. tuberculosis develop an active TB during their life-time. 
Immunocompromised individuals, e.g. with an HIV-coinfection, malnutrition or old-age, are 
highly susceptible for a reactivated TB. As a consequence, the granuloma are not under the 
control of the cellular immune system anymore. Therefore, the number of lesions and the 
number of bacteria increases, leading to necrosis in the lung-tissue and cavity formation. Due 
to the lesions, the bacteria are able to spread by productive cough containing aerosols with a 
massive load of infectious bacteria (Hunter et al., 2007). It has been shown in animal models 
that 1 to 10 tubercle bacilli are sufficient to cause an infection (Bloom & Murray, 1992). 
Besides being able to destroy the lung parenchyma, about 15% of the patients with an active 
disease develop miliary or extra-pulmonary TB. Because of the excessive growth, the bacteria 
start invading the blood stream and disseminate to various parts of the body. The disease then 
spreads among others to the pleura, lymph nodes, liver, spleen, bones and joints. The 
extraordinary success of M. tuberculosis is characterized by the ability of parasitizing the 
macrophages of its host. In contrast to other bacteria, pathogenic mycobacteria are able to 
manipulate the phagosome in a way that they are residing in and prevent the normal 
maturation of this organelle into an acidic, hydrolytic compartment (Russell, 2001, Vergne et 
al., 2004). 
 
It has long been recognized on clinical and epidemiologic facts that M. tuberculosis produces 
two types of disease, primary and postprimary Tuberculosis. This has recently been confirmed 
with genetic studies demonstrating that susceptibility to primary and postprimary 
Tuberculosis is governed by different genes (Alcais et al., 2005). The initial infection of a 
person with M. tuberculosis produces primary Tuberculosis. The infection begins when the 
bacteria are inhaled into the lungs where they induce a granulomatous inflammatory response. 
The organisms rapidly spread from the lung to lymph nodes and hematogenously throughout 
the body. The infection is typically arrested and the lesions heal within 6-8 weeks with the 
development of effective cell-mediated immunity (Hunter et al., 2007). 
Postprimary, also known as secondary or adult Tuberculosis is any disease that develops after 
a state of immunity has been established. It may arise either from reinfeciton with new 
INTRODUCTION 18 
organisms or reactivation of dormant ones. Approximately 80% of all clinical cases and 
nearly all transmissions of infection are due to postprimary Tuberculosis. Postprimary 
Tuberculosis differs from primary Tuberculosis in a way that it requires a strong immune 
response, is confined to the lung, does not spread to lymph nodes or distant sites and does not 
heal. It is characterized by cavities in the lung that produce massive numbers of organisms 
that are coughed into the environment (Hunter et al., 2007). 
Mycobacteria 
M. tuberculosis belongs to the genus Mycobacterium, which comprises more than 
130 species, among others M. bovis BCG, the vaccine strain which is used against 
tuberculosis, M. leprae, the causative agent of leprosy, and M. smegmatis, a non-pathogenic 
mycobacterial model organism. Mycobacteria are aerobic, straight or slightly curved rod-
shaped Gram-positive bacteria with about a size of 3 x 0.3 µm. They are nonmotile, 
nonsporing, without conidia. Mycobacteria stain usually weakly Gram-positive and are acid-
alcohol fast. Colonies are often yellow or orange with a dull and rough surface. A rough 
differentiation of Mycobacteria can be made based on the growth rate: M. tuberculosis is a 
slow growing organism with a generation time of 20 to 24 hours; M. smegmatis belongs to the 
group of rapid growing mycobacteria with a generation time of two to three hours. The 
complete genome sequencing of M. tuberculosis H37Rv, the best characterized laboratory 
strain of M. tuberculosis, showed that it consists of approximately 4000 genes and has a high 
G+C content of 65.6% (Cole et al., 1998). The genome is rich in repetitive DNA, including 
insertion sequences in intergenic or non-coding regions, frequently close to tRNA genes. An 
additional unique feature is the high frequency of genes involved in fatty acid metabolism. 
About 250 enzymes are either involved in lipolysis, required for bacterial survival inside its 
host, or lipogenesis, mainly for cellular envelope synthesis (Ducati et al., 2006). 
The cellular envelope of Mycobacterium spp. is rather complex and consists of three major 
structures: the cytoplasmic membrane, the outer layer and the capsule-like structure. Although 
this structure resembles the cell envelope of Gram-negative bacteria (with the three layers: 
cytoplasmic membrane, periplasm and the outer membrane), Mycobacteria spp. 
phylogenetically belong to the group of (GC-rich) Gram-positive bacteria. The cytoplasmic 
membrane of mycobacteria is composed by phospholipids, as there are phosphatidylglycerol, 
phosphatidylethanolamine and phosphatidylinositol. A major cytoplasmic membrane 
component, which is restricted to bacteria of the Actinomycetes group are 
phosphatidylinositol mannosides (PIMs). Additionally, PIMs form the lipid base of 
lipoarabinomannan (LAM), one of the components of the mycobacterial cell wall (Figure 1). 
INTRODUCTION 19 
The adjacent cell wall skeleton mainly consists of a mycolyl-arabinogalactan-peptidoglycan 
complex. In contrast to most other bacteria, the peptidoglycan-layer of mycobacteria contains 
N-glycolylmuramic acid instead of N-acetylmuramic acid (Brennan & Nikaido, 1995). As an 
additional unique feature, the cell wall core of mycobacteria is composed of arabinogalctan 
which is attached to the peptidoglycan through a phosphodiester link. Like corynebacteria, 
nocardia and rhodococci, the cell envelope of mycobacteria is interspersed with mycolic 
acids. They are high-molecular-weight fatty acids which are bound to the arabinogalactan 
cluster by ester bonds. Compared to the other above mentioned bacteria, mycobacteria have 
the largest mycolic acids (C70 to C90) and contain double bonds or cyclopropane rings 
(Brennan & Nikaido, 1995). By hydrophobic interactions, the mycolic acids interact with free 
glycolipids, phenolic glycolipids and glycopeptidolipids. 
 
 
Figure 1: Schematic representation of the cell wall of M. tuberculosis (adapted from Besra et al. (Besra, 1994)) 
 
LAM are glycosylated phosphatidylinositol analogues, composed of a phosphatidyl-inositol 
anchor, a D-mannan polymer, D-arabinose chains and capping motifs at the nonreducing 
termini of the arbinose residues. Interestingly, the nonpathogenic M. smegmatis lacks 
mannose caps which have been detected in M. tuberculosis. LAMs are supposed to span the 
cell wall skeleton, therefore they can be regarded as a part of the cell wall even though they 
are attached to the cytoplasmic membrane by a phosphatidylinositol anchor (Brennan & 
Nikaido, 1995; Daffe & Draper, 1998). M. tuberculosis LAM has been shown to inhibit 
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phagosomal maturation by inhibition of Ca2+ rise. Nonpathogenic mycobacteria lacking the 
mannose caps of LAM are not able to inhibit the Ca2+ rise (Vergne et al., 2004). The 
outermost structure of the mycobacterial cell envelope, the capsule-like structure consists of 
polysaccarides, proteins, free lipids such as waxes and glycolipids. Even though mycobacteria 
belong to the group of Gram-positive bacteria, recent investigations have shown that they 
possess an outer-membrane-like structure (Hoffmann et al., 2008), which resembles Gram-
negative bacteria with an outer membrane. Overall, the complex and dense architecture of the 
mycobacterial cell envelope turns it into an efficient permeability barrier, which is a necessary 
but not sufficient factor for resistance to a broad variety of antimicrobial agents. 
Drug Resistance of Mycobacterium tuberculosis 
Mycobacterium tuberculosis is naturally resistant to several antibiotics. In contrast to many 
other pathogenic bacteria, plasmid-mediated resistance has never been observed in 
M. tuberculosis. Resistant phenotypes are caused by chromosomal mutations, e.g. nucleotidic 
insertions, deletions or substitutions, in different genes (Ducati et al., 2006). Shortly after the 
first drugs against Tuberculosis have have been introduced, resistance to these drugs was 
observed in clinical isolates of M. tuberculosis (Johnson et al., 2006). All first-line drugs 
being used nowadays have been launched about a half a century ago (streptomycin (STR, 
launch date 1948), isoniazid (INH, 1952), pyrazinamide (PZA, 1954), ethambutol (EMB, 
1962) and rifampicin (RIF, 1963)) (Harper, 2007). With the rise of MDR- and XDR-TB, 
special attention is paid to second-line drugs like fluorquinolones (e.g. ofloxacin (OFL) or 
ciprofloxacin (CIP)), ethionamide (ETH) or aminoglycosides like amikacin (AMK) or 
kanamycin (KAN). These drugs are usually more toxic and less effective than first-line drugs 
and therefore prolong the overall treatment up to 9 or even more months and besides causing 
severe side effects, are difficult in handling concerning patients’ compliance. Table 1 gives an 
overview over the most frequent mutations causing drug-resistances for first- and second-line 
drugs against TB. 
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Drug Gene locus Gene product Most frequently mutated codons associated with resistance Drug target/action
First line drugs INH katG Catalase peroxidase Ser315Thr Activator of prodrug
inhA Enoyl-ACP recuctase Promoter mutations:-24G/T, -16A/G, -15C/T,  -8T-G/A. Structural gene 
mutations: Ile16Thr, Ile21Thr/Val, Ile47Thr, Val78Ala, Ile95Pro, 
Ser94Ala
ahpC Alkyl hydroperoxide reductase Promoter mutations: -46G/A, -39C/T
kasA β-ketoacyl-ACP synthase Asp66Asn, Gly269Ser, Gly312Ser, Phe413Leu
ndh NADH dehydrogenase Thr110Ala, Arg268His
RIF rpoB RNA polymerase Ser531Leu, His526Tyr, Asp516Val Transcription; RIF inhibits the β-
subunit of the bacterial RNA 
polymerase.
PZA pncA Pyrazinamidase No hotspots Activator of prodrug. Final target 
is the cell membrane; PZA lowers 
the pH intracellularly and thereby 
inhibits fatty acid synthesis
EMB embB Arabinosyl transferase Met306Leu/Val/Ile, Gly406Asp/Ser/Arg Cell wall biosynthesis; inhibits 
arabinosyl transferase
STR rrs 16S RNA 491C/T, 513A/C-T, 906A/C
rpsL Ribosomal protein S12 Lys43Arg/Thr, Lys88Gln/Arg
Second line drugs Fluoroquinolones (CIP, OFL) gyrA DNA-gyrase Ala90Val, Ser91Pro, Asp94Asn/His/Gly/Tyr/Ala
gyrB Asn538Asp
Aminoglycosides (KAN, AMK) rrs 16S rRNA 1401A/G, 1402C/T-A, 1408A/G Translation, protein synthesis; 
binding of aminoglycosides to 
ribosomes disturb elongation of 
the peptide chain and induce 
misreading
ETH inhA Enoyl-ACP recuctase Promoter mutations:-24G/T, -16A/G, -15C/T,  -8T-G/A. Structural gene 
mutations: Ile16Thr, Ile21Thr/Val, Ile47Thr, Val78Ala, Ile95Pro, 
Ser94Ala
ethA Flavin monooxygenase Gly43Cys, Asp58Ala, Ile338Ser, Gly385Ser
Table 1: Properties of resistance to various anti-TB drugs
Translation, protein synthesis; 
interaction of STR with 16S rRNA 
Cell wall biosynthesis; final target 
is InhA which is involved in 
mycolic acid synthesis.
ethA  is the activator of the 
prodrug. Final target is InhA which 
is involved in mycolic acid 
synthesis; therefore, cell wall 
biosynthesis is inhibited by ETH
DNA metabolism; 
fluoroquinolones inhibit the DNA 
gyrase and DNA topoisomerase
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First-line drugs 
Isoniazid. INH-resistance mainly has been linked to the following genes: katG, inhA, ahpC, 
kasA and ndh. INH is a pro-drug and has to be activated within mycobacteria. Mutations in 
katG, which encodes the associated activator catalase peroxidase KatG, are a main reason for 
resistance. Most katG mutations have been found between codon 138 and 328, the most 
common cause of resistance is the Ser315Thr mutation. This mutation is observed in 30-60% 
of INH resistant isolates (Slayden & Barry, 2000). One of the targets of INH is InhA, an 
enoyl-acyl carrier protein (ACP) reductase, which is a part of the fatty acid synthase type II 
system (FASII). The FASII is responsible for the synthesis of mycolic acids, the essential 
components of the unique mycobacterial cell wall. Two different types of mutations confer 
INH-resistance: Mutations in the promoter-region of the mabA-inhA-operon (-24G/T, -16A/G, 
-15C/T and -8TG/A) and mutations in the inhA-gene (Ile16Thr, Ile21Thr, Ile21Val, Ile47Thr, 
Val78Ala and Ile95Pro). The mutations in the promoter-region lead to an overexpression of 
InhA and thus cause a low level resistance to INH. Mutations in the target gene itself result in 
reduced drug binding and therefore less efficient mycolic acid synthesis. Although these 
mutations in the structural inhA-gene are associated with INH resistance, they are not 
frequently reported in clinical isolates. kasA is, like inhA, involved in the mycolic acid 
synthesis. The gene encodes for a β-ketoyl-ACP synthase. Four different mutations leading to 
amino acid substitutions have been reported (Table 1). These mutations have been described 
to confer low-level INH-resistance (Johnson et al., 2006). The above mentioned mutation in 
katG (Ser315Thr) often is associated with an increase of alkyl hydroperoxide reductase AhpC 
which is able to detoxify damaging organic peroxides. Five mutations in the related promoter 
(Table 1), leading to an overexpression of AhpC, have been described. As AhpC has a 
detoxifying effect, it contributes in an indirect manner to INH-resistance. It is supposed to 
compensate for decreased katG-dependent catalase activity and does not provide protection to 
the antibiotic itself. To exert its antibiotic activity, INH forms a covalent adduct with NAD. 
Mutations in ndh, the gene encoding for NADH-dehydrogenase, cause defects in the 
enzymatic activity and therefore result in a depletion of NAD. Hence, mutations in the ndh-
gene contribute to INH-resistance in an indirect way. The most prominent mutations are listed 
in Table 1. 
Rifampicin. Together with INH, RIF forms the backbone for the treatment of TB. RIF binds 
to the β-subunit of the mycobacterial RNA-polymerase. The interaction of RIF with this 
subunit, which is encoded by rpoB, inhibits transcription and thereby kills bacteria. 
Resistance to RIF is confered by manifold mutations and short in frame deletions in the rpoB-
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gene with the most prominent changes in codons Ser531Leu, His526Tyr and Asp516Val. 
More than 70% of RIF-resistant isolates are characterized by these mutations (Ramaswamy & 
Musser, 1998). 
Pyrazinamide. PZA is thought to kill mycobacteria by inactivation of a fatty acid synthase 
through lowering the intracellular pH (Rivers & Mancera, 2008). Like INH, PZA is a prodrug 
and has to be activated by pyrazinamidase, encoded by pncA. PZA resistance is caused by all 
kinds of mutations affecting pncA-dependent pyrazinamidase activity, a non-essential 
enzymatic function. Of note, the antituberculosis activity of PZA is highly specific for 
M. tuberculosis as e.g. M. bovis is naturally resistant due to a pncA-point mutation (169G/C). 
Ethambutol. EMB inhibits the cell wall biosynthesis by interaction with an arabinosyl 
transferase, encoded by embB. About 70-90% of all EMB-resistant isolates have been shown 
to carry a variety of mutations in codon 306 (Table 1.), resulting in three different amino acid 
substitutions. Nevertheless, one third of EMB-resistant strains have a wildtype-form of embB. 
The fact that homologous arabinosyl transferases have been found (embCAB) (Telenti et al. 
1997) might explain this uncertainty. 
Streptomycin. By interaction with the 16S rRNA and S12 ribosomal protein, STR causes 
misreading of mRNA and inibition of protein synthesis. Mutations in the two genes rrs (16S 
rRNA) and rpsL (S12 ribosomal protein) are related to STR resistance. Several mutations in a 
loop region of the 16S rRNA, which is a part of the aminoacyl-tRNA binding site, has been 
shown to confer STR resistance (Table 1). Amino acid substitutions at two positions in the 
rpsL gene were detected to be responsible for high level resistance to STR (Springer et al., 
2001). 
 
Second line drugs 
Fluoroquinolones. CIP and OFL, which belong to the group of fluoroquinolones target and 
inactivate DNA gyrase and a type II DNA topoisomerase. DNA gyrase is encoded by gyrA 
and gyrB, both of which do have a quinolone resistance-determining region (QRDR), with a 
size of 320 bp in case of gyrA and 375 bp in gyrB (Table 1, Johnson et al. 2006). 
Aminoglycosides. The two aminoglycosides KAN and AMK bind to bacterial ribosomes and 
interfere with decoding of mRNA. Like in STR-resistant strains, mutations in rrs are 
responsible for resistance to AMK and KAN, but are located at different sites (Table 1). 
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Ethionamide. ETH is a pro-drug, which needs to be activated by the mycobacterial Baeyer-
Villiger monooxygenase EthA to exert its antimicrobial activity by inhibiting the enoyl-ACP 
reductase InhA. Like INH, ETH does not bind directly to InhA but forms a covalent adduct 
with NAD instead. This ETH-NAD adduct inhibits InhA efficiently (Wang et al., 2007). 
InhA, which is also the target of INH, is part of the fatty acid synthase type II system (FASII) 
which synthesizes mycolic acids, the essential components of the unique mycobacterial cell 
wall. The expression of ethA is under control of its natural repressor EthR (Baulard et al., 
2000) which contributes to an increased intrinsic resistance and therefore ETH-based 
Tuberculosis therapy is often not that effective, even when prescribed at high hepatotoxic 
doses (Hollinrake, 1968). Acquired ETH reistance is due to i) mutations in the ethA coding 
region and ii) mutations in the promoter of the mabA-inhA-operon of the target-gene inhA 
(e.g. T-8C, T-8A, C-15T). Therefore, cross-resistance of the potent first-line drug INH and 
second-line drug ETH are common, as mutations in ethA are a frequent mechanism of ETH-
resistance in INH-resistant katG-mutants (Table 1).  
Future perspectives on drug resistance and drug development 
The short overview of the most important antimycobacterial drugs clearly points out several 
issues. Enhanced efforts are needed for intensified investigations on drug resistance 
mechanisms, especially of second-line drugs, as they represent oftenly the last line of defense 
to fight emerging MDR- and XDR-strains of M. tubeculosis. The need for research on either 
new antibiotics with novel mechanisms of action or possibilities to enhance existent 
antibiotics becomes obvious. Additional challenges are the shortening of current treatment of 
Tuberculosis to improve patients’ compliance and therefore embank the rise of drug-resistant 
strains of M. tuberculosis, and detailed research on resistance mechanisms of 
antimycobacterial drugs used nowadays. 
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Abstract 
Lipoproteins are a functionally diverse class of secreted bacterial proteins characterized by an 
N-terminal lipid moiety. The lipid moiety serves to anchor these proteins to the cell surface. 
Lipoproteins are synthesized as pre-prolipoproteins and mature by post-translational 
modifications. The post-translational modifications are directed by the lipobox motif located 
within the signal peptide. Enzymes involved in lipoprotein synthesis are essential in Gram-
negative bacteria but not in Gram-positive bacteria. Inactivation of genes involved in 
lipoprotein synthesis attenuates a variety of Gram-positive pathogens, including 
Mycobacterium tuberculosis. The attenuated phenotype of these mutants indicates an 
important role of lipoproteins and lipoprotein synthesis in bacterial virulence.  
M. tuberculosis, the causative agent of tuberculosis, is one of the most devastating pathogens 
in the world. This article reviews recent findings on the synthesis, localization and function of 
lipoproteins in mycobacteria. 
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Introduction 
Lipoproteins are a functionally heterogeneous class of proteins universally present in bacteria; 
typically between 1% and 3% of bacterial genomes encode lipoproteins (Babu et al., 2006; 
http://www.mrc-lmb.cam.ac.uk/genomes/dolop/). Lipoproteins represent a subgroup of 
secreted proteins characterized by the presence of a lipobox. The lipobox motif is located in 
the C-terminal part of the leader peptide and consists of four amino acids 
[LVI/ASTVI/GAS/C] (Babu et al., 2006). This motif functions as a recognition signal for 
lipid modification, which is made on the conserved and essential cysteine residue. Precursor 
lipoproteins are mainly translocated in a Sec-dependent manner across the plasma membrane 
and are modified subsequently. Recent investigations indicate that lipoproteins may also be 
translocated by the twin-arginine translocation (Tat) system (McDonough et al., 2005). 
However, this pathway presumably is of minor importance because the number of 
lipoproteins translocated via the Tat transporter is rather small. Modification of precursor 
proteins is mediated by the consecutive activity of three enzymes: phosphatidylglycerol–pre-
prolipoprotein diacylglyceryl transferase (Lgt), prolipoprotein signal peptidase/signal 
peptidase II (LspA) and phospholipid–apolipoprotein N-acyltransferase (Lnt) (Fig. 1). While 
Lgt and LspA are universally present in bacteria, Lnt has been reported to be restricted to 
Gram-negatives (Wu, 1996). The lipid residue covalently linked to the conserved cysteine 
moiety is thought to allow for anchoring of proteins in biological membranes by means of 
hydrophobic interaction. In Gram-positive bacteria, cell-associated lipoproteins are found in 
the plasma membrane. In Gram-negative bacteria the majority of cell-associated lipoproteins 
are found in the outer membrane – only about 10% stay anchored in the plasma membrane. 
Lipoproteins may be divided into five general groups according to their function in adhesion 
and invasion, cell wall synthesis, nutrient uptake, degradative processes, and sensing and 
transmembrane signalling (Sutcliffe & Russell, 1995). Enzymes involved in lipoprotein 
synthesis (Lgt, LspA, Lnt) are essential in Gram-negative bacteria but not in Gram-positive 
bacteria (Wu, 1996; Leskela et al., 1999). 
CHAPTER 1 29 
 
H2N – Cys - X 
+1     +2
- N – Cys - X 
+1     +2
O
C
apolipoprotein
N-acyltransferase
(Lnt) 
Leu – Ala – Gly – Cys - X
+1   +2  
Met
lipobox
Leu – Ala – Gly – Cys - X
+1   +2  
Met
prolipoprotein
signal peptidase
(LspA)
pre-prolipoprotein
diacyl glyceryl
transferase (Lgt)
C
C
C
C
C
O
O H
H
H
H
O
O
H
S
C
C
C
C
C
O
O H
H
H
H
O
O
H
S
C
C
C
C
C
O
O H
H
H
H
O
O
H
S
 
Figure 1: Biosynthesis of bacterial lipoproteins. Precursor lipoproteins are post-translationaly modified by 
phosphatidyl glycerol-prolipoprotein diacylglyceryl transferase (Lgt), lipoprotein signal peptidase (LspA). In 
Gram-negative bacteria and mycobacteria, lipoproteins are further processed by apolipoprotein N-acyltransferase 
(Lnt). 
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Mycobacteria belong to the group of GC-rich, Gram-positive bacteria, although the cell 
envelope of these bacteria is rather complex and in some respects resembles the cell envelope 
of Gram-negatives (Brennan & Nikaido, 1995). The lipid-rich outer layer in mycobacteria 
formed by mycolic acids and phospholipids is analogous to the outer membrane of Gram-
negative bacteria. The genus Mycobacterium consists of more than 120 species (Rogall et al., 
1990). The genome sequences of ten mycobacterial species have been determined or 
sequencing is near to completion (http://www.sanger.ac.uk; http://www.tigr.org). With respect 
to pathogenicity mycobacteria may be divided into obligate pathogens, opportunistic 
pathogens or nonpathogenic species.  Mycobacterium tuberculosis and Mycobacterium 
leprae, the causative agents of tuberculosis and leprosy, are major human pathogens. 
Opportunistic infections, in particular in patients with immune suppression, may be due to a 
variety of mycobacteria, e.g. Mycobacterium avium, Mycobacterium intracellulare, 
Mycobacterium marinum, Mycobacterium kansasii and Mycobacterium chelonae. 
Mycobacterium smegmatis, a non-pathogenic, fast-growing mycobacterium, has been 
established as a workhorse in mycobacterial genetics and biochemistry. Bioinformatic 
analyses suggest the presence of at least 48 lipoproteins but potentially twice as many in the 
genome sequence of M. tuberculosis (Sutcliffe & Harrington, 2004); similar numbers are 
found in other mycobacteria (Table 1). Experimental data concerning mycobacterial 
lipoprotein function are rare. Nearly half of the annotated M. tuberculosis lipoproteins do not 
share conserved domains with proteins outside the genus Mycobacterium and thus represent 
unique proteins of mycobacteria (Sutcliffe & Harrington, 2004). We here review recent 
findings on the synthesis, localization and function of lipoproteins in mycobacteria; emphasis 
is given to M. tuberculosis and M. smegmatis. 
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Mycobacterial lipoprotein synthesis 
Lgt. Lipoproteins are synthesized as pre-prolipoproteins and mature by post-translational 
modifications. Lipoprotein-modifying enzymes are membrane-integral proteins located in the 
plasma membrane. The first step of lipoprotein synthesis is conferred by Lgt, which adds a 
diacylglyerol residue to the thiol group of the universally conserved cysteine within the 
lipobox (Fig. 1). In Escherichia coli, the lipid moiety of lipoproteins is derived from the 
membrane lipid phosphatidylglycerol (Wu, 1996). Phosphatidylglycerol is not a 
homogeneous entity, as its acyl chains may be composed of 16–20 carbon atoms. In addition, 
the acyl chains may be saturated or unsaturated. So far, lipid moieties of mycobacterial 
lipoproteins have not been determined at the molecular level. However, in analogy to E. coli it 
may be hypothesized that the lipid moieties reflect the composition of mycobacterial 
membrane phospholipids. Therefore, despite identical protein moieties lipoproteins may vary 
to some extent. 
Lipid modification of proteins can be demonstrated by labelling with radioactive palmitate 
and by detergent solubility. Early investigations exploited incorporation of [14C] palmitic acid 
to demonstrate lipoprotein synthesis in M. tuberculosis (Young & Garbe, 1991). Radioactive 
labelling was also used to demonstrate protein lipidation in M. smegmatis (Kriakov et al., 
2003). M. tuberculosis Lgt (Rv1614) is composed of 468 aa (mol. mass 50.4 kDa) and thus 
considerably larger than its E. coli homologue (291 aa). Compared to E. coli the M. 
tuberculosis Lgt, as well as Lgt of other members of the order Actinomycetales, is 
characterized by an additional C-terminal domain of unknown function. The isoelectric points 
of M. tuberculosis Lgt (pI 4.45) and E. coli (pI 9.66) differ greatly. The high pI of the E. coli 
enzyme is assumed to be important for interaction with acidic phospholipids by ionic as well 
Species No. of predicted lipoproteins No. of ORFs Relative no.of lipoproteins (%) 
M tuberculosis 48 3918 1.2 
M. leprae 25 1604 1.6 
M. avium 75 4350 1.7 
M. marinum 97 5485 1.8 
M. smegmatis 61 6776 0.9 
Table 1. Lipoproteins in representative mycobacterial genomes
LipoP was used as a tool to predict lipoprotein signal peptides (http://www.cbs.dtu.dk/services/LipoP/; Sierakowska et al.,
2003). Protein sequences have been downloaded from the TIGR comprehensive microbial resource (www.tigr.org), 
except for M. marinum which has been downloaded from the Sanger Institute (www.sanger.ac.uk). The lower number of 
predicted lipoproteins in our search as compared to previous reports (e.g. Sutcliffe and Harrington, 2004) is due to the
more restrictive LipoP algorithm. 
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as hydrophobic interactions (Wu, 1996). The low pI of the M. tuberculosis Lgt enzyme is due 
to the unusually high aspartate and glutamate content of the C-terminal extension. In the 
M. smegmatis genome MSMEG3232 is annotated as Lgt. MSMEG3232 is composed of 612 
aa (mol. mass 64.6 kDa) and like its M. tuberculosis homologue has a low pI (3.92). The 
functional consequences of the dramatic pI differences between the E. coli and the 
mycobacterial Lgt remain to be elucidated. In M. smegmatis a second ORF, MSMEG5388, is 
annotated as a putative Lgt. This ORF encodes a protein of 261 aa (mol. mass 31.0 kDa) with 
a pI of 9.38. However, a multiple sequence alignment revealed that the protein encoded by 
MSMEG5388 differs from the Lgt consensus sequence at several conserved residues (data not 
shown). 
 
LspA. Lgt-modified prolipoproteins are further processed by LspA. LspA cleaves off the 
signal peptide directly in front of the modified cysteine. LspA knock-out mutants therefore 
accumulate prolipoproteins (Fig. 1). Due to the presence of the leader peptide, prolipoproteins 
have a slightly (2–3 kDa) higher molecular mass than the mature lipoproteins. Accumulation 
of prolipoproteins was demonstrated in M. tuberculosis lspA (Rv1539) (Sander et al., 2004; 
Banaiee et al., 2006) and recently in M. smegmatis lspA (MSMEG3181) knock-out mutants 
(M. Rezwan, A. Tschumi, T. Grau, S. Kuhn, P. Keller, B. Springer, E. C. Böttger & P. 
Sander, unpublished data). Inactivation of M. tuberculosis LspA by allelic replacement 
revealed an essential role of lipoprotein synthesis in the pathogenesis of M. tuberculosis. An 
M. tuberculosis lspA knock-out mutant exhibited reduced multiplication in the mouse 
macrophage cell line J774, complete absence of lung pathology and a 3–4 log reduced 
number of c.f.u. in a mouse model of tuberculosis infection (Sander et al., 2004). However, 
the molecular mechanisms underlying M. tuberculosis lspA attenuation remain to be 
determined. 
Lipoproteins are potent agonists of TOLL-like receptor (TLR) 2, and extracts of an 
M. tuberculosis LspA knock-out mutant failed to induce a TLR2 response in the TLR2- 
reporter cell line HEK293. However, TLR-dependent activation in macrophages by entire 
mycobacteria or whole-cell lysates was not affected by LspA inactivation (Banaiee et al., 
2006), indicating the existence of TLR ligands other than mature lipoproteins. The 
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redundancy of TLR agonists makes it unlikely that attenuation of the lspA knock-out mutant 
is due to alterations in TLR signalling1. 
Globomycin, a cyclic peptide produced by several Streptomyces species, is a potent and 
specific inhibitor of lipoprotein signal peptidases in different bacterial species. Due to the 
essentiality of lipoprotein-synthesizing enzymes, globomycin exerts a bactericidal effect in 
E. coli (Inukai et al., 1978). Inhibition of lipoprotein maturation by globomycin, as indicated 
by accumulation of precursor lipoproteins, has also been shown for Gram-positive bacteria 
(Harrington et al., 2000). Due to the severe attenuation of the M. tuberculosis lspA knock-out 
mutant, LspA has been proposed as a putative mycobacterial drug target and exploitation of 
globomycin as a prototype inhibitor for further drug development has been suggested (Sander 
et al., 2004). Promising antibacterial activity of globomycin derivatives has recently been 
demonstrated in Gram-positive bacteria (Kiho et al., 2004), but their activity towards 
mycobacteria remains to be determined. 
 
Lnt. In Gram-negative proteobacteria, but not in Gram-positive bacteria, LspA-processed 
lipoproteins are further modified by Lnt (Wu, 1996). Lnt adds a third acyl residue to the 
amino group of the modified cysteine. In vitro and in vivo studies have indicated that any of 
the three major phospholipids in the E. coli cell envelope (phosphatidylethanolamine, 
phosphatidylglycerol, cardiolipin) can serve as an acyl donor (Wu, 1996). In E. coli, Lnt 
modification is a prerequisite for transport of lipoproteins across the periplasm. Based on the 
assumption that N-acylation of lipoproteins is required for transport into the mycolic acid 
layer, the presence of Lnt homologues in mycobacteria may be postulated. Multiple sequence 
alignments (data not shown) confirmed early in silico findings (Gurcha et al., 2002; Baulard 
et al., 2003) that Lnt homologues are present in mycobacteria. M. tuberculosis Rv2051c 
encodes a two-domain protein, where the N-terminal part shows similarity to E. coli Lnt. The 
C-terminal part of the protein encodes a polyprenolmonophosphomannose (Ppm) synthase, 
which transfers mannose from GDP-mannose to endogenous polyprenol phosphates, an 
important metabolic intermediate in the synthesis of the mycobacterial cell wall constituents 
lipomannan and lipoarabinomannan (LAM). The Lnt-homology domain of Rv2051c enhances 
the Ppm synthase activity of the C-terminal domain, while apo-lipoprotein N-acyltransferase 
                                                 
1
 Note added in proof: This assumption was confirmed recently by infection of TLR2-/-mice, in which 
M. tuberculosis lspA::aph was also attenuated (Rampini et al., 2008. LspA inactivation in Mycobacterium 
tuberculosis results in attenuation without affecting phagosome maturation arrest. Microbiology, 154,2991-3001) 
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activity remains to be demonstrated (Baulard et al., 2003)2. Besides the N-terminal domain of 
Rv2051c, ORF Rv2262 has lower but still significant homology to E. coli Lnt. Again, an 
enzymic function remains to be determined. In M. smegmatis, orthologues of the two domains 
of M. tuberculosis Rv2051c are encoded by two distinct ORFs, Msppm1 and Msppm2, of 
which Msppm2 (MSMEG3860) corresponds to Lnt. Thus, the M. tuberculosis Lnt ORF 
encodes a significantly larger protein (874 aa) compared to M. smegmatis (654 aa) and E. coli 
(512 aa). Lnt homologues have been found not only in mycobacteria but also in other 
actinobacteria, including Streptomyces and Corynebacterium. A comprehensive analysis of 
fully sequenced genomes of bacteria representing different phyla suggests that Lnt 
homologues are present in microorganisms with a complex cell envelope (unpublished 
observations) but not in ordinary Gram-positive bacteria. 
The presence of Lnt homologues and the localization of lipoproteins in the mycobacterial cell 
wall (see below) suggest that a transport system for lipoproteins into the mycolic acid layer 
should exist – homologous or analogous to the E. coli Lol system. The E. coli Lol system 
consists of (i) an ABC-transporter complex of three proteins (LolC, LolD and LolE), which 
releases lipoproteins from the plasma membrane; (ii) a periplasmic chaperone (LolA); and 
(iii) a receptor in the outer membrane (LolB), which is itself a lipoprotein. E. coli lipoproteins 
are translocated to the outer membrane unless they possess a Lol-avoidance signal, i.e. an 
aspartate at position +2 (Narita et al., 2004). More complex lipoprotein transport signals may 
be present in other bacterial species (Schulze & Zuckert, 2006). Protein sequence alignments 
so far have not identified Lol homologues in M. tuberculosis. However, recent structural 
analysis of M. tuberculosis lipoprotein LppX revealed structural homologies to E. coli LolA 
and LolB, although the primary substrate seems to be phthiocerol dimycocerosate rather than 
lipoproteins (Sulzenbacher et al., 2006). 
 
Lipoprotein localization 
The function of a protein depends on its correct localization and vice versa. In Gram-positive 
bacteria, cell-associated lipoproteins stay anchored in the plasma membrane. In Gram-
negative bacteria, the vast majority of cell-associated lipoproteins are released from the 
plasma membrane and are anchored to the outer membrane (Tokuda & Matsuyama, 2004). 
Despite recent progress in subcellular fractionation of mycobacteria (Mawuenyega et al., 
                                                 
2
 Note added in proof: Lnt-dependent (Rv2051c and MSMEG3860) N-acylation of mycobacterial lipoproteins 
has recently been demonstrated (for details see chapters 3 and 4, Tschumi et al., 2009. Identification of 
Apolipoprotein N-Acyltransferase (Lnt) in Mycobacteria. J Biol Chem, 284, 27146-27156. and Bruelle et al. 
2010. Cloning, expression and characterization of Mycobacterium tuberculosis lipoprotein LprF. Biochem 
Biophys Res Commun, 391, 679-684.) 
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2005; Rezwan et al., 2006), localization of mycobacterial lipoproteins has rarely been 
addressed. M. tuberculosis LprG and M. smegmatis PhoA were shown to be anchored in the 
cell envelope (Kriakov et al., 2003); likewise M. tuberculosis Mpt83 was shown to be cell 
surface associated by electron microscopy and fluorescence cytometry (Vosloo et al., 1997; 
Harboe et al., 1998). Proteomic analyses of fractionated M. tuberculosis extracts identified 
and located 28 putative lipoproteins (Mawuenyega et al., 2005). Six lipoproteins were found 
in the cell wall fraction, ten in the plasma membrane fraction and seven in the cytosolic 
fraction; five lipoproteins were observed in two or in all three fractions. Localization of 
mature lipoproteins in the cytosol is questionable and these lipoproteins may represent 
recently synthesized (pre-pro-) proteins not yet secreted. Subcellular fractionation of lgt, lspA 
and lnt mutants expressing recombinant proteins will help to elucidate the mechanisms 
underlying mycobacterial lipoprotein sorting. 
 
Lipoproteins 
In an excellent review Sutcliffe & Harrington (2004) discussed the function of individual 
M. tuberculosis lipoproteins in great detail. We therefore limit our discussion to recent 
findings. Most mycobacterial lipoproteins have been predicted by a bioinformatic approach, 
i.e. identification of the lipobox consensus sequence within a typical signal peptide (Sutcliffe 
& Harrington, 2004). Experimentally investigated lipoproteins often are immunodominant 
antigens. However, pleiotropic and seemingly antagonistic, i.e. pro- and anti-inflammatory 
effects, make it difficult to discern the mechanisms by which these proteins contribute to 
immunopathogenesis (Karakousis et al., 2004). Investigations with M. leprae LpK variants 
differing in the length of the peptide and the presence or absence of the lipid moiety revealed 
that both acyl residues and peptide sequences are required for elicitation of an immune 
response. The inability of a non-acylated 27 kDa antigen of M. tuberculosis to induce IFN-γ 
secretion corroborates the importance of the lipid moiety for inducing an immune response 
(Hovav et al., 2004). 
Targeted gene inactivation of individual lipoprotein genes, transposon site hybridization 
mutagenesis and vaccination studies corroborate early findings on the overall importance of 
lipoproteins in the immunopathogenesis of infection with M. tuberculosis. Several puative 
lipoproteins, e.g. LppP (Rv2330c), LprO (Rv2290), LprK (Rv0173), LpqT (Rv1016c), LpqY 
(Rv1235), LpqZ (Rv1244), LprG (Rv1411) and LppX (Rv2945c), are required for optimal 
growth in vivo (Rengarajan et al., 2005; Sassetti & Rubin, 2003; Bigi et al., 2004). Some of 
these M. tuberculosis lipoproteins have homologues in mycobacteria, others represent 
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signature proteins for the Corynebacterium, Mycobacterium, Nocardia (CMN) subgroup of 
the actinobacteria (Gao et al., 2006) (Table 2). 
 
Name M. tuberculosis* M. leprae † M. avium † M. marinum ‡ M. smegmatis §
19kDa LpqH 48/65 75/86 48/ 51 39/51
38kDa PstS1 33/48 36/48 ? 32/ 46 34/49 ¶
PstS2 PstS2 62/77 ¶ 77/85 66/ 77 45/56 ¶
PstS3 PstS3 77/86 78/86 77/ 83 48/61
LpqB LpqB 87/92 86/92 82/87 72/81
LprF LprF 30/48 # 29/51 # 65/ 72 32/48 #
LprJ LprJ 34/56 66/85 71 /82 41/62
RpfB RpfB 82/89 85/92 80/86 73/81
24kDa LppX 76/85 34/52 # 73/ 85 30/47 #
LpqW LpqW 79/85 81/88 72/77 74/82
? Same ORF as identified by PstS2
¶ Same ORF as identified by PstS3.
# Same ORF as identified by LprG.
Table 2.
 Distribution of lipoproteins in mycobacteria and sequence identities/similarities
* M. tuberculosis  H37Rv lipoproteins were used as a query
† BLAST on http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi
‡ BLAST on http://www.sanger.ac.uk/cgi-bin/blast/submitblast/m_marinum
§ BLAST on http://tigrblast.tigr.org/cmr-blast
 
 
Examples of mycobacterial lipoproteins 
The 19 kDa antigen (LpqH, Rv3763) of M. tuberculosis (see Table 2 for summary of 
lipoproteins discussed) is a glycosylated lipoprotein. Early on, this protein was shown to 
induce a TLR-2-dependent bactericidal response in macrophages (Thoma-Uszynski et al., 
2001). Recently, the 19 kDa antigen was described as an adhesin, binding to the mannose 
receptor of THP-1 monocytic cells and thereby stimulating phagocytosis (Diaz-Silvestre et 
al., 2005). The 19 kDa antigen was shown to induce interleukin-1 and -12, and tumour 
necrosis factor-α (TNF-α) through TLR2- signalling in macrophages. Prolonged exposure to 
the 19 kDa lipoprotein inhibits IFN-γ production and major histocompatibility (MHC) class II 
expression. These findings suggest that, at least in part, persistent TLR2 signalling enables 
M. tuberculosis to evade T cell responses and persist as a long-term infection. An 
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M. tuberculosis 19 kDa knockout mutant was reported to be slightly attenuated in IFN-γ 
activated monocyte derived macrophages (Stewart et al., 2005). 
Phosphate transport receptors (Pst): three homologues of the periplasmic ABC phosphate-
binding receptor PstS of E. coli have been described in M. tuberculosis [PstS1 (Rv0934), 
PstS2 (Rv0932c) and PstS3 (Rv0928)]. Expression of these proteins increases under 
phosphate-limiting conditions. M. tuberculosis mutants deficient in PstS1 and PstS2 showed 
decreased c.f.u. in lungs and spleens of mice, indicating a role in virulence (Peirs et al., 2005). 
Vaccination of C57BL/6 mice with PstS3 DNA protected against challenge with 
M. tuberculosis (Romano et al., 2006). Compared to PstS3 vaccination, vaccination with 
PstS2 and PstS1-DNA induced only modest reduction in c.f.u. counts. 
LpqB (Rv3244c) is a particularly interesting lipoprotein, as it is one of the 233 conserved 
signature proteins of the actinobacteria (Gao et al., 2006). lpqB is located immediately 
downstream of the two-component signal transduction system MtrAB. In this system MtrB is 
the transmembrane sensor-kinase and MtrA is the cytoplasmic response regulator. 
Lipoproteins have been shown to function as accessory proteins of sensor-kinase systems and 
it may be assumed that LpqB modulates signal sensing by MtrB (Hoskisson & Hutchings, 
2006). 
Lipoproteins LprF (Rv1368) and LprJ (Rv1690) exhibited protein–protein interactions with 
the histidine kinase KdpD in a two-hybrid screen. Activation of the Kdp signal transduction 
pathway appears to be the primary response to environmental osmotic stress in both 
M. tuberculosis and M. smegmatis. The histidine kinase domain of Kdp has been suggested to 
form ternary complexes with LprF and LprJ and it was speculated that these proteins function 
as ligand-binding proteins. Co-induction of LprJ with a cluster of genes involved in cell wall 
integrity suggests that LprJ is involved in this process (Boshoff et al., 2004). Alternatively, 
LprF or LprJ could function as accessory proteins as discussed for LpqB. 
RpfB (Rv1009) is the only lipoprotein among the five resuscitation-promoting factor (Rpf) 
proteins of M. tuberculosis. Rpf proteins stimulate dormant cells to divide (Keep et al., 2006). 
They have structural homology to glycoside hydrolases and cleave peptidoglycan; however, 
the exact mechanism by which these proteins promote resuscitation remains elusive. 
Investigations in a mouse model of M. tuberculosis persistence and reactivation indicated that 
inactivation of rpfB, but not inactivation of rpfA, C, D or E, delayed reactivation, suggesting a 
unique role of RpfB in resuscitation (Tufariello et al., 2006). Whether this unique role of 
RpfB is related to the lipid anchor remains to be determined. 
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Investigation of LpqW and LppX revealed that these lipoproteins are key players in synthesis 
and transport of the unique components of the mycobacterial cell envelope. LppX (Rv2945c) 
is a lipoprotein involved in translocation of complex lipids, the phthiocerol dimycocerosates 
(DIM), to the outer membrane. Structural elucidation of LppX revealed the presence of a 
hydrophobic cavity suitable for binding the large lipophilic side chain of DIM (Sulzenbacher 
et al., 2006). Orthologues of LppX are only present in mycobacteria which synthesize DIM 
(e.g. M. tuberculosis), and are absent from DIM-negative mycobacteria (e.g. M. smegmatis or 
M. avium). An M. tuberculosis mutant deficient in LppX is attenuated in a mouse model of 
infection. Attenuation is associated with a failure to release DIM into the culture supernatant 
rather than reduced DIM synthesis (Sulzenbacher et al., 2006). LpqW (Rv1166) is a highly 
conserved, essential lipoprotein involved in the synthesis of cell wall components. Structural 
analyses suggest that LpqW is derived from substrate-binding proteins, which in 
mycobacteria and other micro-organisms of the subfamily Corynebacterinae (also producing 
LAM) has evolved to match the specific needs in the synthesis of the cell wall components 
phosphatidyl-myo-inositol mannoside (PIM) and LAM. LpqW acts at the branching point of 
the PIM/LAM pathway and converts the last common intermediate, the tetramannosylated 
phosphatidylinositol mannoside PIM4, into the LAM pathway (Kovacevic et al., 2006; 
Marland et al., 2006). 
 
Conclusions 
Lipidation of proteins is required for their anchoring and sorting to the cellular surface. 
Recent investigations point to the importance of lipoprotein-synthesizing enzymes as well as 
individual lipoproteins in the biology of mycobacteria. Mycobacterial lipoproteins are crucial 
for synthesizing the unique mycobacterial cell envelope, sensing of and protection from 
environmental stress and participation in host– pathogen interaction. Due to their contribution 
to virulence, lipoproteins and the enzymes of the lipoprotein synthesis pathway represent 
promising drug targets. In addition some lipoproteins confer a protective immune response 
and thus may qualify as subunit vaccines. Despite progress in lipoprotein research much 
remains to be learned with respect to the synthesis, localization and function of mycobacterial 
lipoproteins and their role in host–pathogen interaction. 
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Addendum 
 
 
Personal contribution to chapter 1 
 
This Mini-Review gives a short overview of the lipoprotein biosynthesis pathway in 
mycobacteria, as well as of the knowledge about lipoproteins in M. tuberculosis. Lipoproteins 
are a class of secreted, membrane-anchored proteins characterized by a lipidated N-terminus. 
Precursor lipoproteins mature by three enzymatic modifications catalyzed by the integral 
membrane proteins Lgt, LspA and Lnt. Lgt attaches a diacylglycerol to the sulfhydryl group 
of the universally conserved cysteine in the lipoprotein recognition motif termed lipobox. 
Subsequently, LspA cleaves off the signal peptide and finally Lnt adds an acyl chain to the N-
terminal cysteine. We observed by bioinformatic analysis the presence of 25 up to 97 
lipoproteins in different mycobacteria. Out of the 48 putative lipoproteins in M. tuberculosis, 
only a minority of those is charaterized in detail. 
 
My contribution as a second author to this manuscript was as follows: 
 
Bioinformatic analysis 
• Database search for putative lipoproteins in M. tuberculosis, M. leprae, M. avium, 
 M. marinum and M. smegmatis 
• Analysis of the distribution of selected lipoproteins in several mycobacteria and 
 alignments to detect protein sequence identities and similarities 
• Writing of the manuscript 
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Lipoprotein localization and transport in mycobacteria 
Introduction 
Bacterial lipoproteins comprise a subset of membrane proteins that are covalently modified 
with lipids at the N-terminal cysteine. The common feature of lipoproteins is the lipobox 
which is located in the C-terminal part of the singal peptide. The lipobox is rather highly 
conserved and consists of four amino acids [LVI][ASTVI][GAS]C (Babu et al., 2006). 
Synthesized as precursors in the cytoplasm, lipoproteins are translocated across the 
cytoplasmic membrane mainly by the Sec translocation machinery. A recent publication 
reports that lipoproteins may also be translocated by the twin-arginine translocation system 
(Tat-system) (McDonough et al., 2005). Lipoprotein maturation subsequently occurs on the 
periplasmic side of the cytoplasmic membrane by the consecutive action of the three enzymes 
Lgt (pre-prolipoprotein diacyl glyceryl transferase), LspA (prolipoprotein signal peptidase) 
and Lnt (apolipoprotein N-acyltransferase). As a first step, Lgt attaches a diacylglycerol 
residue to the thiol group of the universally conserved cysteine within the lipobox. Secondly, 
LspA cleaves off the signal peptide in front of the modified cysteine, followed by the 
attachment of a third acyl residue to the free amino group of the cysteine by Lnt (Rezwan et 
al., 2007a). The lipoprotein biosynthesis pathway is very well characterized in the Gram-
positive bacterium Bacillus subtilis (Tjalsma et al., 1999) and the Gram-negative bacterium 
Escherichia coli (Tokuda & Matsuyama, 2004). While the first two enzymes involved in 
lipoprotein synthesis, Lgt and LspA, are universally present in bacteria, Lnt has been reported 
to be restricted to Gram-negatives (Tjalsma et al., 1999). Although being considered as Gram-
positive bacteria, the cell envelope of mycobacteria resembles the cell envelope of Gram-
negatives. 
In E. coli, a relatively small number of lipoproteins remain in the plasma membrane 
(Robichon et al., 2005). The vast majority is located in the outer membrane. The release of an 
outer membrane associated lipoprotein from the cytoplasmic membrane and its transport is 
performed by the Lol-system, consisting of five components (LolABCDE) (Tokuda & 
Matsuyama, 2004). The ABC transporter LolCDE recognizes outer membrane-directed 
lipoproteins and dissociates them from the inner membrane. The LolCDE-lipoprotein 
complex passes the lipoprotein to LolA, a periplasmic carrier protein. Upon traversing the 
periplasm, the lipoprotein is transferred to the outer membrane receptor protein LolB - which 
is an outer membrane lipoprotein itself - and incorporates it into the outer membrane (Narita 
& Tokuda, 2006). The signal specificity for the transport in E. coli is the amino acid position 
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+2 and +3 after the highly conserved cysteine (position +1). Aspartate at position +2 functions 
as an inner membrane retention signal. Additional combinations of membrane retention 
signals have been found by systematic mutagenesis of the residue at position +2. According to 
these results, tryptophan, phenylalanine or proline in combination with asparagine at position 
+3 are sufficient to retain lipoproteins in the inner membrane (Seydel et al., 1999; Terada et 
al., 2001). In Pseudomonas aeruginosa it has been observed, that lysine and serine at 
positions +3 and +4 respectively cause inner membrane retention as well as several other 
combinations of amino acids at positions +2 to +4 (Lewenza et al., 2008; Narita & Tokuda, 
2007). 
In order to investigate the mycobacterial lipoprotein biosynthesis pathway and possible 
transport conditions of mycobacterial lipoproteins, several heterogeneously expressed 
lipoproteins of M. tuberculosis have been expressed in different strains of M. smegmatis 
(wild-type, ∆lgt, ∆lspA and ∆lnt). Subcellular fractionation of these strains has been applied to 
examine the localization (either cytoplasmic membrane or cell wall) of lipoproteins. 
Additionally, multiple site directed mutagenesis of different lipoproteins has been applied to 
the amino acid sequences adjacent to the cysteine at position +1 in order to screen for possible 
transport signals. 
 
Results 
Database search for enzymes of the lipoprotein biosynthesis pathway. BLASTp search 
analysis has been performed to elucidate possible homologues of the enzymes involved in the 
lipoprotein biosynthesis pathway in the bacterial kingdom. Protein sequences of Lgt, LspA, 
Lnt and LolA, B, C, D and E of E. coli have been used as queries. Figure 1a shows the results 
of the BLASTp with Lgt (E. coli) as query. Lgt is widely distributed in Gram-negative 
bacteria (α-, β-, γ-, ∆-, ε-Proteobacteria, Spirochetes, Aquifex, Cytophaga, and Thermotoga), 
low GC Gram-positive bacteria (Firmicutes, e.g. Clostridia, Mollicutes and Bacilli) and high 
GC Gram-positive bacteria (Actinobacteria, e.g. Streptomyces, Nocardia, Corynebacteria and 
Mycobacteria). None of the 46 selected species shows an E-value below the given threshold 
of 10-4 (dashed line). E. coli strain K12 has been used as a positive control resulting in an E-
value close to 0 (10-173). LspA is as widely distributed as Lgt (Figure 1b). A protein similar to 
LspA can be found throughout all bacterial strains used in this setup, except in Clostridium 
perfringens str. 13. E. coli strain K12 as a positive control has an E-value of 10-83. According 
to the results shown in Figure 1c, Lnt seems to be completely absent in low GC Gram-
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positive bacteria but is detected in all strains of the group of high GC Gram-positive bacteria, 
including Mycobacteria. Figure 1d shows the results of the BLASTp with E. coli-LolA as a 
representative for the Lol-system. LolA can be found in several but not all Gram-negative 
bacteria. Besides E. coli, the Lol-system seems exist amongst others in Haemophilus 
influenzae, Pseudomonas aeruginosa or Neisseria meningitidis. A total of 8 out of 14 Gram-
negatives do have homologues to LolA. Neither in low GC nor in high GC Gram-positives 
LolA has been detected. BLASTp has been performed for LolB, C, D and LolE as well (data 
not shown). LolB, C and E have not been found in Gram-positives, indicating, that there is no 
need for such a lipoprotein transport system (in case of low GC Gram-positives) because a 
lack of a periplasm, or different proteins have to be responsible for the transport across the 
pseudo-periplasm in case of Actinobacteria. Similar proteins to LolD are broadly found by 
BLASTp-search in all bacteria which can be ascribed to the highly conserved ATP-binding 
cassette-transporter domain (data not shown). 
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LspA-BLAST
0 8 12 16 20
Treponema pallidum subsp. pallidum str. Nichols
Borrelia burgdorferi B31
Vibrio cholerae O1 biovar eltor str. N16961
Pseudomonas aeruginosa PAO 1
Haemophilus influenzae 86-028NP
Escherichia coli K12
Helicobacter pylori 26695
Campylobacter jejuni subsp. jejuni NCTC 11168
Desulfovibrio desulfuricans G 20
Neisseria meningitidis MC58
Burkholderia cepacia R1808
Bordetella pertussis Tohama I
Rickettsia prowazekii str. Madrid E
Agrobacterium tumefaciens str. C58
Rhodobacter sphaeroides
Thermotoga maritima MSB8
Deinococcus radiodurans R1
Cytophaga hutchinsonii
Aquifex aeolicus VF5
Mycoplasma pneumoniae M129
Streptococcus pneumoniae TIGR4
Lactococcus lactis subsp. lactis I1 1403
Enterococcus pneumoniae V583
Clostridium tetani E88
Clostridium perfringens str. 13
Staphylococcus aureus subsp. aureus MSSA476
Listeria monocytogenes str. 4bF2365
Bacillus subtilis subsp. subtilis str. 168
Bacillus anthracis str. Ames
Synechococcus sp. WH 8102
Nostoc sp. PCC 7120
Gloeobacter violaceus PCC 7421
Chlamydia trachomatis D/UW-3/CX
Chlamydia muridarum
Streptomyces coelicolor A3(2)
Streptomyces avermitilis MA-4680
Mycobacterium smegmatis MC2
Mycobacterium tuberculosis H37Rv
Mycobacterium tuberculosis CDC 1551
Mycobacterium leprae TN
Mycobacterium bovis AF122/97
Mycobacterium avium subsp. paratuberculosis str. k10
Corynebacterium efficiens YS-314
Corynebacterium diphteriae NCTC 13129
Corynebacterium glutamicum ATCC 13032
50 75 10
04
-log(E-value)
hi
gh
 
G
C 
G
ra
m
-
po
si
tiv
e
 
ba
ct
e
ria
 
Ac
tin
o
ba
ct
er
ia
 
G
ra
m
-
n
e
ga
tiv
e
 
ba
c
te
ria
 
lo
w
 
G
C 
G
ra
m
-
 
po
s
iti
-
v
e
 
ba
c
te
ria
 
Fi
rm
ic
u
te
s
 
 
Figure 1. BLASTp search for lipoprotein modifying- and transport proteins. E. coli Lgt (a)) and LspA (b)) were 
used as queries to identify homologues on the National Center for Biotechnology Information BLASTp server. 
The sequence filtering option was switched off and the expect value was set at 10, the cut-off value set at 10-4 
(dashed line). 
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c) 
Lnt-BLAST
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d) 
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Figure 1. BLASTp search for lipoprotein modifying- and transport proteins. E. coli Lnt (c)) and LolA (d)) were 
used as queries to identify homologues on the National Center for Biotechnology Information BLASTp server. 
The sequence filtering option was switched off and the expect value was set at 10, the cut-off value set at 10-4 
(dashed line). 
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Lipoprotein reporter constructs. In order to investigate the role of the three enzymes Lgt, 
LspA and Lnt involved in the lipoprotein biosynthesis pathway, subcellular fractionations of 
M. smegmatis wt, ∆lgt, ∆lspA and ∆lnt have been performed according to (Rezwan et al., 
2007b). Four different lipoproteins  (Table 1) derived from M. tuberculosis H37Rv have been 
chosen for examination and heterogeneous expression in M. smegmatis wt- and knock-out 
strains: Mpt83, which has been localized in the cell wall before by electron microscopy 
(Vosloo et al., 1997) and by fluorescence cytometry (Harboe et al., 1998), LppX, which is 
supposed to localize in the cell wall (Mawuenyega et al., 2005; Sulzenbacher et al., 2006), 
LprN, which has been detected in the cell wall fraction (Mawuenyega et al., 2005) and PstSI 
which is supposed to localize in the cytoplasmic membrane because of its assumed 
participation in phosphate uptake and transport across the membrane (Peirs et al., 2005). Due 
to the fact, that no Lol-homologues have been found as indicated by bioinformatic analyses 
above, it can be hypothesized that a different signal sequence for transport to the cell wall in 
mycobacteria has to exist. Additionally, it has been observed by aligning putative 
mycobacterial lipoproteins, that one or two serines at position +2 or +3 after the cysteine of 
the lipobox are predominant in lipoproteins presumably located in the cell wall (Chapter 1, 
data not shown). Therefore, several modified Lpp-constructs have been cloned (Table 1): 
Mpt83 missing 13 amino acids directly after the Cys of the lipobox (Mpt83∆13AA), 
Mpt83∆13AA with two serines at position +2 and +3 (Mpt83∆13AA+SS). To prove the 
existance of a signal sequence determining the subcellular localization of mycobacterial 
lipoproteins within 10 amino acids after the cysteine at position +1, several “hybrid” 
constructs were generated by site directed mutagenesis. LppX with 10 amino acids derived 
from LprN (LppX-10AAN) or PstSI (LppX10AASI) and the counterparts LprN-10AAX and 
PstSI-10AAX, which correspond to LprN containing 10 amino acids derived from LppX and 
PstSI with 10 amino acids derived from LppX, respectively (Table 1). 
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Lipoprotein reporter constructs 
Lipoprotein 
constuct 
Mpt83 
Mpt83∆13AA 
Mpt83∆13AA+SS 
LppX 
*** * ** ******* ***************** 
LSG C SS PKPDAEE QGVPVSPTASDPALLAE 
LprN 
::: : :: ::::::: ::::::::::::::::: 
LAG C QF GGLNSLP LPGTAGHGEGAYSVTVE 
LppX-10AA-N 
*** : :: ::::::: ***************** 
LSG C QF GGLNSLP QGVPVSPTASDPALLAE 
LprN-10AA-X 
::: * ** ******* ::::::::::::::::: 
LAG C SS PKPDAEE LPGTAGHGEGAYSVTVE 
LppX-10AA-SI 
*** ° °° °°°°°°° ***************** 
LSG C GS KPPSGSP QGVPVSPTASDPALLAE 
PstSI-10AA-X 
°°° * ** ******* °°°°°°°°°°°°°°°°° 
AAG C SS PKPDAEE ETGAGAGTVATTPASSP 
Cell wall 
Cytoplasmic 
membrane 
Cell wall 
Cell wall 
Cell wall 
Cell wall 
Cell wall 
PstSI 
°°° ° °° °°°°°°° °°°°°°°°°°°°°°°°° 
AAG C GS KPPSGSP ETGAGAGTVATTPASSP 
Cell wall 
Protein 
sequence 
Expected 
localization 
LAG C SS TKPVSQD TSPKPATSPAAPVTTAA 
LAG C -- ------- ----PATSPAAPVTTAA 
LAG C SS ------- ----PATSPAAPVTTAA 
Cytoplasmic 
membrane 
Cytoplasmic 
membrane 
    +1        +10        +20 
 
Table 1: Lipoprotein reporter constructs used in this study. The displayed protein sequence includes the lipobox, 
with the highly conserved cysteine at position +1. * designates amino acids derived from LppX, : from LprN, ° 
from PstSI. Amino acid deletions are designated by -. 
 
All constructs described above have been fused to the 19 kDa-promoter (a constitutive 
promoter derived from the 19 kDa lipoprotein) and have been provided with an HA-epitope 
tag and were cloned into pMV261, a shuttle-vector for E. coli and mycobacteria (Stover et al., 
1991). The generated vectors were transformed into M. smegmatis wt, ∆lgt, ∆lspA and ∆lnt 
strains. The subcellular localization of the lipoprotein constructs has been explored by 
Western blot upon fractionation of the bacteria according to Rezwan et al. (Rezwan et al., 
2007b) 
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Subcellular localization of lipoproteins of M. tuberculosis heterologously expressed in 
M. smegmatis. Figure 2 shows the results of the fractionation of M. smegmatis wt, -∆lgt, -
∆lspA and ∆lnt strains expressing either Mpt83, LppX, LprN or PstSI, all derived from 
M. tuberculosis H37Rv. In the wt-strain, Mpt83 (upper row, panel left) can be found in all 
fractions (total extract, cell wall and cytoplasmic membrane), indicating that Mpt83 is 
transported to the cell wall which confirms the results obtained with electron microscopy or 
fluorescence cytometry (Harboe et al., 1998; Vosloo et al., 1997). The fractionation of the 
∆lgt strain shows the absence of Mpt83 from the cell wall and the cytoplasmic membrane. 
Mpt83 is absent in the cell wall fractions of the ∆lspA and the ∆lnt strains but can be detected 
in the membrane fractions. 
In wildtype M. smegmatis, LppX shows the same localization Mpt83, which is consistant with 
observations in previous studies (Mawuenyega et al., 2005; Sulzenbacher et al., 2006). The 
lipoprotein is absent in the cell wall- and the membrane fraction of the lgt-mutant, whilst it is 
only missing in the cell wall in ∆lspA and ∆lnt strain. In the wt-strain, double bands are 
detected in the total lysate and in the membrane fraction. The bands in the ∆lgt- and ∆lspA-
strains have a size which corresponds to the upper band in the wt. All bands detected in the 
∆lnt-strain do have the same height, analogous to the lower bands of the wt-strain. 
LprN can not be detected in the cell wall fraction of any strain, indicating that it is not 
transported to the cell wall which is contradictory to the findings of Mawuenyega et al. 
(Mawuenyega et al., 2005). Except in ∆lgt, where LprN is absent in the membrane fraction as 
well, the lipoprotein localizes in the membrane fraction. 
PstSI, which is predicted to be located in the cytoplasmic membrane (Peirs et al., 2005) is 
missing in the cell wall fractions of all strains and additionally is absent in the membrane 
fraction of the ∆lgt-strain. These findings support its presumed localization in the membrane 
as a part of a phospate uptake-system. In summary it has been shown that LppX and Mpt83 
are lipoproteins anchored in the cell wall, while LprN and PstSI are located in the cytoplasmic 
membrane. 
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Subcellular Localization of Mycobacterial Lipoproteins 
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Figure 2: Subcellular localization of M. tuberculosis-derived lipoproteins. Western blot developed with α-HA 
antibody after fractionation of M. smegmatis wt, ∆lgt, ∆lspA, ∆lnt strains, transformed with either pMV261-
Mpt83, -LppX, -LprN or -PstSI. 
 
Subcellular localization of modified lipoproteins in M. smegmatis. We hypothesized, that a 
signal sequence responsible for the transport to the cell wall of mycobacteria can be found 
within a couple of amino acids adjacent to the highly conserved cysteine of the lipobox. 
Therefore recombinant M. smegmatis expressing Mpt83∆13AA and Mpt83∆13AA+SS were 
subjected to fractionations. Figure 3 shows that a deletion of 13 amino acids after the cysteine 
of Mpt83 results in altered localization. Mpt83∆13AA is absent from the cell wall but found 
in the membrane fraction. When two serines are re-inserted at positions +2 and +3, the 
lipoprotein is detected in the cell wall fraction again (Mpt83∆13AA+SS). These results 
suggest that these amino acids are part of the signal sequence directing mycobacterial 
lipoproteins to the cell wall. 
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Subcellular Localization of modified Lipoproteins 
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Figure 3: Subcellular localization of modified Mpt83. Western blot developed with α-HA antibody after 
fractionation of M. smegmatis wt-strain transformed with either pMV261-Mpt83, -Mpt83∆13AA or -
Mpt83∆13AA+SS. 
 
In order to proof whether the cysteine-proximal part of lipoproteins is not only required but 
also sufficient for cell wall transport, several hybrid constructs were generated. As it has been 
shown in Figure 2, the native LppX and LprN are located at the cell wall and in the 
cytoplasmic membrane respectively. The hybrid construct LppX-10AA-N, having replaced 10 
amino acids directly after the cysteine by the analogous sequence of LprN, should elucidate 
whether this sequence of LppX is responsible for cell wall transport. Vice versa, the hybrid 
construct LprN-10AA-X has been generated. This construct consists of LprN with an 
exchange of ten amino acids of LppX after the highly conserved cysteine of the lipobox. If 
these ten amino acids of LppX direct a lipoprotein to the cell wall, the modified LprN is 
expected to locate at the cell wall. 
M. smegmatis wt-strain has been transformed with the vectors pMV261-LppX-10AA-N and 
pMV261-LprN-10AAX, coding for modified lipoproteins LppX and LprN. Figure 4 shows 
the results of these fractionations. As controls, the fractionations of unmodified lipoproteins 
LppX (localization: cell wall) and LprN (localization: cytoplasmic membrane) are displayed. 
When replacing the subsequent 10 amino acids after the highly conserved cysteine of LppX 
by the appropriate amino acid sequence of LprN, the lipoprotein is not transported to the cell 
wall anymore. By contrast, when replacing 10 amino acids of LprN by the according amino 
acids of LppX, the modified LprN is located in the cell wall. 
CHAPTER 2 55 
Subcellular Localization of modified Lipoproteins 
M. smegmatis wt 
Lipoprotein 
 
Ly
sa
te
 
 
 
 
 
 
 
 
 
Ce
ll w
all
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
em
br
an
e 
LppX 
LppX-10AA-N 
LprN 
Protein Sequence 
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*** * ** ******* ***************** 
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::: : :: ::::::: ::::::::::::::::: 
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Figure 4: Subcellular localization of modified LppX and LprN. Western blot developed with α-HA antibody 
after fractionation of M. smegmatis wt-strain transformed with either pMV261-LppX, -LprN, -LppX-10AA-N or 
LprN-10AA-X. Arrows indicate the assumed mature form of the lipoprotein while bands with a lower size are 
derived from unspecific cleavage. 
 
Similar hybrids to LppX-10AA-N and LprN-10AA-X were constructed for LppX and PstSI, 
i.e. LppX-10AA-SI and PstSI-10AA-X and transformed into M. smegmatis wt-strain. Figure 5 
shows the results of these fractionations. LppX and PstSI served as controls (upper panels). 
As expected, the reporter construct LppX-10AA-SI does not localize in the cell wall anymore. 
But when replacing the probable signal sequence in PstSI with 10 amino acids of LppX, the 
hybrid protein localizes in the cell wall. 
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Figure 5: Subcellular localization of modified LppX and LprN. Western blot developed with α-HA antibody 
after fractionation of M. smegmatis wt-strain transformed with either pMV261-LppX, -PstSI, -LppX-10AA-SI or 
PstSI-10AA-X. Arrows indicate the assumed mature form of the lipoprotein while bands with a lower size are 
derived from unspecific cleavage. 
 
 
Discussion and conclusions 
In order to investigate a possible signal sequence responsible for cell wall transport of 
mycobacterial lipoproteins, several M. tubeculosis H37Rv reporter constructs have been 
designed. The lipoproteins under expression of the well known constitutive promoter of the 
19 kDa lipoprotein were transformed into different strains of M. smegmatis; expression after 
subcellular fractionation was analyzed by Western blot analyses. As expected, two 
lipoproteins, Mpt83 and LppX are localized in the cell wall- and the cytoplasmic membrane 
compartment in wt-strain of M. smegmatis. This indicates that these two lipoproteins are 
transported to the cell wall of mycobacteria. PstSI and LprN only have been found in the 
membrane fraction of M. smegmatis which in case of LprN is contradictory to the results of 
Mawuenyega et al. (Mawuenyega et al., 2005). In their study, they found peptides of LprN in 
the cell wall fraction of M. tuberculosis upon two-dimensional liquid chromatography tandem 
mass spectrometry-analysis. However, this method neither is quantitative, nor did they find 
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full-length LprN in the cell wall. Peptides of any lipoprotein, localizing in the membrane or in 
the cell wall, might be found in the cell wall fraction, after their natural degradation by 
processes called shaving of shedding (Antelmann et al., 2001). 
Lipoprotein transport to the outer membrane of E. coli is well charactized (Narita & Tokuda, 
2006). The first two steps of the lipoprotein biosynthesis are performed by Lgt and LspA. 
Homologues of these two enzymes have been found by extended protein database search in a 
wide range of bacteria. Lnt, responsible for the attachment of a third acyl residue to the 
universally conserved cysteine of the lipobox has been found in Gram-negative but not Gram-
positive bacteria. Surprisingly, homologues of Lnt have been found by performing BLASTp 
in the group of high GC Gram-positive bacteria (Actinobacteria). Even though mycobacteria 
belong to the group of Gram-positive bacteria, the cellular envelope resembles the envelope 
of Gram-negative bacteria with an outer membrane. In E. coli, the Lol-system is responsible 
for the release of lipoproteins from the inner membrane and for the transport to the outer 
membrane. The restrictive conditions for retention of a lipoprotein in the cytoplasmic 
membrane are the amino acids at position +2 and +3 directly after the modified cysteine of the 
lipobox. Besides few other combinations, an Asp at position +2 is the major retention signal, 
meaning that they are not recognized by the Lol-system (Seydel et al., 1999; Terada et al., 
2001). By BLASTp search, the five components of the Lol-system solely have been found in 
some of the examined Gram-negative bacteria. Therefore it is likely that transport to the cell 
wall of mycobacteria is performed by a completely different mechanism. Likewise, signal 
sequences responsible for transport to the outer layer of mycobacteria might differ 
substantially. 
In order to identify a signal which directs lipoproteins to the cell wall of mycobacteria, the 
reporter protein Mpt83∆13AA has been examined concerning localization in M. smegmatis 
wt-strain. In contrast to the full-length lipoprotein Mpt83, which localizes in the cell wall, the 
shortened version, missing 13 amino acids directly after the modified cysteine of the lipobox 
is not transported to the cell wall anymore and remains in the cytoplasmic membrane. This 
indicates that the construct still is processed as a lipoprotein and therefore is anchored in the 
membrane with its acyl residues. Secondly, one or a combination of several amino acids 
within the 13 missing amino acids seems to act as a transport signal to the cell wall. As shown 
in Table 1 and Figure 3, lipoproteins that are located in the cell wall of mycobacteria do have 
at least one serine directly after the cysteine of the lipobox. Thus the reporter protein 
Mpt83∆13AA+SS has been subjected to subcellular fractionation of M. smegmatis. This 
variant of the lipoprotein LppX lacks 11 amino acids after position +3, positions +1 to +3 are 
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derived from its native precursor (CSS). Like the native Mpt83, this reporter construct is 
transported to the cell wall of M. smegmatis. These findings indicate that a positive signal 
sequence for cell wall transport is located within 13 amino acids after the modified cysteine 
and two serines inserted directly after the lipobox might direct a lipoprotein to the cell wall. 
To narrow down the possible signal sequence for transport to the cell wall of mycobacteria, 
further constructs have been generated and subjected to subcellular fractionation. By site 
directed mutagenesis, 10 amino acids after the modified cysteine of LppX, which naturally 
localizes at the cell wall, have been shuffled with 10 amino acids of the membrane-localized 
lipoproteins LprN and PstSI respectively. In general, unspecific cleavage of these hybrid 
constructs has been observed, as demonstrated in Figures 4 and 5. Nevertheless, LppX with 
10 amino acids derived from one of those lipoproteins localizes in the membrane, indicating 
that it lacks a sequence which directs it to the cell wall. Vice versa, both lipoproteins that 
normally are retained in the membrane are directed to the cell wall upon replacing 10 amino 
acids after the cysteine with the corresponding sequence of LppX. 
In summary this study illustrates that the transport of mycobacterial lipoproteins substantially 
differs from the transport of lipoproteins to the outer membrane of E. coli. First of all, no 
homologues of the Lol-system are present in mycobacteria. Secondly, this study shows that 
the restrictive conditions for transport to the cell wall of mycobacteria are located within 10 
amino acids after the cysteine of the lipobox. Additionally it is more likely that lipoprotein 
transport in mycobacteria is directed by a “positive” signal sequence (e.g. by two serines at 
positions +2 and +3), rather than by an avoidance signal like in E. coli. More detailed 
investigations will narrow down a possible transport signal, e.g. by replacing amino acids of 
membrane-localized lipoproteins at position +2 and +3 by two serines. Knowledge about the 
cell wall signal sequence of mycobacteria will facilitate the detection of the complete 
transport system for lipoproteins in mycobacteria. 
 
Experimental section 
Bacterial strains and growth conditions. E. coli was used for initial cloning and propagation 
of plasmids. An overnight culture of E. coli strain XL-1 blue was inoculated into 1 l of LB 
medium and cultivated at 37 °C until OD600 reached 0.5-0.6. To prepare electrocompetent 
bacteria, cells were collected by centrifugation at 5000 g at 4 °C for 15 min and washed twice 
with an equal volume ice-chilled 1 mM HEPES (pH 7.0). The washing procedure was 
repeated twice with an equal volume of 10% glycerol. Finally, bacteria were resuspended in 
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5-10 ml of 10% glycerol. The suspension was divided into 40 µl aliquots, frozen in liquid 
nitrogen and stored at -80 °C until use. For electroporation, 40 µl of competent bacteria were 
mixed with 2 µl of precipitated ligation reaction or 0.1 µg of supercoiled plasmid DNA 
(transformation control) respectively and kept on ice for 5 min. Electroporation was 
performed in 0.1 cm cuvettes with a single pulse (1.8 kV, 2 µF, 200 Ω, Gene Pulser XcellTM, 
BioRad). After a recovery phase of 1 h, the bacteria were selected by plating 100 µl of 
electroporated bacteria on LB agar plates containing the appropriate antibiotic. Plates were 
incubated at 37 °C for 14-20 h. 
M. smegmatis strains have either been cultivated in LB-Tween or 7H9 medium. After having 
reached an OD600 of 0.6-0.8 bacteria were incubated on ice for 30 min. For preparation of 
competent cells, the bacteria were collected by centrifugation at 5000 g at 4 °C for 15 min, 
washed several times with ice-cold glycerol (10% v/v) and finally resuspended in 5 ml 
glycerol. The suspension was divided into 400 µl aliquots, frozen in liquid nitrogen and stored 
at -80 °C until use. For electroporation, competent bacteria were thawed on ice and washed 
once with ice-chilled glycerol (10%). Then, 100 µl competent bacteria were mixed with 1 µg 
of plasmid DNA and placed on ice for 10 min. Electroporation was performed in 0.4 cm 
cuvettes with a single pulse (2.5 kV, 25 µF, 1000 Ω, Gene Pulser XcellTM, BioRad). Bacteria 
were immediately resuspended in 1 ml of LB-Tween 80 medium and incubated at 37 °C for 3 
h. Electroporated bacteria were selected by plating 100 µl on LB agar or 7H10 plates. Plates 
were incubated at 37 °C for 3-4 days. When appropriate, gentamicin was added at a 
concentration of 10 µg ml-1. Strain designations were as follows: M. smegmatis Smr5 (wt), a 
strain carrying a non-restrictive rpsL mutation conferring streptomycin resistance (Sander et 
al., 1995), lgt::aph = lgt knock out mutant (∆lgt); lspA::hyg = lspA knock out mutant (∆lspA); 
lnt::aph = lnt knock-out mutant (∆lnt). 
Generation of lipoprotein reporter proteins. All lipoproteins of M. tuberculosis were 
expressed under control of the 19 kDa antigen (lpqH) promoter. In general, the recombinant 
lipoproteins were generated by fusion-PCR; fragment 1 (F1) contains the 19 kDa promoter 
while fragment 2 (F2) contains the according lipoprotein, including the leader peptide and an 
HA-epitope tag (hemagglutinin protein) at the carboxy terminus. All reporter proteins have 
been provided with restritction sites for HpaI and EcoRI at both ends. The amplified and 
fused fragments were cut with EcoRI (Fermentas) and cloned into vector pMV261-gem, an 
E.coli - mycobacteria shuttle vector with a gentamicin resistance cassette and subsequently 
transformed into the according strains of M. smegmatis. Table 2 gives an overview of the 
vectors used and generated in this study. 
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The reporter proteins were generated with the following sets of primer (Table 3): Mpt83: F1 
#1, #2; F2 #3, #4; fusion-PCR: #1, #4. LppX: F1 #1, #5; F2 #6, #7; fusion-PCR: #1, #7. 
LprN: F1: #1, #8; F2 #9, #10; fusion-PCR: #1, #10. PstSI: F1 #1, #11; F2 #12, #13; fusion-
PCR: #1, #13. Mpt83∆13AA+SS (amplified from pMV261-Mpt83∆13AA): F1 #1, #14; F2 
#15, #16; fusion-PCR: #1, #16. LppX-N10AA (amplified from pMV261-LppX): F1 #17, #18; 
F2 #19 #16; fusion-PCR: #17 #16. LppX-SI10AA (amplified from pMV261-LppX): F1 #17, 
#20; F2 #21, #16; fusion-PCR: #17, #16. LprN-X10AA (amplified from pMV261-LprN): F1 
#17, #22; F2 #23, #16; fusion-PCR: #17, #16. PstSI-X10AA (amplified from pMV261-PstSI): 
F1: #17, #24; F2: #25, #16; fusion-PCR: #17, #16. If not indicated else, the fragments were 
amplified from genomic DNA of M. tuberculosis strain H37Rv. 
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Plasmid Characteristics Source
pMV261 E. coli  - mycobacteria shuttle vector, Kmr (Stover et al. , 1991)
pMV261-gem E. coli  - mycobacteria shuttle vector, Gmr this study
pMV261-Mpt83 E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-gem, encoding HA-
tagged Mpt83 with 19 kDa promoter
this study
pMV261-LppX E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-gem, encoding HA-
tagged LppX with 19 kDa promoter
this study
pMV261-LprN E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-gem, encoding HA-
tagged LprN with 19 kDa promoter
this study
pMV261-PstSI E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-gem, encoding HA-
tagged PstSI with 19 kDa promoter
this study
pMV261-Mpt83-∆13AA E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-Mpt83, encoding HA-
tagged Fus83 with 19 kDa promoter, 13 
amino acids deleted after Cys of lipobox
M. Rezwan, internal 
communication
pMV261-Mpt83-∆13AA+SS E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-Mpt83, encoding HA-
tagged Fus83 with 19 kDa promoter, 13 
amino acids deleted after Cys of lipobox and 
re-insertion of  two Ser at positions +2 and +3
this study
pMV261-LppX-10AA-N E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-LppX, encoding HA-
tagged LppX with 19 kDa promoter, 10 
amino acids substituted by LprN after Cys of 
lipobox
this study
pMV261-LppX-10AA-SI E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-LppX, encoding HA-
tagged LppX with 19 kDa promoter, 10 
amino acids substituted by PstSI after Cys of 
lipobox
this study
pMV261-LprN-10AA-X E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-LprN, encoding HA-
tagged LprN with 19 kDa promoter, 10 amino 
acids substituted by LppX after Cys of 
lipobox
this study
pMV261-PstSI-10AA-X E. coli  - mycobacteria shuttle vector, Gmr, 
derivate of pMV261-PstSI, encoding HA-
tagged PstSI with 19 kDa promoter, 10 amino 
acids substituted by LppX after Cys of 
lipobox
this study
 
Table 2: Vectors used and generated in this study. 
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Subcellular fractionation. Subcellular fractionation was performed as described before 
(Rezwan et al., 2007b) with some minor adaptations. Cells of 1 l culture (7H9) were 
harvested at 4400 x g and washed once in NaCl solution (0.16 M). Wet weight of the cells 
was determined and for each gram of bacteria, one ml lysis buffer (0.05 M potassium 
phosphate, 0.022% (v/v) β-mercaptoethanol, pH 6.5) was added. Cells were broken with a 
French press (American Instrument Company) two times at 1.1 x 108 Pa. The cell lysate was 
then subjected to a low speed centrifugation at 1000 x g (10 min) to remove unbroken cells. 
Three to five centrifugation steps (27 000 x g, 45 min) were applied to pellet outer layer 
material, the supernatant was called SN27.1. All pellets were resuspended with lysis buffer 
subjected to a second cell lysis step. A single centrifuation at 28 000 x g resulted in pellet P27 
(cell wall) and supernatant SN27.2. The supernatants SN27.1 and SN27.2 were pooled, 
centrifuged at 100 000 x g for 2 hours and thereby seperated into pellet P100 (plasmic 
membrane) and supernatant SN100 (cytoplasm). All work was done at 4 °C. Subcellular 
fractions were separated by SDS-PAGE and analyzed by Western blot using anti-HA-
antibodies (1:300, Roche). Fractionation was controlled by NADH-oxidase assays 
(cytoplasmic membrane fraction) and Western blot analyses of cell wall protein MspA (MspA 
antiserum provided by M. Niederweis, University of Alabama). 
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Nr. Sequence Function Reporter protein
1 5'- GGG TTA ACG AAT TCT ACA TTG CCA CTA CTA 
CGG TGC -3'
2 5'- CTG AAC GTT GAT CAT CCT GTG CTC CTT TG -3'
3 5'- CAA AGG AGC ACA GGA TGA TCA ACG TTC AG -3'
4 5'- CCG TTA ACG AAT TCT AAG TGG CGT AGT CGG 
GGA CGT CGT AGG GGT  ACT GTG CCG GGG GCA TCA 
5 5'- TTT TCC ATC ATT CAT CCT GTG CTC CTT TG -3' amplification of 19kDa promoter and signal 
peptide of lppX
6 5'- CAA AGG AGC ACA GGA TGA ATG ATG GAA AA -3'
7 5'- CCG TTA ACG AAT TCT AAG TGG CGT AGT CGG 
GGA CGT CGT AGG GGT  AGT CGA CGT TGA CGG GTT 
8 5'- CCA GAT TCG GTT CAT CCT GTG CTC CTT TG -3' amplification of 19 kDa promoter and signal 
peptide of lprN
9 5'- CAA AGG AGC ACA GGA TGA ACC GAA TCT GG -3'
10 5'- CCG TTA ACG AAT TCT AAG TGG CGT AGT CGG 
GGA CGT CGT AGG GGT  ACT GTC CCG ACG CCG TAC CG 
11 5'- CAA ACG AAT TTT CAC CCT GTG CTC CTT TG -3' amplification of 19 kDa promoter and signal 
peptide of pstSI
12 5' CAA AGG AGC ACA GGG TGA AAA TTC GTT TG -3'
13 5'- CCG TTA ACG AAT TCT AAG TGG CGT AGT CGG 
GGA CGT CGT AGG GGT  AGC TGG AAA TCG TCG CGA 
14 5'- GGT CGC CGG GCT CGA ACA ACC CGC TAA GAA CGC 
A -3'
amplification of 19 kDa promoter and signal 
peptide of mpt83∆13AA+SS
15 5'- TTA GCG GGT TGT TCG AGC CCG GCG ACC AGC CCG 
-3'
16 5'- CCG TTA ACG AAT TCT AAG TGG CGT AGT CGG  -3'
17 5'- GGG TTA ACG AAT TCT ACA TTG -3'
18 5'- CAG CGA GTT CAG CCC GCC AAA CTG ACA TCC TGA 
TAG CCA CAA C -3'
19 5'- GGC GGG CTG AAC TCG CTG CCG CTG GTG TTC CCG 
TGA GCC C -3'
amplification of lppX  with 10 amino acids of 
lprN  including HA-tag
20 5'- CGA ACC GCT CGG TGG TTT CGA GCC ACA TCC TGA 
TAG CCA CAA C -3'
amplification of 19 kDa promoter and signal 
peptide of lppX  with 10 amino acids of pstSI
21 5'- AAA CCA CCG AGC GGT TCG CCT GAA GGT GTT CCC 
GTG AGC CC -3'
amplification of lppX  with 10 amino acids of 
pstSI  inclucing HA-tag
22 5'- CTC GGC ATC AGG TTT CGG CGA AGA ACA GCC GGC 
AAG CAG CG -3'
amplification of 19 kDa promoter and signal 
peptide of lprN  with 10 amino acids of lppX
23 5'- CCG AAA CCT GAT GCC GAG GAA CAG CCT GGC ACC 
GCC GGG -3'
amplification of lprN  with 10 amino acids of 
lppX
24 5'- CTC GGC ATC AGG TTT CGG CGA AGA ACA GCC CGC 
CGC TGC TA -3'
amplification of 19 kDa promoter and signal 
peptide of pstSI  with 10 amino acids of lppX
25 5'- CCG AAA CCT GAT GCC GAG GAA CAG ACG GGC 
GCC GGC GCC -3'
amplification of pstSI  with 10 amino acids of 
lppX
amplification of 19 kDa promoter and signal 
peptide of lppX  with 10 amino acids of lprN
amplification of  mpt83∆13AA+SS including HA-
tag
Mpt83
(pMV261Mpt83)
amplification of 19 kDa promoter and signal 
peptide of mpt83
amplification of mpt83  including HA-tag
amplification of pstSI  including HA-tag
amplification of lppX  including HA-tag
amplification of lprN  including HA-tag
LprN-X10AA
(pMV261LprN-X10AA)
PstSI-X10AA
(pMV261PstSI-X10AA)
LppX
(pMV261LppX)
LprN
(pMV261LprN)
PstSI
(pMV261PstSI)
Mpt83∆13AA+SS (pMV261Mpt83∆13AA+SS)
LppX-N10AA
(pMV261LppX-N10AA)
LppX-SI10AA
(pMV261LppX-SI10AA)
 
Table 3: Primer used in this study. GTT’AAC¦G”AATC: restriction sites (‘: HpaI, “: EcoRI), GG CGT AGT 
CGG GGA CGT CGT AGG GGT: HA-tag. 
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Abstract 
Lipoproteins of Gram-negative and Gram-positive bacteria carry a thioether-bound 
diacylglycerol but differ by a fatty acid amide bound to the α-amino group of the universally 
conserved cysteine. In Escherichia coli the N-terminal acylation is catalyzed by the N-
acyltransferase Lnt. Using E. coli Lnt as a query in a BLASTp search, we identified putative 
lnt genes also in Gram-positive mycobacteria. The Mycobacterium tuberculosis lipoprotein 
LppX, heterologously expressed in Mycobacterium smegmatis, was N-acylated at the N-
terminal cysteine, whereas LppX expressed in a M. smegmatis lnt::aph knock-out mutant was 
accessible for N-terminal sequencing. Western blot analyses of a truncated and tagged form of 
LppX indicated a smaller size of about 0.3 kDa in the lnt::aph mutant compared with the 
parental strain. Matrix-assisted laser desorption ionization time-of-flight/time-of-flight 
analyses of a trypsin digest of LppX proved the presence of the diacylglycerol modification in 
both strains, the parental strain and lnt::aph mutant. N-Acylation was found exclusively in the 
M. smegmatis parental strain. Complementation of the lnt::aph mutant with 
M. tuberculosis ppm1 restored N-acylation. The substrate for N-acylation is a C16 fatty acid, 
whereas the two fatty acids of the diacylglycerol residue were identified as C16 and C19:0 
fatty acid, the latter most likely tuberculostearic acid. We demonstrate that mycobacterial 
lipoproteins are triacylated. For the first time to our knowledge, we identify Lnt activity in 
Gram-positive bacteria and assigned the responsible genes. In M. smegmatis and M. 
tuberculosis the open reading frames are annotated as MSMEG_3860 and M. tuberculosis 
ppm1, respectively. 
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INTRODUCTION 
Proteins of various organisms are modified in numerous ways, one of them is lipidation. Lipid 
modification of proteins is common in eucaryal and bacterial organisms and can involve 
myristoyl, palmitoyl, and isoprenyl polymers of various lengths or aminoglycan-linked 
phospholipids (1, 2). Lipoprotein modifications investigated here are restricted to bacteria. 
The lipoprotein biosynthesis pathway is a major virulence factor in Mycobacterium 
tuberculosis, the causative agent of human tuberculosis. Every year 1.6 million people fall 
prey to tuberculosis and one-third of the population of the world are infected. Thus, 
tuberculosis is responsible for 2.5% of deaths in the world, which is the highest rate claimed 
by a single infectious agent. An M. tuberculosis knock-out mutant deficient in lipoprotein 
signal peptidase lspA showed reduced multiplication in bone marrow-derived macrophages, 
complete absence of lung pathology and a 1000-fold reduced number of colony forming units 
in a mouse model of infection (3, 4). Likewise, lipoprotein synthesis contributes to virulence 
of other Gram positive pathogens, Listeria, Staphylococci, and Streptococci (5).  
Bacterial lipoproteins are a functionally diverse class of lipidated proteins involved in cell 
wall synthesis, nutrient uptake, adhesion, and transmembrane signaling (6) and about 2% of 
open reading frames encode this kind of proteins (7). Lipidation allows anchoring of these 
proteins to the cell surface. Lipoproteins are characterized by the presence of a consensus 
sequence, the “lipobox,” located in the C-terminal part of the leader sequence and consisting 
of four amino acids (LVI/ASTVI/GAS/C) (7). Precursor lipoproteins are mainly translocated 
in a Sec-dependent manner across the plasma membrane and modified subsequently on the 
universally conserved, essential cysteine residue located in the lipobox motif. The 
modifications taking place after translocation are consecutively mediated by three enzymes: 
1) formation of a thioether linkage between the conserved cysteine residue and a 
diacylglycerol catalyzed by phosphatidylglycerol:pre-prolipoprotein diacylglycerol 
transferase (Lgt), 2) cleavage of the N-terminal signal peptide by the prolipoprotein signal 
peptidase/signal peptidase II (LspA), and 3) in the case of Gram-negative bacteria, 
aminoacylation of the N-terminal cysteine residue by phospholipid: apolipoprotein N-
acyltransferase (Lnt) (6–8). In Escherichia coli, most of the mature triacylated lipoproteins 
are finally transported across the periplasm by the LolABCDE transport system (9). 
Homologues of the Lol-transport system are absent in Mycobacteria. Although lipoprotein 
modifying enzymes act sequentially, Lgt-independent LspA-mediated signal sequence 
cleavage has recently been demonstrated in Listeria monocytogenes (10). Although Lgt and 
LspA are universally present in both Gram-positive and Gram-negative bacteria, Lnt has been 
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reported to be restricted to Gram-negative bacteria (11), although some indications for N-
acylation in Bacillus subtilis and Staphylococcus aureus were reported (12–15). 
Mycobacterial lipoproteins are immunodominant antigens (16) and several manipulate innate 
immune mechanisms and antigen presenting cells (17). It is known that mycobacterial 
lipoproteins, e.g. the 19-kDa lipoprotein, activate Toll-like receptor 2 (TLR2) and co-
receptors TLR1, which recognize triacylated peptides, but also TLR6, which recognize 
diacylated peptides (18, 19). However, the lipid linkage of mycobacterial lipoproteins has not 
been determined. In this study, we show that Lnt activity is more widely distributed than 
previously assumed. We demonstrate apolipoprotein N-acyltransferase activity in a Gram-
positive Mycobacterium and give complete structural information about the lipid modification 
of mycobacterial lipoproteins. Hereby, the functionality of Lnt homologues in actinomycetes 
is revealed (5). We show that mycobacterial lipoproteins are triacylated and carry 
mycobacteria-specific fatty acids.  
 
EXPERIMENTAL PROCEDURES 
Bacterial Strains and Growth Conditions—Mycobacterium smegmatis was grown on 
Middlebrook 7H10 agar supplemented with oleic acid albumin dextrose (OADC, Difco) or 
LB agar. Tween 80 (0.05%) was added to liquid broth to avoid clumping; when appropriate, 
antibiotics were added at the following concentrations: 50 µg ml-1 kanamycin, 100 µg ml-1 
streptomycin, and 25µg ml-1 hygromycin. Strain designations were as follows: M. smegmatis 
SmR5 (20), a derivative of M. smegmatis mc2 (21) carrying a non-restrictive rpsL mutation 
conferring streptomycin resistance (=parental strain); lnt::aph = lnt knock-out mutant; 
lnt::aph-lntMs = M. smegmatis lnt::aph transformed with complementing vector pMV361- 
hyg-lntMs; lnt::aph-ppm1Tb = M. smegmatis lnt::aph transformed with complementing vector 
pMV361-hyg-ppm1Tb. 
Complementation of Conditional E. coli lnt Mutant PAP8508— LntMs was amplified by PCR 
and cloned into the EcoRI/BamHI sites of pUC18 resulting in pUC18-lntMs. Plasmids 
pUC18- lntMs323W, pUC18-lntMs477Y, and pUC18-lntMs323W/ 477Y were generated by 
standard mutagenesis PCR techniques. The E. coli conditional lnt mutant PAP8508 and its 
parental strain PAP105 (a generous gift of N. Buddelmeijer) were used for complementation 
analysis (22). Strains were plated on LB agar supplemented with 1 mM isopropyl 1-thio-β-D-
galactopyranoside, 100µg/ml ampicillin, and either 0.4% (w/v) glucose or 0.2% (w/v) 
arabinose. 
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Disruption of lnt in M. smegmatis—A 3.8-kbp genomic fragment of M. smegmatis from 
position 3,929,396 to 3,933,223 spanning the entire lntMs gene was PCR amplified and 
cloned into pGem-T Easy (Promega) to result in pGem-T Easy-lntMs. For functional 
inactivation of lntMs, a 1.04-kbp SfiI/EcoRV fragment was replaced with a 1.4-kbp 
SnaBI/HpaI kanamycin resistance cassette from pUC4K (GE Healthcare) subcloned in 
pMCS5-Kan.2 Subsequently a 4.6-kbp PvuII fragment containing the inactivated lntMs allele 
(lntMs::aph) was inserted into the EcoRV site of ptrpA1-rpsL (20) to result in ptrpA1- rpsL-
lntMs::aph. The lntMs::aph allele was substituted for lntMs in the M. smegmatis chromosome 
as described previously (23) and confirmed by Southern blot analyses with a 0.2-kbp 
SmaI/NcoI lntMs upstream probe. 
For complementation with M. smegmatis lnt, a 4.3-kbp PvuII fragment from pGem-T Easy-
lntMs comprising the entire lntMs gene was cloned into the HpaI site of plasmid pMV361- 
hyg (24) to result in pMV361-hyg-lntMs. For complementation with M. tuberculosis ppm1 a 
6.3-kbp fragment from M. tuberculosis genomic position 2,306,187 to 2,312,526 spanning the 
entire ppm1 gene was cloned into pGem-T Easy to result in pGem-T Easy-ppm1Tb and 
subsequently subcloned as a 6.3- kbp EcoRI fragment into the HpaI site of plasmid pMV361-
hyg (24) to result in pMV361-hyg-ppm1Tb. Complementation was confirmed by Southern 
blot analyses with a 0.2-kbp SmaI/NcoI lntMs upstream probe and a 0.2-kbp KpnI/HindIII 
ppm1Tb upstream probe. 
Construction of Expression Vector pMV261-Gm-FusLppX— Plasmid pMV261-Gm, a 
derivative of pMV261, is a shuttle vector replicating in E. coli as well as in mycobacteria 
(25). M. tuberculosis LppX was amplified by PCR from genomic DNA and fused to the 
M. tuberculosis 19-kDa promoter. Two sequences encoding a hemagglutinin and a His6 
epitope were fused to the 3’ part of the gene to facilitate subsequent purification and detection 
on Western blot and the insert was cloned into the EcoRI site to result in pMV261-Gm-
FusLppX. 
Preparation of Cell Extracts and Western Blot Analysis—Bacteria from 2-liter cultures were 
harvested, resuspended in phosphate- buffered saline containing Complete EDTA-free tablets 
(Roche) to inhibit protein degradation, and subjected to two French press cycles (American 
Instrument Co.) at 2 x 108 pascal. Extracts were treated with 2% sodium N-lauroylsarcosine 
for 1 h at room temperature and subsequently incubated at 4 °C overnight. Soluble and 
insoluble fractions were separated by centrifugation at 30,000 x g for 1 h at 4 °C. Extracts 
corresponding to 1–5 µg of total protein were separated by SDSPAGE (12%) and analyzed by 
Western blot. Antiserum against the HA3 epitope (Roche) was diluted 1:300.  
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Fast Protein Liquid Chromatography Protein Purification— The soluble fraction of cell 
extracts was diluted with buffer containing 20 mM NaH2PO4, 0.5 M NaCl to 1% sodium N-
lauroylsarcosine and loaded on a HisTrapTM HP column (GE Healthcare) equilibrated with 
buffer containing 20 mM NaH2PO4, 0.5 M NaCl, 0.2% sodium N-lauroylsarcosine, and 
20 mM imidazole. Proteins were eluted with 0.125– 0.5 M imidazole. 
Thrombin Cleavage of RecLppX—Purified RecLppX was dialyzed against phosphate-
buffered saline, pH 7.4, at 4 °C because imidazole can lower thrombin activity (26). About 
0.1–1 µg of RecLppX was digested with 4–30 NIH units of thrombin from bovine plasma 
(Sigma) for 16 h at 37 °C with continuous shaking (25 rpm). The reaction was stopped 
through incubation at 95 °C for 5 min.  
MALDI-TOF/TOF—Purified lipoprotein (100–200 pmol) were prepared and analyzed 
according to Ujihara et al. (27). After tryptic digestion samples were resuspended in 5 µl of 
0.1% trifluoroacetic acid, 66% acetonitrile. 1.2 µl were loaded onto the target and covered 
with 1 µl of matrix (α-cyano-4-hydroxycinnamic acid (Bruker Daltonics), 5 mg/ml in 0.1% 
trifluoroacetic acid, 50% acetonitrile). Mass spectra were recorded on an Ultraflex II MALDI-
TOF/TOF instrument with smartbeam laser upgrade (Bruker, Germany). The frequencytripled 
Nd:YAG laser using a structured-focus profile (smartbeam, Bruker Daltonics) was set to a 
repetition rate of 100 Hz and the ion acceleration voltage was 29.5 kV. The mass 
measurements were performed in the positive ion reflector mode.  
 
RESULTS  
Mycobacterial Lipoproteins Are Modified at the N-Terminus— We chose the well 
characterized M. tuberculosis lipoprotein LppX (28) as a model substrate for mycobacterial 
lipoprotein synthesis and generated the expression vector pMV261-Gm-FusLppX. Plasmid 
pMV261-Gm-FusLppX was transformed into M. smegmatis SmR5 (20), M. smegmatis ∆lspA, 
and complemented M. smegmatis ∆lspA-lspA. Whole cell extracts of these strains were 
subjected to Western blot analysis with anti-HA antibody. We observed bands with an 
apparent size of 23 kDa in parental and complemented strains and 26 kDa in the ∆lspA mutant 
and to a small amount also in the parental strain. After purification of LppX, the 26-kDa band 
was also detected to a higher amount in the parental strain. The 23-kDa band corresponds to 
the predicted mass of mature recombinant LppX-HA-His and 26-kDa band to the predicted 
mass of the prolipoprotein form of LppX-HA-His. These results indicate LspA-dependent 
signal peptide cleavage of recombinant LppX-HA- His in M. smegmatis and verify its post-
translational modification within the lipoprotein synthesis pathway (Fig. 1a). 
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FIGURE 1. Western blot analysis of LppX. a, total lysates of the M. smegmatis parental strain, ∆lspA, ∆lspA-
lspA expressing LppX with HA and the His6 epitope analyzed with mouse anti-hemagglutinin monoclonal 
antibody; b, amino acid sequence of LppX-HA-His. Inverted commas show trypsin cleavage sites. The arrow 
shows the +1 cysteine modified by Lgt and Lnt. Bold letters indicate the signal sequence cleaved off by LspA 
reducing the molecular mass by 2.6 kDa. Italic letters indicate the modified tryptic peptide in the ∆lspA mutant, 
underlined is the N-terminal tryptic peptide found in the M. smegmatis parental strain, lnt::aph mutant, and 
lnt::aph-ppm1Tb.  
 
Purified LppX-HA-His from the M. smegmatis parental strain was subjected to protein 
sequence analysis. Edman degradation of the prolipoprotein revealed a sequence starting at 
the initial methionine of the signal peptide of LppX (Fig. 1b). In contrast, no sequence was 
obtained from the mature LppX indicating a modification of the N-terminal amino group. 
Identification of Putative N-Acyltransferases in Bacterial Genomes—In E. coli, N-acylation 
of lipoproteins is conferred by Lnt (29). We performed a BLAST search analysis with E. coli 
Lnt as a query to investigate the distribution of Lnt homologues in the bacterial kingdom and 
to identify putative homologues in mycobacteria. Lnt homologues are widely distributed in 
Gram-negative bacteria (α, β, γ, ∆, ε Proteobacteria, Spirochetes, Aquifex, Cytophaga, and 
Thermotoga), but absent from all classes (Clostridia, Mollicutes, and Bacilli) of low GC 
Gram-positive bacteria (Firmicutes), although some indications for N-acylation in low GC 
Gram-positive bacteria have been reported (12–15). In contrast, Lnt homologues were 
identified in all classes of high GC Gram-positive bacteria (Actinobacteria, e.g. Streptomyces, 
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Nocardia, Corynebacteria, and Mycobacteria) (Fig. 2a), but Lnt activity of those homologues 
could not be demonstrated (22). The cell envelope of the phylum Actinobacteria is more 
complex than the cell envelope of Firmicutes. In M. tuberculosis and M. smegmatis, Rv2051c 
(Ppm1) and MSMEG_3860 (Ppm2) have the highest similarity to E. coli Lnt. M. tuberculosis 
Rv2051c encodes a two-domain protein, of which the N-terminal part shows similarity to 
E. coli Lnt. The C-terminal part of the protein encodes a polyprenol-monophosphomannose 
(Ppm) synthase, an enzyme involved in lipomannan and lipoarabinomannan synthesis (30). 
MSMEG_3860 has been shown to stabilize M. smegmatis Ppm1 in the bacterial membrane 
and therefore has been annotated as Ppm2 (31). MSMEG_3860 will be referred to here as 
LntMs. Lnt homologues are also present in Mycobacterium avium and Mycobacterium leprae 
and are encoded by a separate open reading frame as in M. smegmatis. The genomic region 
surrounding Lnt homologues is conserved in mycobacteria (Fig. 2b). 
M. smegmatis Lnt Does Not Restore Growth of a Conditional E. coli lnt Mutant—All 
enzymes of the lipoprotein synthesis pathway are essential in Gram-negative bacteria. We 
intended to demonstrate mycobacterial Lnt activity by complementation of an E. coli 
conditional lnt mutant. Because LntMs is encoded by a separate open reading frame and not 
fused to a second domain as in M. tuberculosis, we chose M. smegmatis Lnt (MSMEG_3860) 
instead of M. tuberculosis Ppm1 (Rv2051c) for complementation. LntMs encodes a protein of 
654 amino acids with a 25% identity and 40% similarity to E. coli and a 63% identity and 
73% similarity to the N-terminal part of M. tuberculosis Rv2051c. LntMs was cloned into 
vector pUC18 (Fermentas) to result in pUC18-lntMs and transformed into the conditional E. 
coli lnt mutant PAP8508 (22).  
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FIGURE 2. Lnt-BLASTp. a, E. coli Lnt was used as a query to identify homologues on the National Center for 
Biotechnology Information BLASTp server. The sequence filtering option was switched off and the expect value 
was set at 10, the cut-off value set at 10-4. b, a comparison of the genomic region of Lnt (black) and Ppm1 (gray) 
homologues in mycobacteria.  
 
However, we could not restore growth of the PAP8508 mutant under restrictive conditions 
(data not shown). Seven amino acids (Trp-237, Glu-267, Lys- 335, Glu-343, Cys-387, Tyr-
388, and Glu-389) are reported to be essential for E. coli Lnt function (22). Five of these 
seven residues are conserved in LntMs, whereas two are altered (LntEc Trp-237 corresponds 
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to LntMs Glu-323, LntEc Tyr-388 corresponds to LntMs Trp-477). We exploited site-directed 
mutagenesis to introduce these E. coli codons into the M. smegmatis sequence of pUC18-
lntMs to result in pUC18- lntMs323W, pUC18-lntMs477Y, and pUC18-lntMs323W/477Y. 
However, transformation of none of these vectors complemented the conditional E. coli lnt 
mutant (data not shown). 
Generation and Characterization of M. smegmatis lnt::aph Mutant— Because we were 
unable to complement an E. coli lnt mutant, we decided to investigate Lnt activity directly in 
mycobacteria by generating a M. smegmatis lnt deletion mutant. The deletion mutant was 
constructed by transformation of M. smegmatis SmR5 with the suicide plasmid ptrpA1-
rpsLlntMs:: aph using rpsL counter-selection strategy (20). The mutant strain resulting from 
allelic replacement is here referred to as M. smegmatis lnt::aph. Deletion of lntMs was 
verified by Southern blot analysis using a 5’ lntMs DNA probe (supplemental Fig. S1). The 
probe hybridized to a 1.4-kbp fragment of the parental strain and a 6.4-kbp fragment of the 
lnt::aph mutant. The difference in size results from the deletion of a BstEII restriction site and 
insertion of a kanamycin resistance cassette. We cloned two complementation vectors 
(pMV361- hyg-lntMs and pMV361-hyg-ppm1Tb) expressing M. smegmatis Lnt and 
M. tuberculosis Ppm1 under control of their native promoters. Transformation of these 
plasmids into the M. smegmatis lnt::aph mutant resulted in strains M. smegmatis lnt::aph-
lntMs and M. smegmatis lnt::aph-ppm1Tb. 
Western blot analysis of extracts from M. smegmatis lnt::aph expressing LppX-HA-His 
revealed a molecular mass of the detected protein, which cannot be distinguished from that of 
LppX-HA-His expressed in the M. smegmatis parental strain. However, N-terminal 
sequencing revealed that LppX-HA-His purified from M. smegmatis lnt::aph is accessible to 
Edman degradation (sequence CSSP) indicating that the N-terminal amino group is not still 
blocked. 
LntMs and Ppm1Tb Are Apolipoprotein N-Acyltransferases— Because fatty acids of 
membrane phospholipids are the substrates for N-acylation of lipoproteins in E. coli (32–34), 
its lipoproteins are modified with myristic, palmitic, palmitoleic, oleic, or vaccinic acid (35). 
Phospholipids in mycobacteria mainly consist of palmitic, palmitoleic, oleic, and 
tuberculostearic acid (10-methyloctadecanoic acid) (36). Therefore we hypothesized that N-
acylation of lipoproteins in mycobacteria increase the molecular mass by ~0.3 kDa. To 
differentiate between lipoproteins with a free or acylated N terminus, we cloned an additional 
expression vector, RecLppX. It differs from LppX-HA-His by a hemagglutinin epitope 
followed by a thrombin cleavage site inserted after amino acid Ala (+19) of the mature LppX 
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(Fig. 1b). The thrombin cleavage site LVPRGS was inserted to produce a small N-terminal 
fragment of 33 residues (about 3.5 kDa) after thrombin cleavage. To ensure that the insertion 
of a HA epitope and a thrombin site does not abolish recognition of RecLppX as a 
lipoprotein, we analyzed total lysates of the M. smegmatis parental strain, M. smegmatis 
∆lspA, and M. smegmatis ∆lspA-lspA by Western blot (Fig. 3a). 
 
 
FIGURE 3. Western blot analysis of RecLppX. a, total lysates of M. smegmatis wild type (wt), ∆lspA, and 
∆lspA-lspA expressing RecLppX with hemagglutinin and the His6 epitope analyzed with mouse anti-
hemagglutinin monoclonal antibody. b, RecLppX isolated from indicated strains was digested with thrombin and 
analyzed with mouse anti-hemagglutinin monoclonal antibody.  
 
Temperature-sensitive lspA mutants of E. coli and lspA knock-out mutants of Gram-positive 
bacteria accumulate prolipoproteins (37, 38). Immunoblotting of total lysates of the 
M. smegmatis parental strain, ∆lspA and ∆lspA-lspA with antiserum against the HA epitope 
(Roche) revealed the presence of a 25-kDa band in parental and complemented strains. In 
contrast, a band with a slightly larger size (approximately 27 kDa, the increase corresponds to 
the mass of the signal sequence) was observed in the ∆lspA strain. This result shows that 
insertion of a HA epitope and a thrombin cleavage site did not impair the recognition of 
RecLppX as a lipoprotein. We then investigated thrombin-digested RecLppX for Lnt-
dependent modification by Western blot analyses (Fig. 3b). In the lnt::aph mutant we 
observed a slightly smaller size of the N-terminal part of RecLppX suggesting, that there are 
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fewer modifications on the protein compared with the parental strain and both complemented 
strains lnt::aph-lntMs and lnt::aph-ppm1Tb. In all strains, we also found a double band of the 
N-terminal part of RecLppX, indicating partial modification of RecLppX by enzymes other 
than Lnt or LspA. We also observed a deviation from the calculated size of the N-terminal 
part of mature RecLppX. The molecular mass was calculated to be 3.5 kDa but in the parental 
strain we found a band corresponding to a size of about 6 kDa. This difference in size is 
probably due to an altered migration behavior because of lipid modifications. It can be 
excluded that these bands at 6 kDa are prolipoprotein forms, still containing the signal 
peptide, because the N-terminal part of pro-RecLppX from the ∆lspA mutant is running at 
about 8.5 kDa. These results show that RecLppX is modified by LspA as well as LntMs. 
Ppm1Tb is sufficient to replace LntMs implicating that similar lipoprotein modifications take 
place in M. tuberculosis. Recombinant M. tuberculosis LppX (FusLppX) was heterologously 
expressed and purified. Tryptic fragments of FusLppX were analyzed by MALDI-TOF/TOF 
mass spectrometry to characterize modifications taking place on lipoproteins in M. smegmatis 
at the molecular level. Purified mature LppX from parental strain, lnt::aph mutant, and 
lnt::aph-ppm1Tb was prepared for analysis according to Ujihara et al. (27). For identification 
of the modifications of the universally conserved cysteine, the structure of the N-terminal 
tryptic peptide was determined. Experimentally found m/z values are summarized and 
compared with calculated m/z values in Table 1. 
 
Peptide Calculated Parental strain lnt::aph lnt::aph-ppm1Tb
m/z
CSS...EIR 2964.46
CSS...EIR
    +Diacyglycerol (C19, C16)
3557.01
(+592.54)
3557.01
(+592.55)
3557.07
(+592.61)
CSS...EIR
    +Diacyglycerol (C19, C16)
    +N -acyl (C16)
3795.24
(+830.77)
3795.42
(+830.95)
3795.32
(+830.86)
TABLE 1
Comparison of m/z values of LppX N-terminal tryptic peptides found in the different mutants
CSS...EIR corresponds to the N-terminal tryptic peptide of LppX upon cleavage of the signal peptide by LspA (Fig. 1b). Mass differences to 
the corresponding unmodified peptide (upper row) due to modifications are given in paren-theses. Observed modifications are: diacylglycerol 
with a C16 fatty acid and tuberculostearic acid (C19:0) (+ 592.54 Da), plus eventually N -acyl with C16 fatty acid (+ 238.23 Da, Σ = 830.77 
Da).
 
 
Trypsin cleavage sites of LppX are given in Fig. 1b. The expected monoisotopic molecular 
mass of the unmodified N-terminal tryptic peptide of LppX is 2963.46 Da. Instead, we found 
a [M + H]+ signal at m/z = 3795.42 for the N-terminal tryptic peptide of LppX from the 
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parental strain and a signal at m/z = 3557.01 from the lnt::aph mutant. The N-terminal tryptic 
peptide from lnt::aph-ppm1Tb is a mixture and showed signals of m/z = 3795.32 and 3557.07 
(Fig. 4). This indicates that the N-terminal peptide of LppX is modified in an LntMs-
dependent manner. To identify the found modification, we calculated diacylglycerol 
modifications with all theoretical combinations of the four fatty acids found in mycobacterial 
phospholipids: palmitic acid (C16:0), palmitoleic acid (C16:1), oleic acid (C18:1), and 
tuberculostearic acid (C19:0). The difference in molecular mass between the peptide of the 
lnt::aph mutant and the unmodified peptide is 592.55 Da indicating a diacylglycerol 
modification with ester-linked C19:0 and C16:0 fatty acid. These fatty acids are most likely 
tuberculostearic acid and palmitic acid. The difference in molecular mass of 238.41 Da 
between the lnt::aph mutant (m/z = 3557.07) and parental strain (m/z = 3795.42) indicates an 
additional modification with a C16:0 fatty acid in the parental strain. By thoroughly analyzing 
the signal at m/z = 3795.42 in high resolution, we also observed a minor signal 
(approximately 10%) at m/z = 3793.35. This indicates the presence of a C16:1 fatty acid in 
place of the C16:0 fatty acid, but only a small amount (data not shown). In the complemented 
mutant lnt::aph-ppm1Tb both forms of the N-terminal tryptic peptide of LppX were found. 
This finding indicates partial complementation of LntMs by M. tuberculosis Ppm1. In the 
lnt::aph and the lnt::aph-ppm1Tb mutant we additionally found an N-terminal tryptic peptide 
at m/z = 3739.18 and 3739.32, respectively. But no evidence for an aminoacyl modification 
was found in the MS/MS fragmentation pattern. In contrast, the release of 183 Da most likely 
corresponds to a covalent modification of the free N-terminal amino group of LppX in these 
two strains with 4-(2-aminoethyl)-benzenesulfonyl fluoride, a component of the protease 
inhibitor mixture that has been used. 4-(2-Aminoethyl)-benzenesulfonyl fluoride is known to 
modify hydroxylated amino acids and to a lesser extent also free amino groups. 
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FIGURE 4. MALDI-TOF analysis of a trypsin digest of purified LppX. MS analysis of LppX tryptic peptides 
purified from the M. smegmatis parental strain (1); M. smegmatis lnt::aph (2), and M. smegmatis lnt::aph-
ppm1Tb (3). Filled triangle, diacylglycerol plus N-acyl modified N-terminal peptide; open triangle, 
diacylglycerol-modified N-terminal peptide.  
 
To obtain information about linkage of the modifications, the structure of the triacylated N-
terminal tryptic peptide of LppX (m/z ± 3795.42) was investigated by MS/MS (Figs. 5 and 
supplemental S2). A summary of all found eliminations in the three strains are given in Table 
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2. The ions at m/z = 3539.59 and 3496.52 correspond to the neutral loss of a C16 (∆ = 255.82 
Da) and a C19:0 fatty acid (∆ = 298.89 Da), respectively. The most intense fragment ion at 
m/z ± 3169.21 corresponds to the elimination of a diacylthioglycerol carrying both O-linked 
C19:0 and C16 fatty acids (∆ = 626.22 Da). In addition, the release of 370.38 Da from the ion 
at m/z = 3539.59 corresponds to the elimination of a C19:0 fatty acid α-thioglycerol ester and 
the release of 327.31 Da from the ion at m/z = 3496.52 corresponds to the elimination of a 
C16 fatty acid α-thioglycerol ester. This fragmentation pattern shows that the +1 cysteine is 
modified at the sulfhydryl group by a diacylglycerol residue carrying esterbound C16 fatty 
acid and C19:0 fatty acid. Whether the C19:0 fatty acid is in the Sn1 or Sn2 position cannot be 
determined. The release of 255.08 Da from the ion at m/z = 3169.21 indicates the release of a 
palmitamide derived from an amide-bound C16 fatty acid. The MS/MS fragmentation pattern 
of the LppX N-terminal tryptic peptide of the lnt::aph mutant (m/z = 3557.07) showed only 
the elimination of the diacylthioglycerol, but no release of palmitamide, as expected (Fig. 5). 
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FIGURE 5. MALDI-TOF-TOF analysis of the N-terminal peptides of LppX. MS/MS analysis of N-terminal 
peptides of LppX purified from M. smegmatis parental strain (1), M. smegmatis lnt::aph (2), and M. smegmatis 
lnt::aph-ppm1Tb (3). A schematic drawing of the modified +1cysteine with the cleavage sites of each identified 
m/z signal is depicted in the upper part of each spectrum. The eliminated fragments of LppX modifications are 
shown on the right side of the spectrum (1): ➀, palmitic acid; ➁, tuberculostearic acid; ➂, diacylthioglycerol; ➃, 
tuberculostearic acid α-thioglycerol ester; ➄, palmitic acid α-thioglycerol ester; ➅, palmitamide. Note that the 
ester-linked palmitic acid and tuberculostearic acid may be coupled to either positions Sn1or Sn2. Only one 
conformation is depicted.  
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To verify the diacylglycerol modification, we also analyzed tryptic peptides of LppX from the 
∆lspA mutant by MALDITOF/ TOF mass spectrometry (Fig. 6). Experimentally found m/z 
values are summarized and compared with calculated m/z values in Table 3. Trypsin cleavage 
sites of pro-LppX are given in Fig. 1b. We found three m/z signals corresponding to the 
tryptic peptide containing the +1 cysteine. The signal at m/z = 4887.30 corresponds to the 
peptide with a disulfide bridge between the two present cysteines (position +8 and +1). The 
signal at m/z = 5041.23 corresponds to the peptide with both cysteines being modified by β-
mercaptoethanol, a buffer component used for SDS-PAGE. The signal at m/z = 5558.12 
corresponds to the peptide with one cysteine being modified with a β-mercaptoethanol but the 
other being modified with the diacylglycerol carrying O-linked C16 and C19:0 fatty acids 
also found in the previously analyzed strains (Fig. 6). 
 
Modification Eliminated fragment Calculated mass of 
eliminated fragmenta
Parental strain lnt::aph lnt::aph-ppm1Tb
Da Da
O -Linked palmitoyl Palmitic acid 256.24 255.84 256.36 255.68
N -Linked palmitoyl Palmitamide 255.26 255.08 255.8
O -Linked tuberculostearyl Tuberculostearic acid 298.29 298.92
Diacylglycerol (C16, C19) Diacylthioglycerol (C16, C19) 626.53 626.22 626.78 626.16
C16 fatty acid α-thioglycerol ester 328.24 327.3
Tuberclostearic α-thioglycerol ester 370.29 370.38 370.43 370.48
a
 Calculated masses are monoisotopic masses.
Experimentally determined mass
of eliminated fragment
TABLE 2
Comparison of experimentall determined eliminations from N-terminal tryptic peptides of LppX in the MALDI-TOF/TOF spectra of the 
different mutants with theoretically calculated eliminations
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FIGURE 6. MALDI-TOF analysis of peptides resulting from trypsin digestion of LppX from ∆lspA mutant. MS 
analysis of LppX tryptic peptides purified from the M. smegmatis ∆lspA mutant. Asterisk, N-terminal peptide 
without fatty acid modifications; open triangle, diacylglycerol modified N-terminal peptide.  
 
Peptide Calculated ∆lspA
m/z
AVT...EIR with unmodified cysteines 4888.55
AVT...EIR with S-S 4886.53 4887.3
AVT...EIR
    + 2X Mercaptoethanol
5040.54
(+152.00)
5041.23
(+152.68)
AVT...EIR
    + 1X Mercaptoethanol
    + Diacylglycerol (C19, C16)
5557.09
(+668.54)
5558.12
(+669.57)
TABLE 3
Comparison of m/z  values of tryptic peptides of pro-LppX containing the +1 cysteine found in the 
∆lspA  mutant
AVT...EIR corresponds to the tryptic peptide of pro-LppX containing the +1 cysteine (Fig 1b). Mass 
differences to the corresponding unmodified peptide due to modifica-tions are given in parentheses. 
Observed modifications are: diacylglycerol with C16 and C19 fatty acid (+ 592.54 Da), β-mercaptoethanol 
(+ 76.00 Da).
 
 
This result shows that LppX purified from the ∆lspA mutant is a mixture of pre-pro-LppX and 
pro-LppX. Taken together the results show that the universally conserved cysteine of 
M. tuberculosis LppX is modified with a thioether-linked diacylglycerol residue carrying an 
ester-bound C19:0 and an esterbound C16 fatty acid. In addition, it is modified with an 
amide-linked third C16 fatty acid. The C19:0 fatty acid corresponds most likely to the 
mycobacterial specific tuberculostearic acid. It is also proved that LntMs is an N-
CHAPTER 3 84 
acyltransferase and M. tuberculosis Ppm1 is able to complement the M. smegmatis lnt::aph 
mutant and therefore Ppm1 seems to be a bifunctional protein. Within this protein the N-
terminal domain presumably exhibits N-acyltransferase activity (our data) and the C-terminal 
domain exhibits mannosyltransferase activity (30).  
 
DISCUSSION 
The lipoprotein biosynthesis pathway consisting of the three enzymes Lgt, LspA, and Lnt has 
been intensively studied in E. coli and has been shown to be essential and necessary for 
transport of lipoproteins to the outer membrane of Gram-negative bacteria (11, 39, 40). In 
mycobacteria, little is known about synthesis and localization of lipoproteins, only a few 
lipoproteins are functionally characterized and annotation is mainly based on theoretical 
considerations instead of experimental evidence. However, consistent with the biosynthetic 
pathway in E. coli, putative lgt (Rv1614) and lsp (Rv1539) genes have been identified in the 
M. tuberculosis genome (41). In previous studies (3, 4) we showed that in mycobacteria the 
lipoprotein pathway is a major virulence factor. For fundamental knowledge and further 
investigations, we were interested in how lipoproteins are modified in mycobacteria. In the 
present study, we investigated the lipid moieties of a representative mycobacterial lipoprotein. 
We identified Lnt homologues in mycobacteria, corynebacteria, and streptomyces species. In 
low GC Gram-positive bacteria Lnt homologues are completely absent (Fig. 2), but in 1985 
the first indirect detection of N-acylation in the Gram-positive B. subtilis was published and in 
S. aureus triacylation of lipoprotein SitC was recently reported (14, 15), whereas another 
lipoprotein (SAOUHSC_02699) was only found to be diacylated (13). The protein 
responsible for attaching the third fatty acid to lipoproteins in S. aureus has not been 
identified. It may be differentially expressed depending on culture conditions or may have a 
narrow substrate specificity. In M. tuberculosis the Lnt homologue found is annotated as 
Rv2051c. This open reading frame was originally annotated as a two-domain enzyme with a 
putative N-terminal Lnt domain and a C-terminal polyprenol monophosphomannose synthase 
(Ppm1) domain and was characterized as the latter one (30). Although the putative Lnt 
domain is not needed for Ppm1 activity, on overexpression in M. smegmatis it appeared to 
enhance the mannosyltransferase activity. Interestingly, the two domains of M. tuberculosis 
Ppm1 are encoded by separate, adjacent open reading frames in the genomes of other 
mycobacteria (Fig. 2b). 
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Previous attempts to complement a conditional E. coli lnt mutant with Lnt homologues from 
other bacterial species corresponding to the order Actinomycetales (Streptomyces and 
Corynebacterium) failed (22). Likewise we were unable to complement this E. coli strain with 
a mycobacterial Lnt homologue. Even after exchange of the two essential amino acids 
differing between M. smegmatis and E. coli, complementation of the E. coli lnt mutant failed. 
LntMs as E. coli Lnt attaches a C16 fatty acid to the free amino group of the universally 
conserved cysteine. Therefore the failure of complementation is not due to the absence of 
fatty acid substrates. Rather mycobacterial lipoproteins are modified with a diacylglycerol 
carrying mycobacterial specific fatty acids. Failure of complementation of PAP8508 therefore 
is probably due to the fact that LntMs recognizes only lipoproteins modified with a 
diacylglycerol residue carrying at least one ester-bound mycobacterial specific fatty acid. This 
implies that LntMs does not recognize lipoproteins modified with diacylglycerol residues 
carrying only small fatty acids like palmitic or palmitoleic acid. Specificity could be tested in 
an in vitro assay system. Alternatively, the expression level or enzymatic activity of 
mycobacterial Lnt homologues may not sustain growth of fast growing E. coli. 
We then investigated LntMs and M. tuberculosis Ppm1 activity in a mycobacterial 
background. As lntMs is not an essential gene in mycobacteria, we generated an isogenic 
M. smegmatis lnt::aph mutant. After thrombin cleavage, the recombinant lipoprotein 
(RecLppX) extracted from the M. smegmatis lnt::aph mutant showed a faster running 
behavior on SDSPAGE than RecLppX extracted from the parental strain. The size was about 
0.3 kDa smaller corresponding to fewer modifications of RecLppX in the lnt::aph mutant. We 
also recognized a double band of digested RecLppX in all strains used as well as a 
discrepancy between the calculated and the apparent molecular mass. The altered running 
behavior is probably due to the modifications on the small N-terminal fragment and the 
observed double band indicates partial processing of RecLppX by enzymes other than Lgt, 
LspA, or Lnt. Glycosylation of RecLppX is one possibility, but information about the 
structure, function, and biosynthetic pathways of prokaryotic glycoproteins is scarce. 
Glycosylation of M. tuberculosis lipoproteins has been confirmed for the 45/47 kDa protein, 
SodC, and for the Mycobacterium bovis MPB83 protein (Rv2873) (42–44). Glycosylation of 
SodC influences its ultimate subcellular localization and also its proteolytic processing. 
By performing MALDI-TOF/TOF analyses of a trypsin digest of purified LppX we 
unambiguously identified modifications at the universally conserved cysteine. After trypsin 
cleavage of LppX, the N-terminal peptide from the parental strain has a mass of 3794.41 Da 
instead of 2963.46 Da predicted for the unmodified peptide, whereas the N-terminal peptide 
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from the isogenic lnt::aph mutant showed a mass of 3556.01 Da. This strongly indicates that 
LntMs covalently links a C16 fatty acid (C16:0 or C16:1) to the N-terminus of the peptide. 
The additional increase by 592 Da corresponds to a diacylglycerol residue with C16 fatty acid 
and a C19:0 fatty acid, which corresponds most likely to tuberculostearic acid (10-
methyloctadecanoic acid), forming a thioether linkage to the sulfhydryl group of the cysteine. 
Whether the C19:0 fatty acid is in the Sn1 or Sn2 position cannot be determined. The same 
diacylglycerol modification was also found in the ∆lspA mutant. The loss of the N-acyl 
modification in the lnt::aph mutant is complemented by the M. tuberculosis homologue Ppm1 
suggesting that mature M. tuberculosis lipoproteins are N-acylated. N-Acylation affects the 
interaction of lipoproteins with innate immune receptors (45). Ppm1 was shown to exhibit 
polyprenol-monophosphomannose synthetase activity (30) although the major part of the 
protein has homology to E. coli Lnt. Both masses of the N-terminal tryptic peptide (3556.07 
and 3794.32 Da) were found in the complemented mutant indicating that not all 
apolipoprotein was converted to mature lipoprotein by Ppm1. As M. tuberculosis has a 
generation time of about 24 h and M. smegmatis only of about 3 h, it is possible that 
M. tuberculosis Ppm1 has a lower enzymatic activity than LntMs. Alternatively, the 
expression level of M. tuberculosis Ppm1 is lower than that of M. smegmatis Lnt. The 
identification of O-linked tuberculostearic acid shows that mycobacterial lipoproteins are 
modified with mycobacterial specific fatty acids and differ from lipoproteins modified in 
E. coli. 
In this study we directly show that Gram-positive mycobacteria synthesize triacylated 
lipoproteins. This is the first time to our knowledge that responsible genes for Lnt activity are 
assigned in Gram-positive bacteria. LntMs and M. tuberculosis Ppm1 are functional 
homologues of E. coli Lnt as they catalyze the transfer of the third acyl moiety to the free α-
amino group of the N-terminal amino acid of lipoproteins. Most likely mycobacterial Lnt 
homologues differ in substrate specificity from E. coli Lnt. N-Acylation is a prerequisite for 
transport of E. coli lipoproteins to the outer membrane (46). Likewise, N-acylation of 
mycobacterial lipoproteins may be required for transport to the outer most lipid layer of 
mycobacteria, which according to recent investigations resembles the outer membrane of 
Gram-negative bacteria (47, 48).  
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Addendum 
 
Personal contribution to chapter 3 
In this article, the expression of M. tuberculosis lipoprotein LppX, heterologously expressed 
in M. smegmatis was exploited with respect to N-terminal modifications at the molecular 
level. The lipoprotein biosynthesis pathway of the Gram-negative bacterium E. coli was 
intensively studied previously. It was shown that lipoprotein maturation is mediated by the 
consecutive activity of Lgt, which attaches a diacylglycerol unit to the sulfhydryl group of the 
universally conserved cysteine, LspA cleaves off the signal peptide and finally Lnt adds an 
acyl chain to the N-terminal cysteine. As Lnt was not identified in Gram-positive bacteria, 
triacylation was uniquely attributed to Gram-negative bacteria. By BLASTp search using 
E. coli Lnt as a query, the last enzyme of the lipoprotein biosynthesis pathway was identified 
in the Gram-positive genus of Mycobacterium. By comparison of LppX-expressing wildtype- 
or ∆lnt strains of M. smegmatis and MALDI-TOF/TOF analysis, it was shown that 
mycobacterial lipoproteins are triacylated and carry mycobacteria-specific fatty acids. 
 
My contribution as a second-last author to this manuscript was as follows: 
 
• Development of the fusion-PCR and linker-PCR strategy 
• Generation of the initial HA-tagged expression vector 
• Transformation into M. smegmatis wildtype-, ∆lgt-, ∆lspA- and ∆lnt strains 
• Expression control of the LppX-expressing strains of M. smegmatis 
• Analysis of the lipoprotein properties of HA-tagged LppX by TritonX114-
 extraction and LspA-dependent signal peptide cleavage by Western blot 
 Bioinformatic analysis 
• BLASTp search on a wide spectrum of bacteria to identify homologues of Lnt 
• Writing of parts of the paper 
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Abstract 
 
Lipoproteins are well known virulence factors of bacterial pathogens in general and of 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, in particular. 
Lipoprotein lipidation between Gram-positive and Gram-negative bacteria differs 
significantly as these are di- and triacylated, respectively. Little is known about the lipid 
anchor of mycobacterial lipoproteins. We reported recently that mycobacterial LppX, a 
lipoprotein involved in synthesis of cell wall components is triacylated, although 
mycobacteria are classified as GC-rich Gram-positive bacteria. We here exploited the model 
organism Mycobacterium smegmatis for the expression of Mtb LprF and characterized N-
terminal modifications at the molecular level. LprF is a putative lipoprotein of Mtb involved 
in signalling of potassium-dependent osmotic stress. LprF is extensively modified in a 
mycobacterium-specific manner by a thioether-linked diacylglyceryl residue with one ester-
bound tuberculostearic- and one C16:0 fatty acid and additionally by a third N-linked C16:0 
fatty acid, and a hexose. 
 
* These authors contributed equally to this work 
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Introduction 
Tuberculosis is a major cause of death around the world, with 9.3 million new cases and 1.8 
million deaths occurring in 2007, which is the highest rate claimed by a single bacterial 
pathogen (WHO TB-factsheet, 2009). The causative agent of the disease is Mtb, an acid-fast 
bacillus that is primarily transmitted via the respiratory route. The reasons for the pathogens 
extraordinary success are diverse: it is slow-growing which makes antibiotic treatment 
complicated and lenghty, it has a thick waxy cell wall and therefore is resistant to different 
kinds of mechanical and chemical stress and it evades the immune system by parasitizing the 
macrophages of its host. 
The high immunogenic potential of Mtb is based on its unusual cell envelope which is 
exceptionally rich in lipids, glycolipids and polysaccharides (Daffe & Draper, 1998). 
Amongst others, uncommon cell wall components like mycolic acids, mycocerosic acid, 
phenolthiocerol, lipoarabinomannan (LAM) and arabinogalactan trigger inflammatory host 
reactions (Daffe & Draper, 1998). On the other hand, Mtb is able to subvert the immune 
response of the host by inhibiting its innate defense by several mechanisms. It prevents 
inflammasome activation (Master et al., 2008), delays phagosome maturation in macrophages 
(Russell, 2001) and suppresses MHC class II antigen presentation (Baena & Porcelli, 2009). 
Suppression of MHC II antigen expression is conferred by several lipoproteins, e.g. the 
19 kDa lipoprotein (LpqH) (Noss et al., 2001). 
Lipoproteins are a subclass of proteins found in the cell envelope of all bacteria. Lipoproteins 
are either di- (in case of Gram-positive bacteria) or triacylated (in case of Gram-negative 
bacteria) on a highly conserved cysteine located at the N-terminus, which is part of the 
lipobox [LVI][ASTVI][GAS][C] (Rezwan et al., 2007a). By the consecutive action of the 
three enzymes pre-prolipoprotein diacyl glyceryl transferase (Lgt), prolipoprotein signal 
peptidase (LspA) and apolipoprotein N-acyltransferase (Lnt), lipoproteins are post-
translationally modified after translocation over the cytoplasmic membrane. Lgt attaches a 
diacylglyceryl residue to the universally conserved cysteine in the lipobox by thioether-
linkage. Then LspA removes the lipoprotein signal peptide and Lnt attaches a third acyl chain 
to the amino group of the modified cysteine. Despite the fact that N-acylation in Bacillus 
subtilis and Staphylococcus aureus was reported (Hayashi et al., 1985; Kurokawa et al., 2009; 
Tawaratsumida et al., 2009), Lnt was found exclusively in Gram-negative bacteria. Even 
though Mtb is deemed to be a Gram-positive bacterium because of its staining properties, it 
has been shown recently that mycobacteria have a periplasmic-like structure (Zuber et al., 
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2008). Furthermore it has been shown that mycobacteria express a functional Lnt as at least 
one lipoprotein, LppX was found to be triacylated (Tschumi et al., 2009). 
The functions of lipoproteins are manifold; they may be involved in protein export and 
folding, in antibiotic resistance, in ABC transporter systems, act as substrate-binding proteins 
and are involved in cell signalling. Examples of mycobacterial lipoproteins which have been 
explored are Mpt83, LppX, LpqW and the 19 kDa lipoprotein. Mpt83 is assumed to be an 
adhesin and it has been shown that RNA encoding Mpt83 induces protective immune 
responses against Mtb infection (Xue et al., 2004). LpqW and LppX have been shown to be 
key players in synthesis and transport of unique components of the mycobacterial cell 
envelope. Whilst LppX is involved in translocation of phthiocerol dimycocerosates (DIM) to 
the outer membrane (Sulzenbacher et al., 2006), LpqW has been shown to be essential in the 
synthesis of the cell wall components phosphatidyl-myo-inositol mannoside (PIM) and LAM 
(Kovacevic et al., 2006; Marland et al., 2006). The 19 kDa lipoprotein has been described as 
an adhesin (Diaz-Silvestre et al., 2005). It induces IL-1, IL-2 and TNF-α through TLR2-
signalling in macrophages. Overall, lipoproteins are important in host-pathogen interactions 
and they have a high pathogenic potential which has been proven by disruption of lspA, the 
lipoprotein signal peptidase. An lspA-deficient strain of Mtb exhibited reduced multiplication 
in mouse macrophages and reduced number of colony forming units in a mouse model by 3-4 
logs (Sander et al., 2004). 
The putative lipoproteins LprF and LprJ of Mtb recently have been described to interact with 
the histidine kinase KdpD in a yeast two-hybrid screen (Steyn et al., 2003). Both lipoproteins 
have been suggested to form ternary complexes with the histidine kinase domain of KdpD 
which in turn seems to be activated after potassium-dependent sensing of environmental 
osmotic stress and activates a signal transduction pathway.  
Even though advances in the past few years contributed to the knowledge of the function of 
lipoproteins, there is scarcely known anything about the chemical composition of the lipid 
modifications. Modern tools like mass spectrometry instead of incorporation of radioactive 
precursors provide support to understand post-translational modifications by lipidation and 
glycosylation of lipoproteins. Mycobacterial lipoprotein LppX is the first and only lipoprotein 
characterized at the molecular level (Tschumi et al., 2009). Investigations in other bacteria 
indicate that lipids of lipoproteins may differ significantly within one species (Kurokawa et 
al., 2009; Tawaratsumida et al., 2009). Therefore we extended our studies on mycobacterial 
lipoproteins. 
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In this study, we cloned, expressed and purified LprF of Mtb in M. smegmatis, a non-
pathogenic but phylogenetically close relative of Mtb. We show for the first time that a 
putatively membrane-localized lipoprotein of Mtb is N-acylated and determine the 
predominant fatty acids by matrix-assisted laser desorption ionization time-of-flight tandem 
mass spectrometry (MALDI-TOF/TOF MS). 
 
Material and Methods 
Bacterial strains and growth conditions. Mycobacterium smegmatis strains were cultivated in 
LB medium or on LB agar. If necessary, gentamicin was added at a final concentration of 
5 µg/ml. Strains used in this study were M. smegmatis SmR5 (Sander et al., 1995), a strain 
carrying a non-restrictive rpsL mutation conferring streptomycin resistance, and 
M. smegmatis lnt::aph mutant (Tschumi et al., 2009).  
 
Expression of recombinant lipoprotein LprF. LprF of Mtb was expressed under control of the 
19 kDa antigen (lpqH) promoter. The recombinant protein was generated by fusion PCR; 
fragment 1 contains the sequence of the 19 kDa promoter, fragment 2 contains the functional 
domain of the LprF lipoprotein including the leader peptide and the sequence of a C-terminal 
thrombin cleavage site and a HA-epitope tag (hemagglutinin protein), followed by a 6x His-
epitope tag. Fragment 1 was amplified with primers 1a (5’-GGGTTAAC 
GAATTCTACATTG-3’, bold letters indicate sites of restriction enzymes HpaI and EcoRI) 
and 1b (5’-CTTGTGAGATCAAGCCATTCATCCTGTGCTCCT-3’, italic letters indicate the 
linker for lprF) from plasmid pMV261-Gm-FusLppX (Tschumi et al., 2009). Fragment 2 was 
amplified with primers 2a (5’-AGGAGCACAGGATGAATGGCTTGATCTCACAAG-3’, italic 
letters indicate the linker for lprF) and 2b (5’-CCGTTAACGAATTCTAG 
TGGTGGTGGTGGTGGTGAGTGGCGTAGTCGGGGACGTCGTAGGGGTAACTACCA
CGTGGAACTAGTCCCGCCGGGTTCGG-3’, bold letters indicate sites of restriction 
enzymes HpaI and EcoRI, underlined letters indicate thrombin cleavage site, HA- and His-
tag) from Mtb genomic DNA. Fusion PCR was performed with primers 1a and 2b. The 
recombinant lprF gene was cloned into pMV261-Gm (a shuttle vector replicating in E. coli as 
well as in mycobacteria, derived from pMV261) using the EcoRI-restriction sites. The 
resulting plasmid pMV261-Gm-lprF was transformed into M. smegmatis SmR5 and 
M. smegmatis lnt::aph. 
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Preparation of cell extracts and Western blot analysis. Bacteria transformed with pMV261-
Gm-lprF were cultured in 2 l LB medium for 3 days at 37 °C. The cultures were harvested 
(4400 rpm, 1 h) and resuspended in PBS containing Complete EDTA-free tablets (Roche). 
Cells were lysed by three French press cycles (American Instrument Company) at 1.1 x 106 
Pa. Extracts were treated with 2% sodium N-lauroylsarcosine (SLS) for 1 h at room 
temperature, and for 16 h at 4 °C thereafter. Soluble and insoluble fractions were separated by 
centrifugation at 30000 g for 1 h at 4 °C. Extracts corresponding to 1-5 µg of total protein 
were separated by a 12.5% SDS-PAGE gel and subsequently analyzed by Western blot using 
anti-HA-antibodies (1:300, Roche). 
 
Protein fingerprinting. Proteins were digested with trypsin and dissolved in 25 µl 0.1% formic 
acid. Samples were desalted by using a Ziptip C18 column, mixed 1:1 with matrix solution (5 
mg/ml α-cyano-4-hydroxy-cinnamic acid (Bruker Daltonics) in 0.1% trifluoroacetic acid, 
50% acetonitrile) and spotted onto the target. 
 
FPLC protein purification. The soluble fraction of cell extracts expressing epitope-tagged 
proteins was mixed with dilution buffer (20 mM NaH2PO4, 0.5 NaCl, 1% SLS, pH 7.4) and 
loaded on a HisTrapTM HP column (GE Healthcare) previously equilibrated with equilibration 
buffer (20 mM Na2HPO4, 0.5M NaCl, 0.2% SLS, 20 mM imidazole, pH 7.4). Proteins were 
eluted applying an imidazole gradient (0.125 - 0.5 M). 
As a further purification step, the column flow through from His-tag purification was dialyzed 
against equilibration buffer (20 mM Tris-hydroxymethyl-aminomethane, 0.1 M NaCl, 0.1 
mM EDTA, pH 7.5), loaded onto an anti-HA-affinity matrix (Roche), washed with a buffer 
containing 20 mM Tris-hydroxymethyl-aminomethane, 0.1 M NaCl, 0.1 mM EDTA, 0.05% 
(v/v) Tween 20, pH 7.5 and eluted with column regeneration buffer (0.1 M glycine, pH 2.0). 
 
MALDI-TOF/TOF. 100-200 pmol of purified lipoprotein were prepared and analyzed 
according to Ujihara et al. (Ujihara et al., 2008). Lipoproteins were digested with AspN. 
Extracted peptides were dried and dissolved in 5 µl 0.1% trifluoroacetic acid, 50% 
acetonitrile. Samples were mixed 1:1 with matrix solution (5 mg/ml α-cyano-4-hydroxy-
cinnamic acid (Burker Daltonics) in 0.1% trifluoroacetic acid, 50% acetonitrile) and spotted 
onto the target. The MALDI-TOF/TOF mass spectra were recorded on an Ultraflex II 
MALDI-TOF/TOF instrument with smartbeam laser upgrade (Bruker Daltonics). The laser 
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was set to a repetition rate of 100 Hz and the ion acceleration voltage was 29.5 kV. The mass 
measurements were performed in the positive ion reflector mode. 
 
Edman degradation. For N-terminal sequencing, proteins were separated by 12.5% SDS-
PAGE-gels, blotted onto a PVDF membrane and stained with Coomassie Brilliant Blue 
(0.03% (w/v) Coomassie Brilliant Blue R-250, 25% (v/v) isopropanol, 10% (v/v) acetic acid) 
for 5 min. The membrane was destained (10% acetic acid, 35% methanol) and washed once 
with Aqua B. Braun (Ecotainer®). Visible bands were cut out and analyzed by Edman 
degradation (Procise 492 cLC protein sequencer, Applied Biosystems), according to the 
manufacturer’s instructions. 
 
Results and Discussion 
To analyze the putative lipoprotein LprF from Mtb concerning the lipoprotein specific 
modifications with fatty acids we generated the expression vector pMV261-Gm-lprF. Plasmid 
pMV261-Gm-lprF was transformed into Mycobacterium smegmatis SmR5 wildtype and an 
isogenic lnt::aph mutant strain, lacking a functional apolipoprotein-N-acyl-transferase (Lnt). 
Recombinant LprF from whole cell extracts was purified using the His epitope and 
subsequently analyzed by Western blot using anti-HA-antibodies. Depending on the kinetics 
of the enzymes of the lipoprotein biosynthesis pathway [7], the cell extract may contain 
different forms of the lipoprotein, the pre-prolipoprotein, prolipoprotein, apolipoprotein and 
the mature lipoprotein. The theoretically calculated molecular masses for LprF are in the 
range of 26 kDa to 30 kDa. However, the apparent molecular masses estimated from an SDS-
PAGE gel may differ significantly. Analysis of the elution fractions from wildtype and 
lnt::aph mutant by Western blot and Coomassie stained SDS-PAGE gels showed bands with 
an apparent size of 30 and 35 kDa in both strains (data not shown).  
 
Protein analysis. Fingerprint analysis of the 30 and 35 kDa proteins from wildtype and 
lnt::aph mutant confirmed these proteins as LprF from Mtb. For characterization and 
identification of the N-terminal modifications of LprF only the mature lipoprotein is needed. 
To characterize the 30 and 35 kDa forms of LprF which have been detected after His-tag 
purification we applied several methods. Edman degradation provides a suitable method to 
identify the pre-prolipoprotein, prolipoprotein and apolipoprotein. N-acylation blocks Edman 
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degradation. Therefore, MALDI-TOF/TOF MS was used to confirm N-acylated LprF forms 
and to identify modifications at the molecular level.  
 
Edman degradation. The proteins with an apparent size of 35 kDa (Figure 1a) revealed the 
sequence MNGLI, which is an LprF sequence starting with the initial methionine of the signal 
peptide (Figure 1c) thereby confirming these forms as pre-pro-LprF or pro-LprF in both 
strains. The proteins with a size of 30 kDa (Figure 1a) revealed the sequence KKPTT in 
wildtype and TVVAG in the lnt::aph mutant. These determined sequences start at position +3 
and at position -5, respectively, in relation to the cysteine (+1) of the lipobox (Figure 1c). 
These results indicate that the 30 kDa forms of LprF are not the desired LspA-cleaved LprF 
but LprF forms cleaved by other proteases. The 30 kDa protein form isolated from the 
lnt::aph mutant and starting with the sequence TVVAG contains potentially diacylglycerol 
modified cysteine and therefore was subjected to MALDI-TOF/TOF MS analysis. The 30 
kDa band isolated from the wildtype strain may be a mixture of triacylated LprF and truncated 
LprF with the N-terminal residues KKPTT. As triacylated lipoprotein is not accessible to 
Edman degradation due to the blocked N-terminus, the 30 kDa band from wildtype was also 
subjected to MALDI-TOF/TOF MS. 
 
MALDI-TOF/TOF MS analysis. The Copper chloride stained SDS-PAGE gels of His-tag-
purified LprF showed the same bands detected before on Western Blot and Coomassie stained 
SDS-PAGE gels (Figure 1a). AspN-digested peptides from the 30 kDa recombinant LprF of 
both strains were analyzed with MALDI-TOF/TOF MS to confirm the N-terminal sequence 
of mature LprF and to characterize the predominant modifications occurring in M. smegmatis 
lipoprotein LprF at the molecular level. The calculated monoisotopic m/z value for the AspN 
digested unmodified N-terminal peptide of the LspA cleaved LprF is m/z = 2496.2 (Figure 
1c). The fatty acids found in mycobacterial phospholipids are palmitic (C16:0), palmitoleic 
(C16:1), oleic (C18:1) and tuberculostearic acid (10-methyloctadecanoic acid) (C19:0) 
(Goren, 1979). Since fatty acids of membrane phospholipids are used for N-acylation of 
lipoproteins in E. coli (Jackowski & Rock, 1986; Lai & Wu, 1980), we calculated the 
theoretical mass of the N-terminal peptide of LprF with all possible combinations of the 
above mentioned four fatty acids. Lipoproteins sometimes are glycosylated (Sartain & Belisle, 
2009) and putative sites for O-glycosylation are also present in the N-terminal AspN-fragment 
of LprF. Therefore we also calculated the mass with several hexose modifications. However, 
no signals corresponding to the free or acylated N-terminal peptides (with or without 
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glycosylations) were found in the mass spectrum (data not shown). So, the analyzed 30 kDa 
proteins of LprF are most likely the non-modified but truncated proteins, as indicated by the 
results of the Edman degradation.  
 
Analysis of HA-tag purified LprF. Since the 35 kDa LprF clearly was identified as the (pre-) 
pro-LprF and the 30 kDa forms were not the LspA-processed LprF we assumed that the 
expected mature forms were not yet isolated. Concentrating again on the Western blots and 
Coomassie stained SDS-PAGE gels from His-tag purification, we found another distinct band 
on the Western blots from the column flow throughs. This band had an apparent size of 
28 kDa possibly corresponding to the LspA-cleaved LprF (data not shown).  
Due to the fact that this protein form did not bind to the HisTrapTM HP column, we used the 
HA-epitope in the recombinant LprF to purify this protein from the flow through fractions. 
After purification with the HA-affinity matrix, the proteins with the size of 28 kDa in 
wildtype and lnt::aph mutant were observed on Western blot, Coomassie and Copper chloride 
stained SDS-PAGE gels as well (Figure 1b).  
 
 
Figure 1: Copper chloride stained SDS-PAGE gels and amino acid sequence of purified LprF  
a) HisTrapTM-column purified LprF from M. smegmatis wildtype and lnt::aph mutant. b) HA-affinity matrix 
purified LprF from M. smegmatis wildtype and lnt::aph mutant. Proteins at 25 kDa were identified as histone-
like protein HupB from M. smegmatis. c) Amino acid sequence of recombinant LprF. Italic letters indicate the 
signal peptide cleaved by LspA. Bold letters indicate the lipobox including the conserved cysteine at position +1 
modified by Lgt and Lnt. Inverted commas indicate AspN cleavage sites. The modified N-terminal peptide after 
AspN digestion found in M. smegmatis wt and lnt::aph mutant is underlined. 
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Edman degradation of HA-tag purified LprF. To determine whether these 28 kDa forms from 
wildtype and lnt::aph mutant are the LspA-cleaved LprF or LprF at all, Edman degradation 
was performed although for the mature lipoprotein from wildtype N-terminal sequencing is 
expected to be blocked by the modified N-terminus.  
 
Figure 2: MALDI-TOF MS analysis of AspN digested purified LprF (28 kDa) 
MS data of AspN digested LprF peptides from a) M. smegmatis wildtype and b) M. smegmatis lnt::aph mutant. 
Black arrow indicates triacylated monoglycosylated N-terminal peptide. Open arrow indicates diacylated 
monoglycosylated N-terminal peptide. The mass at m/z = 3368.5 corresponds to an internal AspN peptide of 
LprF (residue 201 – 232 of the mature lipoprotein). 
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The analyses revealed the unique sequence xxKKP in LprF indicating that these proteins start 
with the cysteine at position +1 (Figure 1c) thereby confirming these proteins as the LspA-
cleaved LprF in the wildtype and the mutant. As the resolution of the SDS-PAGE gel is not 
sufficient to separate triacylated and diacylated lipoproteins, the 28 kDa band from wildtype 
may be a mixture of both forms.  
MALDI-TOF/TOF MS analysis of HA-tag purified LprF. For the identification of the 
lipoprotein specific modifications at the conserved cysteine the AspN digested peptides from 
the 28 kDa LprF from wildtype and lnt::aph mutant were investigated by MALDI-TOF MS. 
Instead of the [M+H]+ signal at m/z = 2496.2 as calculated for the AspN-digested, unmodified 
N-terminal peptide we found a signal at m/z = 3488.9 for the modified N-terminal peptide of 
LprF from wildtype (Figure 2a). In the lnt::aph mutant we found a signal at m/z = 3250.5 
(Figure 2b), indicating a smaller size of the N-terminal peptide and thus suggesting an Lnt 
dependent modification in the wildtype. The difference in molecular mass between the 
unmodified N-terminal peptide (m/z = 2496.2) and the peptide found in the lnt::aph mutant 
(m/z = 3250.5) is 754.3 Da indicating a diacylglyceryl modification with ester-linked 
tuberculostearic acid and C16:0 fatty acid (592.5 Da) and a glycosylation with one hexose 
(162.2 Da, Σ = 754.7). The difference in molecular mass of 238.4 Da between wildtype (m/z = 
3488.9) and mutant indicates an additional modification of the N-terminal peptide with a 
C16:0 fatty acid in the wildtype. 
In order to confirm the modifications of the AspN digested N-terminal peptide of LprF from 
wildtype (m/z = 3488.9) and lnt::aph mutant (m/z = 3250.5), the structure of the N-terminal 
peptide was analyzed with MALDI-TOF/TOF MS. In wildtype (Figure 3a) the ion at m/z = 
3326.7 corresponds to the cleavage of a hexose (∆ = 161.2 Da). The ion at m/z = 2698.7 is the 
most intense ion and corresponds to the release of the diacylthioglyceryl carrying both, an O-
linked tuberculostearic and a C16:0 fatty acid (∆ = 628.0 Da). The release of 257.1 Da from 
the ion at m/z = 3326.7 corresponds to the elimination of a C16:0 fatty acid and the release of 
370.9 Da from the ion at m/z = 3069.6 corresponds to the elimination of a tuberculostearic 
acid α-thioglyceryl ester. The difference in molecular mass between the MS signal for the N-
terminal peptide from wildtype and lnt::aph mutant is 238.4 Da which indicates a third 
acylation with a C16:0 fatty acid in the wildtype peptide in an Lnt dependent manner.  
In the lnt::aph mutant (Figure 3b) the ions at m/z = 3088.8 and 2461.9 correspond to the 
release of a hexose (∆ = 161.8) and a diacylthioglyceryl carrying both O-linked 
tuberculostearic and C16:0 fatty acid (∆ = 626.9), respectively. Of note - a loss of the His-
epitope in this 28 kDa LprF forms was assumed to be responsible for the failure to extract this 
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proteins by the His-tag purification. But, the presence of the tag was confirmed by MALDI-
TOF/TOF MS analysis (data not shown).  
 
 
 
Figure 3: MALDI-TOF/TOF MS analysis of N-terminal peptides of LprF 
MS/MS data of the N-terminal peptides of LprF from a) M. smegmatis wildtype and b) M. smegmatis lnt::aph 
mutant. Schematic drawings of the structure of the modified N-terminal peptide of LprF are shown in the upper 
part of each MS/MS spectrum. Dotted frames indicate the modified conserved cysteine at molecular level. 
Cleavage sites of each identified m/z signal are indicated. Eliminated fragments of LprF modifications are 
depicted in the spectra.  
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Conclusions 
This study shows for the first time the modifications of a putative membrane located 
lipoprotein of Mtb on the molecular level. The LprF of Mtb wildtype is a triacylated and 
glycosylated lipoprotein carrying a thioether linked diacylglyceryl residue with an ester-
bound tuberculostearic- and C16:0 fatty acid and a third C16:0 fatty acid most likely at the 
amino terminal cysteine residue. These results together with the recent analysis of LppX [16] 
indicate that N-acylation seems to be a common motif in mycobacterial lipoproteins. As 
expected for the lnt::aph mutant the cysteine in LprF is modified with the diacylglyceryl 
residue, but is missing the third acylation (only glycosylated and modified with the 
diacylglyceryl residue,) thereby confirming lipoprotein acylation by MSMEG_3860 in 
mycobacteria. Due to the close phylogenetic relation between M. smegmatis and Mtb the same 
acylation pattern of LprF in Mtb is assumed. Although glycosylation of the N-terminal AspN 
peptide of LprF was identified, the exact glycosylation site of seven possible sites within the 
peptide could not be determined. 
Fingerprinting and Edman degradation identified several proteins isolated either by His- or 
HA-affinity purification as LprF. However, the N-terminal lipidated LprF could not be 
purified by His-tag purification suggesting that the lipidation interferes with His-purification 
despite the presence of the His-tag which was proved by analysis of the C-terminus (data not 
shown) or somehow reduces the binding affinity of the protein. Beside the pre-pro-
lipoprotein, apolipoprotein and the mature LprF a protein with an apparent size of 32 kDa 
found only in the wildtype was confirmed by fingerprint as LprF as well, but was not 
subjected to further analysis in this study. This LprF may result from cleavage by proteases 
other than LspA. 
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Addendum 
 
Personal contribution to chapter 4 
In this article, the post-translational modifications of LprF, a lipoprotein derived from 
M. tuberculosis, expressed in M. smegmatis was characterized. It was shown for the first time 
that lipoproteins which are localized in the cytoplasmic membrane are tri-acylated in the same 
manner as lipoproteins which are localized at the cell wall of mycobacteria. By applying 
MALDI-TOF/TOF analysis it was shown that LprF is modified by a thioether-linked 
diacylglycerol residue with one ester-bound C19:0- (tuberculostearic acid) and one C16:0 
(palmitic acid) fatty acid and additionally by a third N-linked C16:0 fatty acid and a hexose. 
 
My contribution as shared-first author to this manuscript was as follows: 
 
 
• Design of the study 
• Generation of expression vectors 
• Data analysis 
• Writing of the manuscript 
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Abstract 
Synthetic biology provides insight into natural gene-network dynamics and enables assembly 
of engineered transcription circuitries for production of difficult-to-access therapeutic 
molecules. In Mycobacterium tuberculosis EthR binds to a specific operator (OethR) thereby 
repressing ethA and preventing EthA-catalyzed conversion of the prodrug ethionamide, which 
increases the resistance of the pathogen to this last-line-of-defense treatment. We have 
designed a synthetic mammalian gene circuit that senses the EthR–OethR interaction in human 
cells and produces a quantitative reporter gene expression readout. Challenging of the 
synthetic network with compounds of a rationally designed chemical library revealed 2-
phenylethyl-butyrate as a nontoxic substance that abolished EthR’s repressor function inside 
human cells, in mice, and within M. tuberculosis where it triggered derepression of ethA and 
increased the sensitivity of this pathogen to ethionamide. The discovery of antituberculosis 
compounds by using synthetic mammalian gene circuits may establish a new line of defense 
against multidrug-resistant M. tuberculosis. 
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Introduction 
Up to 9 million people contract tuberculosis every year and 50 million people are presently 
infected with Mycobacterium tuberculosis resistant to both first-line drugs isoniazid and 
rifampicin (1) [World Health Organization (WHO), fact sheet no. 104, March 2007]. 
Ethionamide, a structural analogue of isoniazid, is currently the last line of defense in the 
treatment of multidrug-resistant tuberculosis (MDR-TB). During 35 years of its clinical use, 
ethionamide has fortunately elicited little cross-resistance with isoniazid because both 
prodrugs have to be activated by different mycobacterial enzymes to develop their 
antimicrobial activity (2). Ethionamide is activated by the Baeyer–Villiger monooxygenase 
EthA, which converts the prodrug into an antimycobacterial nicotinamide adenine 
dinucleotide derivative (3, 4). Because ethA is repressed by EthR (5), ethionamide-based 
tuberculosis therapy is often unsuccessful even when prescribed at high hepatotoxic doses (6). 
Therefore, compounds preventing EthR from binding to the ethA promoter could increase the 
sensitivity of multidrug-resistant M. tuberculosis to ethionamide and make tuberculosis 
treatment safer, more efficient, and affordable. Crystallography-based structural analysis 
implied that hexadecylocanoate copurifying with EthR could abolish EthR’s operator-binding 
capacity (7). However, hexadecyloctanoate turned out to be too hydrophobic to confirm this 
hypothesis in any cell/microbial culture system suggesting that it remains a nontrivial 
challenge to discover bioavailable EthR-binding compounds. Because M. tuberculosis is an 
intracellular pathogen, EthR inhibitors do not only have to specifically target the bacterial 
repressor, but also need to reach the cytosol without eliciting any cytotoxic effect. Therefore, 
integrated screening approaches assessing specificity, bioavailability, and cytotoxicity in a 
single assay are expected to rapidly reveal valid drug candidates. Although synthetic 
mammalian gene networks designed so far, including epigenetic toggle switches (8), 
hysteresis networks (9), time-delay circuits (10), and synthetic ecosystems (11), have resulted 
in important information on the dynamics of physiologic control systems, the EthR-based 
gene circuit pioneers a direction with a more practical purpose: providing a generic screening 
platform to discover drug candidates with the potential to efficiently kill M. tuberculosis, the 
causative agent of one of the most devastating human diseases. 
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Results 
Design of an EthR-Based Synthetic Mammalian Gene Circuit. Structural analysis (7, 12) 
classifying EthR as a TetR/CamR family repressor suggested the existence of compounds that 
could modulate the affinity of EthR for its OethR operator (13, 14). Adopting a synthetic 
biology approach we have designed a gene network whose topology enabled detection of 
EthR-binding molecules inside human cells, thereby scoring for noncytotoxic and 
bioavailable compounds accessing the pathogenic habitat of M. tuberculosis (Fig. 1a). The 
gene circuit consists of a synthetic transactivator, EthR, fused to the VP16 transactivation 
domain of Herpes simplex (pWW489, PSV40-EthR-VP16-pA), which induces SEAP (human 
placental secreted alkaline phosphatase) expression in human embryonic kidney cells (HEK-
293) after binding to a chimeric promoter containing the EthR-specific operator (OethR) 5’ of a 
minimal Drosophila heat shock protein 70 promoter (Phsp90min; pWW491, OethR-Phsp70min-SEAP-
pA) (8.2 ± 0.8 units/liter; background level of pWW491, 0.4 ± 0.1 units/liter) (Fig. 1a). Cell-
permeable EthR-interacting compounds were expected to release EthR-VP16 from 
OethRPhsp70min, thereby repressing SEAP production to basal levels (Fig. 1a). Interestingly, 
hexadecyloctanoate (10 mM), identified in crystallography studies to compromise EthR’s 
DNA-binding capacity (7), failed to decrease SEAP expression in HEK-293 cells containing 
pWW489 and pWW491 (data not shown), which is probably because of its highly lipophilic 
structure (ClogP = 11.29). Therefore, it remains a nontrivial challenge to discover 
bioavailable EthR-binding compounds as they must be sufficiently lipophilic to fit into the 
hydrophobic tunnel of EthR (7) while being hydrophilic enough to reach therapeutic levels in 
the bloodstream and inside infected cells. 
Discovery of Compounds Affecting the DNA-Binding Affinity of EthR. Capitalizing on 
crystallography data describing EthR’s small-molecule binding site as “hydrophobic tunnel-
like cavity fitting a lipophilic ligand” (7, 12) and on the observation that repressors are often 
feedback-controlled by the products of their target gene (15, 16), we have synthesized a 
library of hydrophilic esters (ClogP < 4), a substance class, which is the main product of 
EthA-catalyzed Baeyer–Villiger oxidation (Fig. 1b). When HEK-293 populations containing 
the EthR-based gene circuit (Fig. 1a) were exposed to 0–3.2 mM individual library 
components, only benzylacetate, 3-phenylpropyl-propionate, 2-phenylethyl- butyrate, and 4-
phenyl-2-butanone [a ketone class control (7)] induced a significant decrease in SEAP 
expression, suggesting that these compounds may trigger the release of EthR from OethR (Fig. 
1c). However, because 3-phenylpropyl-propionate and 4-phenyl-2-butanone were also 
reducing SEAP levels of HEK-ET-SEAP cells transgenic for constitutive SEAP expression 
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(Fig. 1c), these substances were considered cytotoxic at EthR-releasing concentrations [SEAP 
production and viability of HEK-ET-SEAP cells were shown to correlate; supporting 
information (SI) Fig. S1]. Therefore, only benzylacetate (IC50 = 1 mM) and 2-phenylethyl-
butyrate (IC50 = 0.5 mM) were used for further studies (Fig. 1c). 
Fig. 1. EthR-based synthetic gene network in mammalian cells. (a) A gene fusion of ethR with the Herpes 
simplex-derived vp16 transactivation domain is expressed under the control of the simian virus 40 promoter 
(PSV40, plasmid pWW489) in HEK-293. The chimeric transactivator EthR-VP16 binds to its operator OethR 
thereby activating transcription from the minimal Drosophila heat shock 70 promoter (Phsp70min), driving 
expression of human placental secreted alkaline phosphatase (seap, plasmid pWW491). In the presence of a cell-
permeable, noncytotoxic inducer, binding of EthR-VP16 to the promoter is inhibited, thereby resulting in 
transcriptional silence (red lines). Non-cell-permeable or cytotoxic compounds are automatically excluded from 
the hit list. (b) Compounds selected for testing as potential inducers of EthR. The ClogP value indicates the 
calculated distribution coefficient between n-octanol and water. (c) Screening of a rationally designed compound 
library by using the EthR-based gene network. 30,000 HEK-293 containing either the EthR-based gene network 
(pWW489 and pWW491, EthR-HEK-SEAP cells) or an isogenic constitutive SEAP expression network 
(pWW35 and pWW37, HEK-ET-SEAP cells) were cultivated for 48 h in the presence of potential inducers 
before SEAP profiling. SEAP expression was normalized to 100%.  
 
Validation of EthR-Modulating Compounds in Bacteria and in Vitro. When exposing 
Escherichia coli engineered for PethR-driven GFP expression to benzylacetate and 2-
phenylethyl-butyrate concentrations used for the aforementioned experiments with 
mammalian cells, dose-dependent GFP expression could be observed, indicating that these 
compounds were also able to trigger release of EthR from OethR in prokaryotes (Fig. 2 a and b; 
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see Fig. S2 for expression constructs and experimental setup). Similar to mammalian cells, 
hexadecyloctanoate was unable to modulate EthR’s PethR-binding affinity in E. coli at 
concentrations up to 10 mM (data not shown). Benzylacetate efficiently released EthR from 
its operator but did so only at elevated concentrations (10 mM) that are known to be 
mutagenic and likely incompatible with future therapeutic use (Material Safety Data Sheet, 
Sigma). We have therefore focused on 2-phenylethyl-butyrate and further characterized the 
adjustable EthR-OethR release capacity of this licensed food additive in a cell-free ELISA 
system (Fig. 2c): Hexahistidine-tagged EthR (EthR-His6) was allowed to bind to agarose 
beads containing immobilized OethR in the presence of increasing concentrations of 2-
phenylethyl-butyrate and OethR interacting EthR-His6 was quantified after a washing step by 
using a His6-specific horseradish peroxidase-coupled antibody and a standard assay system 
(Fig. 2c). The inverse correlation of 2-phenylethyl-butyrate and OethR-bound EthR indicates 
that this compound is able to induce release of EthR from its operator. The specificity of 2-
phenylethyl-butyrate’s EthR-releasing capacity was confirmed by an identical control 
experiment with an unrelated repressor–operator interaction (Fig. S3). 
2-Phenylethyl-butyrate Modulates EthR Activity in Mice. To evaluate whether the 
licensed food additive 2-phenylethyl-butyrate [Joint Food and Agriculture Organization 
(FAO)/WHO Expert Committee on Food Additives, JECFA no. 991], retains its regulating 
activity in vivo, we stably transfected the EthR-based gene circuit into HEK-293 cells 
(EthRHEK-SEAP, transgenic for pWW489 and pWW491; see Fig. S4 a and b for clonal 
variation, Fig. S4c for adjustability, and Fig. S4d for reversibility of the gene circuit). 
EthRHEK-SEAP cells were microencapsulated and implanted i.p. into mice. Animals treated 
with 2-phenylethyl-butyrate showed significantly reduced SEAP serum levels (without 2-
phenylethyl-butyrate, 420 ± 43 milliunits/liter; with 625 µl/kg 2-phenylethyl-butyrate, 207 ± 
29 milliunits/liter) suggesting that this compound was bioavailable and reached EthR-
inactivating concentrations inside target cells. Mice with implanted control cells harboring 
only pWW491 showed background SEAP expression (84 ± 16 milliunits/liter). 
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Fig. 2. Validation of the inducer in bacteria and in a cell-free system. (a) Effect of benzylacetate in E. coli. E. 
coli BL21(DE3), transformed with pWW488 and pWW856 (see Fig. S2a), was grown in the presence of IPTG 
(to induce EthR expression) at the indicated benzylacetate concentrations for 5.5 h before analyzing the cells by 
FACS (for FACS gates and parameters; see Fig. S2b). The optical density at 600 nm (OD600) after the growth 
period is indicated as well. As a control, E. coli BL21(DE3) transformed with pWW856 alone were used in 
parallel. (b) Effect of 2-phenylethyl-butyrate in E. coli. Experimental setup as described in a. (c) Impact of 2-
phenylethyl-butyrate on the interaction between EthR and OethR in vitro. Biotinylated operator OethR (O) 
immobilized on streptavidin-agarose beads (SA-Agarose) was incubated in the presence or absence of 2-
phenylethyl-butyrate at the indicated concentrations in a cell lysate of E. coli BL21(DE3) transformed with 
pWW862 (PT7-ethR-his6-term) for production of hexahistidine-tagged EthR (R-his6). After washing, his6-tagged 
EthR was detected by a monoclonal anti-his6 antibody coupled to horseradish peroxidase (HRP), resulting in the 
conversion of 3,3’,5,5’-tetramethylbenzidine (TMB) to a colored formazane. As negative controls, 
nonrecombinant cell lysate was used (neg). 
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2-Phenylethyl-butyrate Increases the Sensitivity of Mycobacterium bovis and 
M. tuberculosis to Ethionamide. Growth of M. tuberculosis is significantly impaired in the 
presence of ethionamide because of EthA-mediated conversion of this prodrug into an 
antimycobacterial nicotinamide adenine dinucleotide derivative (3, 17). EthR-mediated 
repression of ethA transcription requires rather high clinical doses of ethionamide [up to 
1 g/day (6, 18)], which is associated with severe side effects including neurotoxicity (19) and 
fatal hepatotoxicity (6), yet is often still insufficient to reach minimum inhibitory levels in the 
bloodstream (20). Therefore, 2-phenylethyl-butyrate-triggered dissociation of EthR from the 
ethA promoter resulting in derepression of ethA, which was confirmed by quantitative RT-
PCR of ethA transcripts (2.93 ± 0.04- and 9.7 ± 1.7-fold increase in the presence of 0.5 and 2 
mM 2-phenylethyl-butyrate, respectively), may increase the sensitivity of Mycobacterium to 
ethionamide-based therapy. Growth of M. bovis bacillus Calmette–Guérin and 
M. tuberculosis H37Rv in the presence of subinhibitory ethionamide concentrations (0.25 and 
0.5 µg/ml), which are easily reached by therapeutic doses [cmax (250 mg oral) = 2 µg/ml; t1/2 
= 2 h (18)] was dosedependently inhibited by 0.5 and 2 mM 2-phenylethyl-butyrate (Fig. 3). 
Because 2-phenylethyl-butyrate alone did not show any growth inhibitory effect, we suggest 
that it acted synergistically with ethionamide to kill the pathogen (Fig. 3). 4-Phenyl-2-
butanone, which was previously suggested to neutralize EthR, was found to be cytotoxic (Fig. 
1c and Fig. S1) and did not act synergistically with ethionamide to kill M. bovis at 
concentrations that were higher than the ones at which 2-phenylethyl-butyrate was effective 
(Fig. S5). 
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Fig. 3. Effect of 2-phenylethyl-butyrate and ethionamide on M. bovis bacillus Calmette–Guérin and 
M. tuberculosis. (a) Synergistic effect of 2-phenylethyl-butyrate and ethionamide (ETH) on the growth inhibition 
of M. bovis bacillus Calmette–Guérin. A–D correspond to serial dilutions (10-2, 10-3, 10-4, and 10-5) of an 
M. bovis bacillus Calmette–Guérin settling culture (OD600: 0.6). (b) Synergistic effect of 2-phenylethyl-butyrate 
and ethionamide (ETH) on growth inhibition of M. tuberculosis H37Rv. A–D correspond to serial dilutions    
(10-2, 10-3, 10-4, and 10-5) of an M. tuberculosis H37Rv settling culture (OD600: 0.4).  
 
 
Discussion 
Synthetic gene circuits have dramatically increased progress on gene-function relationships in 
the postgenomic era (8–11, 21– 25). They also continue to provide the key parts for synthetic 
biologists to decipher natural gene network dynamics (8–10) and to reprogram cellular 
function for production of important precursor drugs (23). We have engineered a synthetic 
gene network in human cells for screening of functional antimicrobial agents with precise 
target specificity, undetectable cytotoxicity, and the capacity to reach the cytosol to eliminate 
intracellular pathogens. The network setup is generic so that it can, in principle, be adapted to 
essential transcription regulators of other pathogens. With the integration of EthR (4), which 
controls the resistance of M. tuberculosis to ethionamide, into a synthetic mammalian gene 
network we have been able to identify the licensed food additive 2-phenylethyl-butyrate as a 
potent inhibitor of EthR in M. tuberculosis, as well as in vivo, which dramatically increases 
the sensitivity of this pathogen to the last-line-of-defense drug ethionamide and potentially to 
other ethA-dependent compounds (26). Therefore, 2-phenylethyl-butyrate could set up an 
efficient and safe line of defense against multidrug-resistant tuberculosis. 
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Materials and Methods 
Vector Design. pWW489 (PSV40-ethR-vp16-pA) was constructed by PCR-mediated 
amplification of ethR from genomic M. bovis DNA by using oligonucleotides OWW400 (5’-
gcatccatatgaattccaccatgaccacctccgcggcca-3’) and OWW401 (5’-cgatcgcgcgcggctgtac 
gcggagcggttctcgccgtaaatgc-3’) followed by restriction and ligation (EcoRI/BssHII) into 
pWW35 (27). pWW491 (OethRPhsp70min- SEAP-pA) was obtained by direct cloning of a 
synthetic OethR sequence (5’-gacgtcgatccacgctatcaacgtaatgtcgaggccgtcaacgagatgtc 
gacactatcgacacgtagcctgcagg-3’) (AatII/SbfI) into pMF172 (27). pWW488 (PT7- ethR-vp16-
his6) was constructed by PCR-mediated amplification of ethR-vp16 from pWW489 by using 
oligonucleotides OWW400 and OWW60 (5’- gctctagagcaagcttttaatggtgatg 
gtgatgatgcccaccgtactgtcaattccaag-3’) followed by cloning (NdeI/HindIII) into pRSETmod 
(28). pWW856 (PethR-gfp-pA) was constructed in three steps: (i) gfp was PCR-amplified from 
pLEGFP-N1 (Clontech) by using oligonucleotides OWW848 (5’-ggcttgaattcaaa 
ggagatataccatggtgagcaagggcgag-3’) and OWW849 (5’-ggctttctagacaaaaaacccctcaagacccgttta 
gaggccccaaggggttatgctagttacttgtacagctcgt ccatgccg-3’) and cloned (EcoRI/XbaI) into pWW56 
(27) (pWW854). (ii) A synthetic OethR sequence was directly cloned (HindIII/EcoRI) into 
pWW854 (pWW855). (iii) PethRgfp was excised (BamHI/StuI) from pWW855 and ligated 
(BamHI/ScaI) into pACYC177 (NEB) (pWW856). pWW862 (PT7-ethR-his6) was assembled 
by annealing oligonucleotides OWW479 (5’-cgcgca tcatcatcatcatcattaagcggccgca-3’) and 
OWW480 (5’agcttgcggccgcttaatgatgatgatgatgatg-3’) and cloning the double-stranded DNA 
BssHII/HindIII into pWW488. pWW871 (5’LTR-Ψ+-ethR-vp16-PPGK-neoR-3’LTR) was 
designed by cloning ethR-vp16 of pWW489 (EcoRI/ BamHI) into pMSCVneo (Clontech). 
pWW35 (PSV40-E-vp16-pA), pWW37 (ETRPhCMVmin-seap-pA) and pWW313 (PT7-E-his6-pA) 
have been described (28). 
Cell Culture. Human embryonic kidney cells (HEK-293, American Type Culture Collection 
CRL-1573) were cultivated in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) 
supplemented with 10% FCS (Pan Biotech GmbH, catalog no. 3302, lot P231902) and 1% of 
a penicillin/streptomycin solution (Sigma, catalog no. 4458). Cells were transfected by using 
standard calcium phosphate procedures (29) and retroviral particles were produced according 
to the manufacturer’s protocol (Clontech). EthRHEK, transgenic for constitutive EthR-VP16 
expression, was constructed by transducing HEK-293 with pWW871- derived retroviral 
particles followed by selection in DMEM containing 200 µg/ml neomycin and single-cell 
cloning. Cotransfection of EthRHEK with pWW491 and pPUR (Clontech), subsequent 
selection in 200 µg/ml neomycin, 1 µg/ml puromycin followed by single-cell cloning resulted 
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in EthRHEK-SEAP. The cell line HEK-ET-SEAP, transgenic for constitutive SEAP expression, 
was described in ref. 27. SEAP was quantified in cell culture supernatants by using a p-
nitrophenylphosphate- based assay (30) and in mouse serum by employing a commercial 
chemiluminescence test (Roche Applied Science, catalog no. 11779842001). The impact of 
chemicals on the viability of human cells was assessed by using the WST-1 cell proliferation 
assay according the to manufacturer’s protocol (Roche Applied Science, catalog no. 
05015944001). 
Chemicals. Pentyl-acetate, methyl-phenylacetate, 2-phenylethyl-acetate, 4-phenyl-2-butanone 
(all Fluka) and 2-phenylethyl-butyrate (Sigma) were commercially obtained. Methyl-
hexanoate was obtained by reacting hexanoic acid with thionylchloride in methanol. Butyl-
propionate, 2-phenylethyl-propionate, 2-phenylethyl-isopentanoate, and 3-phenylpropyl-
propionate were prepared by reacting the corresponding alcohol with the acid chloride in 
dichloromethane by using triethylamine as a base. Hexadecyloctanoate and benzylacetate 
were synthesized from the bromide and the acid with K2CO3 as the base in 
dimethylformamide. All esters were purified either by column chromatography (silica, 
ethylacetate/ hexane) or distillation. ClogP was determined by using Chemdraw Ultra 10.0 
(CambridgeSoft). Erythromycin (Sigma, catalog no. E5389) was used as a 1,000x stock 
solution of 5 mg/ml in ethanol. Ethionamide was purchased from Sigma (catalog no. E6005) 
and prepared as 200x stock solution in DMSO. 
FACS Analysis. E. coli BL21(DE3) (Invitrogen), transformed with pWW488 and pWW856 
or pWW856alone, were grown overnight in Luria Bertani (LB) media containing 100 µg/ml 
ampicillin and 30 µg/ml kanamycin (for pWW856- transformed cells only). Then, 150 µl of 
E. coli suspension (OD600 1.3) was added to 2 ml of fresh LB media containing antibiotics and 
1 mM isopropyl β-D-thiogalactoside (IPTG) where indicated. After growth for 5.5 h at 37°C, 
500 µl of the suspension was transferred to a new tube and centrifuged for 3 min at 800 x g. 
The pellet was washed twice with 1 ml of PBS and resuspended in 2 ml of PBS for FACS 
analysis (>10,000 cells per sample), which was performed on a Cytomics FC500 (Beckman 
Coulter) with 405 nm used for excitation and 510 nm for emission. FACS gates are shown in 
Fig. S2 
ELISA. The EthR-his6-specific ELISA was performed as previously described for the E-his6-
based ELISA (28) with the exception that the biotinylated operator sequence (OethR) was 
immobilized on streptavidin agarose beads (Novagen, catalog no. 69203) instead of a 
microtiter plate. 
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In Vivo Methods. EthRHEK-SEAP was encapsulated in alginate-poly(L-lysine)- alginate 
capsules (200 cells per capsule) as described in ref. 27. Female OF1 (Oncins France souche 1, 
Charles River Laboratories) mice were injected i.p. with 700 µl of capsule suspension 
containing 2 x 106 cells. One and 25 h post-capsule implantation, the mice were injected with 
2-phenylethyl-butyrate at the indicated concentration [the injection volume was adjusted to 
100 µl by adding canola oil (Migros)]. Forty-eight hours post-capsule implantation, serum 
samples were analyzed for SEAP expression. Dissection of the animals revealed no 
inflammation at the injection site. Animal experiments were conducted by M.D.-E. at the 
Institut Universitaire de Technologie A (Lyon, France) in accordance with European 
Community legislation (86/609/ EEC) and approved by the French Republic (no. 69266310). 
For each experimental condition mean values including the standard deviation of at least eight 
mice are indicated. 
Mycobacteria Cultivation and Susceptibility Testing. M. tuberculosis H37Rv 
(ATCC27294) and M. bovis bacillus Calmette–Guérin no. 1721, a streptomycin resistant 
derivative of bacillus Calmette–Guérin Pasteur, carrying a nonrestrictive rpsL mutation 
(K42R) (31) were grown in Middlebrook 7H9 supplemented with oleic acid, albumin, 
dextrose, catalase (Difco) and Tween 80 (0.05%) until midlog phase. Tenfold serial dilutions 
(20µl) were streaked on Middlebrook 7H10-OADC agar plates containing solvent (DMSO, 
200-fold dilution), ethionamide (0.25–0.5 µg/ml) and 2-phenylethyl-butyrate (0.5 or 2 mM) 
where indicated. Plates were incubated at 37°C and growth was documented after 2 and 3 
weeks. For quantitative analysis of ethA transcripts, M. tuberculosis H37Rv were treated at 
midlog phase with DMSO (40-fold dilution) or 2-phenylethyl-butyrate (0.5 or 2 mM) for 24 h 
at 37°C, harvested by centrifugation (4,400 x g, 10min, 4°C) and total RNA was extracted by 
using the RiboPure-Bacteria Kit (Ambion, catalog no. AM1925) according to the 
manufacturer’s protocol. Total RNA was reverse transcribed (25°C, 10 min; 48°C, 30min; 
95°C, 5min) by using TaqMan reverse transcription reagents (Applied Biosystems, catalog 
no. N8080234) and ethA-specific cDNA was quantified on an Applied Biosystems 7500 real-
time PCR device by using the following ethA-specific primers: forward primer, 5’-
cgatcacgacgatgttcttagc-3’; reverse primer, 5’-tcgggccgatcatccat-3’; probe labeled with 5’FAM 
and 3’TAMRA, 5’-FAM-cgtagtcgaggtcctcgggccagt-TAMRA-3’. All samples were 
standardized by using the M. tuberculosis sigA gene [Rv2703 (32)] and the following sigA-
specific primers: forward primer, 5’-ccgatgacgacgaggagatc-3’; reverse primer, 5’-
ggcctccgactcgtcttca-3’; probe labeled with 5’FAM and 3’TAMRA dyes, 5’-FAM-
aaggacaaggcctccggtgatttcg-TAMRA-3’. 
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Addendum 
 
 
Personal contribution to chapter 5 
 
In this article, a synthetic gene network in human cells was used for screening of a rationally 
designed chemical library with compounds which are sensing the interaction of EthR and its 
operator OethR. EthR is the repressor of ethA, whose gene-product EthA converts ETH, a 
second-line drug fighting the causative agent of Tuberculosis, into its active form with 
antimicrobial activity. The network identified the licensed food additive 2-phenylethyl-
butyrate as a potent inhibitor of EthR in M. tuberculosis H37Rv and M. bovis BCG. The study 
showed that 2-phenylethyl-butyrate acts synergistically in combination with ETH in a way 
that growth of M. tuberculosis H37Rv and M. bovis BCG was inhibited in subinhibitory 
concentrations of ETH. The 2-phenylethyl-butyrate-triggered dissociation of EthR from the 
ethA promoter resulting in derepression of ethA was confirmed by quantitative RT-PCR of 
ethA transcripts. 
 
My contribution as a co-author to this manuscript was as follows: 
 
• Cultivation of M. tuberculosis H37Rv and M. bovis BCG, including design of the 
 drug susceptibility tests with the two potential EthR-inhibitors 2-phenylethy-
 butyrate and 4-phenyl-2-butanone 
• Isolation of total RNA of M. tuberculosis H37Rv 
• Reverse transpcription total RNA to generate cDNA 
• Writing of mycobateria-related part of the paper 
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1. Abstract 
The rise of Tuberculosis caused by multi-drug resistant strains of M. tuberculosis (MDR-TB) 
brings second-line drugs more and more into focus. One of these drugs is ethionamide (ETH). 
Being a prodrug itself, ETH has to be activated within the bacterium by the monooxygenase 
EthA. Expression of EthA is controlled by its natural repressor EthR and thus mycobacteria 
have an intrinsic resistance. Besides activating ETH, EthA also converts the prodrugs 
thiacetazone (TAC) and isoxyl (ISO) into their lethal form. These two antibiotics have been 
used in low-income countries as antitubercular drugs. Although all three drugs are activated 
by EthA, their molecular targets are divers. ETH inhibits the enoyl-acyl carrier protein 
reductase InhA, an enzyme involved in synthesis of mycolic acids, the essential components 
of the mycobacterial cell wall. TAC also affects mycolic acid biosynthesis but by inhibiting 
their cyclopropanation. ISO in turn affects mycolic acid synthesis by a yet not fully 
understood mechanism and additionally inhibits the stearoyl-CoA desaturase DesA3 which is 
involved in oleic- and tuberculostearic acid synthesis. We have shown previously that 2-
phenylethyl-butyrate (2-PEB), a licensed food additive, efficiently inhibits EthR-binding and 
thereby enhances the expression of EthA. Therefore, a combination of 2-PEB and ETH has a 
synergistic effect on growth inhibition of M. tuberculosis laboratory strain H37Rv. Here we 
show that combinations of 2-PEB and either ETH, ISO or TAC enhance the growth inhibitory 
effect on M. tuberculosis H37Rv, on a set of drug susceptible and even on drug resistant 
clinical M. tuberculosis isolates. 
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2. Introduction 
 
With more than 9.3 million new cases and more than 1.8 million deaths every year (24), 
tuberculosis (TB) still remains a global health problem. The recommended standard treatment 
to fight the causative agent Mycobacterium tuberculosis is a regimen of four out of five first 
line drugs isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), ethambutol (EMB) and 
streptomycin (STR) for initial two months, followed by a four months treatment with INH 
and RIF. With the rise of drug-resistant strains of M. tuberculosis, the urge for new antibiotics 
or improved traditional antitubercular drugs is increasing. Multidrug-resistant strains (MDR) 
are resistant at least to the two first-line drugs INH and RIF (18) and require prolonged 
treatment with second line drugs, such as fluoroquinolones, aminoglycosides, ETH or p-
aminosalicylic acid. However, extensively resistant strains (XDR) being additionally resistant 
to a fluorquinolone and one second-line injectable agent (amikacin, kanamycin or 
capreomycin) also occurred (10). Recently, even totally drug-resistant (TDR) strains have 
been reported (19), being resistant to all second-line antibiotics, including ethionamide 
(ETH). ETH is a pro-drug, which needs to be activated by the mycobacterial Baeyer-Villiger 
monooxygenase EthA to exert its antimicrobial activity by inhibiting the enoyl-ACP 
reductase InhA. ETH does not bind directly to InhA but forms a covalent adduct with NAD 
instead. This ETH-NAD adduct inhibits InhA efficiently (22). InhA, which is also a target of 
INH, is part of the fatty acid synthase type II system (FASII) which synthesizes mycolic 
acids, the essential components of the unique mycobacterial cell wall (21, 26). The expression 
of ethA is under control of its natural repressor EthR (3) which contributes to an increased 
intrinsic resistance and therefore ETH-based tuberculosis therapy is often unsuccessful, even 
when prescribed at high hepatotoxic doses (8). Acquired ETH-resistance is due to i) mutations 
in the ethA-gene and ii) mutations in the promoter region of the mabA-inhA operon (e.g. T-
8C, T-8A, C-15T). Therefore, cross-resistance of the potent first-line drug INH and ETH are 
common, as mutations in ethA are a frequent mechanism of ETH-resistance in INH-resistant 
katG-mutants. 
Besides ETH, thioamide drugs such as thiacetazone (TAC) and isoxyl (ISO) are also activated 
by EthA (6). TAC is an inexpensive, antitubercular, bacteriostatic drug that has widely been 
used in combination with INH in low-income countries. TAC has been replaced by EMB as it 
is often associated with dermatological side effects and Stevens-Johnson syndrome in AIDS 
patients with sometimes fatal skin reactions (9). In contrast to INH and ETH, which have a 
common target, the exact mechanism of action of TAC is not fully understood. It has been 
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shown that TAC alters the mycolic acid biosynthesis by inhibiting the cyclopropanating 
mycolic acid synthases (CMASs) (2). Interestingly, not all of the CMASs are inhibited by 
TAC. It has been found that MmaA4, a member of the CMAS family, is involved in the 
activation of the drug but is not inhibited. A new model has been proposed which claims that 
TAC has to be activated by EthA and MmaA4 to exert its fully lethal effect (1). Efforts have 
been made to synthesize chemical more effective TAC-analogues. Two of these analogues, 
SRI-224 and SRI-286, have been found to be more effective in growth inhibition of M. avium 
and M. tuberculosis than the parental drug (2, 4). ISO was used for the clinical treatment of 
TB in the 1960s. ISO monotherapy demonstrated modest efficacy in cases of pulmonary TB, 
but a combination of INH and ISO was more effective than treatment with either alone (15). 
Besides affecting the mycolic acid synthesis, ISO also targets the oleic acid synthesis (13). 
While the target in mycolic acid synthesis remains to be identified, ISO inhibits the stearoyl-
CoA desaturase DesA3 and reduces therefore the amount of oleic- and tuberculostearic acid in 
mycobacteria (14). Although ISO has other targets than ETH and TAC it is activated by EthA 
as well (7, 11). Chemical analogues of ISO have been synthesized and tested against M. 
tuberculosis or M. bovis BCG. Modifications improved the activity of ISO against M. 
tuberculosis, MIC values nearly reached those of the first-line anti-tuberculosis drugs INH 
and RIF (5, 12). 
The use of second line drugs like ETH, TAC and ISO or its derivatives often is accompanied 
by strong side effects. One of the reasons for those side effects is that the drugs have to be 
administered in high therapeutic doses to overcome the EthR-dependent EthA repression.  
However, it has been shown that chemical compounds like benzylacetate and 2-
phenylethylbutyrate (2-PEB) inhibit EthR-binding and thus enhance the expression of EthA 
(23). In turn, increased expression of EthA enhances the antibacterial effect of ETH on M. 
tuberculosis H37Rv and M. bovis BCG. Also it has been shown, that substance BDM31343 
exerts a synergistic effect with ETH in mice infected with M. tuberculosis laboratory strains 
H37Rv (25). Here we show that 2-PEB enhances the growth inhibitory effect of the three 
EthA-activated antibiotics ETH, ISO and TAC on M. tuberculosis H37Rv, on drug 
susceptible and drug resistant clinical isolates of M. tuberculosis. 
 
 
. 
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3. Materials and Methods 
 
Strains 
A total of 13 drug-susceptible, mono-resistant and multidrug-resistant clinical isolates of 
M. tuberculosis were studied. Strains 176914, 176861, 176747, 176587 and 176389 were 
sensitive to all first-line drugs. Strains 2694, 4269, 117 and 179987 were resistant to INH (0.1 
µg/ml) due to a mutation in the promoter region of the mabA-inhA operon (C-15T). Strains 
186038, 186137, 130 and 177836 were multidrug-resistant (INH, RIF) due to mutations in the 
katG gene and in the rpoB gene (S531L) (16, 17). As a control, the laboratory strain M. 
tuberculosis H37Rv (ATCC27294) was used. 
 
Antimicrobial agents 
ETH, TAC and 2-PEB were purchased from Sigma-Aldrich, ISO from Cayman-Chemical. 
 
 
Molecular detection of resistance mutations 
For the detection of mutational alterations associated with resistance to ETH, ISO and TAC, 
PCR-driven gene amplification and nucleic acid sequence determination of the ethA/ethR 
gene-region was applied. Primers 5’-GATGCAGAGGCGGTGTTC-3’ and 5’-
GTGTTCGGCGTCCACCCA-3’ were used to amplify a 3.2 kbp fragment comprised of ethA 
(Rv3845c) and its upstream and downstream sequences. Amplified gene fragments were 
sequenced using the BigDye Terminator cycle-sequencing ready reaction kit (Applied 
Biosystems Inc.) and an ABI 3130 DNA genetic analyzer (Applied Biosystems Inc.). 
 
 
Susceptibility testing using the MGIT 960 system with EpiCenter TB eXiST software 
For drug susceptibility testing, the MGIT 960 system (Becton Dickinson) was used according 
to the manufacturers' manual. Briefly, 0.8 ml of MGIT 960 SIRE supplement (Becton 
Dickison) and 0.2 ml of the drug solution were added to the MGIT tubes. The tubes were 
inoculated with 0.5 ml of test strain suspension. As a control, a drug-free MGIT tube was 
inoculated with 0.5 ml of a 1:100 diluted (sterile H2O) suspension of the test strain. Growth of 
the bacteria was monitored by the EpiCenter software (version 5.6.6), equipped with the TB 
eXiST module (Becton Dickinson) and was expressed as growth units (GU). A strain was 
considered to be resistant (R) to a drug when the test tube reached ≥100 GU earlier than the 
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drug-free control tube reached a GU-value of 400. Sensitivity (S) of a strain was defined 
when the control tube reached 400 GU and the test tube remained ≤100 GU for more than 7 
days after the control tube has reached 400 GU. A strain was considered to be intermediate (I) 
when the test tube reached ≥100 GU within 7 days after the control tube reached 400 GU. 
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4. Results 
Effect of 2-PEB in combination with ETH on growth of drug-susceptible M. tuberculosis. 
In an initial phase, all strains have been challenged with 5 different concentrations of ETH, 
ranging from 12.5 µg/ml to 0.16 µg/ml in combination with 0.75 mM 2-PEB and without the 
addition of 2-PEB as a control. Table 1 indicates that all (6/6) drug-susceptible clinical 
isolates and M. tuberculosis H37Rv show a synergistic effect of ETH and 2-PEB. These 
strains change their resistance profile by shifting from resistance (R) to intermediate (I) or I to 
sensitive (S). The lowest concentration of ETH on which 2-PEB showed a synergistic effect 
was 0.625 µg/ml, below this concentration no additional benefit could be detected. Also, 2-
PEB alone does not induce a growth inhibition effect as the resistance profile shows no 
shifting with the compound alone (data not shown). 
In a second phase, 8 strains being resistant to at least one of the first-line drugs have been 
tested. The strains have been challenged with 5 concentrations of ETH, ranging from 
12.5 µg/ml to 1.25 µg/ml, with and without adding 0.75 mM 2-PEB. Table 1 shows that 2/8 of 
the drug-resistant strains (2694 and 117) showed a synergistic effect of ETH and 2-PEB. In 
both cases, the shift from R to either I (2694) or S (117) can be seen at an ETH-concentration 
of 5 µg/ml. At lower concentrations no synergistic effect of 2-PEB can be detected. 
Effect of 2-PEB in combination with ISO and TAC on growth of M. tuberculosis. As ISO 
and TAC share the same activator as ETH (6), possible synergistic effects of 2-PEB have 
been examined in combination with these two antibiotics. A subset of the above tested strains 
(176914, 176747, 2694, 4269 and 117) has been chosen for challenging in the MGIT-system 
with the following concentrations: ISO: 2.7, 0.9, 0.3 and 0.1 µg/ml and TAC: 0.66, 0.22, 0.08 
and 0.03 µg/ml. All concentrations have been tested with and without the addition of 0.75 
mM 2-PEB. Four out of 5 strains (176914, 2694, 4269 and 117) showed an increased 
susceptibility to ISO when adding 2-PEB (Table 1). Remarkably, three of these strains are 
resistant to the major first-line drug INH. Strain 2694 showed a synergism in combination 
with 2-PEB at a concentration of 0.3 µg/ml ISO, while strains 4269 and 117 showed a 
synergism at 0.9 µg/ml instead. A synergistic effect of 2-PEB with TAC was observed in 4/5 
strains (176914, 176747, 2694 and 117) while strain 4269 is resistant to TAC, even at the 
highest concentration of 0.66 µg/ml, also tested in combination with 2-PEB (Table 1). 
Molecular detection of mutations in the ethR/ethA region. In order to elucidate the 
molecular mechanism of resistance to ETH particularly in those strains without an inhA-
promoter mutation, we amplified and sequenced the ethR/ethA gene-region of all above tested 
strains. All INH-sensitive strains showed a wild-type ethR/ethA sequence (Table 1). Of the 
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INH low-level resistant strains, i.e. those with an inhA-promoter mutation C-15T only one 
strain (4269) exhibited an altered ethR/ethA sequence, due to two nucleotide exchanges. One 
of the mutations is silent (TCG1326TCT, S442S), the second leads to an Asn to Lys 
conversion at position 345. The strains which are high-level resistant to INH because of the 
mutation S315T1 in the according activator KatG also all carry mutations in ethA. Only one 
mutation in strain 130 turned out to be silent (CCA771CCG, P257P), while the other 
mutations affect the EthA protein. Strains 186137 and 186036 do not express fully mature 
EthA, either because of a frameshift mutation at position 7 or a conversion of Trp to Stop in 
case of 186038. Strain 177836 has a point mutation which leads to conversion of a Ser into an 
Arg at position 256. 
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5. Discussion 
The global rise of MDR and XDR strains indicates the increasing need for new treatment 
regimens of patients with TB. The three antitubercular drugs ETH, ISO and TAC are 
considered as a last line of defense to fight TB. These antibiotics are pro-drugs and have to be 
activated within the bacterial cell. ETH, ISO and TAC share the same activator EthA (6). The 
expression of EthA is under control of its natural repressor EthR (3). Previous studies showed 
that several compounds prevent EthR from binding to the ethA promoter, e.g. 2-PEB (23) or 
BDM31381 (25). Additives like 2-PEB therefore have the potential to reduce the therapeutic 
dose of those antibiotics and thereby would be able to decrease the severe side effects. 
Here we demonstrate that the sensitivity of thioamide drugs like ethionamide, isoxyl and 
thiacetazone is increased by 2-PEB, also when applying to drug resistant strains of M. 
tuberculosis. Upon co-administration of 2-PEB together with ETH, all (6/6) drug-sensitive 
strains and 2/4 INH-resistant strains with a C-15T mutation showed a synergism. All MDR-
strains (130, 186137, 186038 and 177836) with mutations in katG did not show a synergism 
when administering ETH and 2-PEB. As a matter of fact, all MDR-strains carry mutations in 
ethA additionally to the katG mutations. The most severe mutations were found in strain 
186137, which has a frameshift mutation at position 7, and in strain 186038, which encodes a 
stop instead of a tryptophan at position 256. Hence, mutations in ethA are a frequent 
mechanism of ETH resistance in high-level INH-resistant strains with katG mutants. Upon 
co-administration of 2-PEB and ISO, one of two drug-sensitive strains and three out of three 
drug-resistant strains had an enhanced sensitivity towards ISO. The growth inhibitory effect 
of TAC was enhanced in two out of two drug-sensitive strains when applying 2-PEB, while 
the same effect was seen in two out of three drug-resistant strains. However, not all strains 
tested showed the same resistance profile and the same behavior concerning the synergism 
with 2-PEB. Even though we analyzed the gene sequence of the ethR/ethA-region, not every 
resistance phenotype could be explained. Remarkably, no mutation has been found in the 
region of ethR, which could lead to a higher binding capacity of EthR and therefore lower the 
transcription of the ethA-gene. We found that strain 130, which neither carries a mutation in 
the inhA promoter region nor in the ethA-gene but anyhow is resistant to ETH.  This may be 
explained by recent findings, that not only EthA is responsible for the activation of ETH. 
Vilchèze et al. (20) showed that the activation of ETH is depending as well on a functional 
mshA-gene, which is involved in the production of mycothiol and therefore plays a role in the 
pro-drug activation by ethA. 
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One strain (176747) showed a synergistic effect of either ETH or TAC together with 2-PEB 
but not when administering ISO. Probably, the affinity of EthA for ISO is much higher than 
its affinity for ETH. The basal level of EthA produced in the bacterium in some cases might 
be sufficient to activate ISO very efficiently but not sufficient for ETH. This might support 
earlier observations of Dover et al. (7). The study shows that the overproduction of EthA in an 
ethR knock-out strain of M. bovis BCG does not result in significantly higher yields of 
activated drug in comparison to the parental strain. The low -hypersensitivity effect of ISO 
may be linked to the instrinsic structure of ISO, which is very efficiently metabolized by 
endogenous EthA.  Boosting TAC with 2-PEB worked well with the exception of strain 4269 
which was completely resistant to all applied concentrations. As this strain is resistant to ETH 
even at the highest concentration and it carries a mutation in the ethA-gene (N245K) the 
resistance phenotype can be explained. Nevertheless, isolation of spontaneous mutants in 
Mycobacterium bovis BCG that are highly resistant to TAC but carry a functional EthA has 
been reported recently (1). These TAC-resistant strains had mutations in mmaA4, a gene 
encoding for a methyltransferase, which is required for synthesis of keto- and methoxy-
mycolic acids. Therefore these mutants lacked keto-mycolic acids, which are long-chain fatty 
acids associated with the cell wall. The drug-sensitive phenotype could be restored by 
complementation with a functional mmaA4 gene. As these mutants had an increased 
susceptibility to TAC upon overexpression of MmaA4, it has been hypothesized that a 
functional MmaA4 is necessary for activation of the pro-drug, rather than being a target for 
TAC. An altered MmaA4 may explain the resistance of strain 4269 to TAC while being still 
sensitive to ISO. 
The notion that chemical analogues of both drugs, ISO and TAC, are available and showed to 
be more efficient than the parental drugs is very intriguing. It might be interesting to test 
whether they are boosted by 2-PEB as well and therefore may be developed as valuable 
alternatives for existing second-line drugs but with lower side-effects. Willand et al. (25) 
showed lately that substance BDM31381 is able to inhibit EthR and hence boost the 
antibacterial activity ETH on a laboratory strain of M. tuberculosis in vitro and in mouse 
infection experiments. They also showed that the growth inhibition effect of TAC can be 
enhanced by BDM31381 but the enhancement of ISO failed. A possibility to improve the 
efficacy of the already licensed food additive 2-PEB (Joint Food and Agriculture 
Organization (FAO)/WHO Expert Committee on Food Additives, JEFCA no. 991), is the 
application of further rational drug design by synthetic mammalian gene circuits (23). 
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In conclusion, our data show that it is possible to enhance the growth inhibitory effect of the 
three thioamide drugs ethionamide, isoxyl and thiacetazone by adding 2-PEB. Most 
interestingly, this synergistic effect has been demonstrated against M. tuberculosis H37Rv, 
several drug-sensitive clinical isolates and, most important, also to drug-resistant strains of 
M. tuberculosis. Our findings might contribute to a re-consideration of ETH, ISO and TAC as 
low-cost second-line drugs, which are getting more important because of emerging MDR- and 
XDR strains of M. tuberculosis. Additionally, the ability of 2-PEB to lower the applied 
concentrations of the antibiotics might reduce the side effects of these drugs and thus improve 
patients well-being. However, the ethA locus should be characterized, particularly in high 
level INH resistant strains. 
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Strain Conc.[µg/ml] w/o PEB PEB Synergism
Conc.
[µg/ml] w/o PEB PEB Synergism
Conc.
[µg/ml] w/o PEB PEB Synergism katG inhA ethA
H37Rv 12.5 S S No wt wt wt
5 S S No
2.5 S S No
1.25 I S Yes
0.625 R I Yes
0.31 R R No
0.16 R R No
176914 12.5 I S Yes wt wt wt
5 I S Yes
2.5 R I Yes
1.25 R I Yes 2.7 S S No 0.66 S S No
0.625 R I Yes 0.9 S S No 0.22 S S No
0.31 R R No 0.3 I I No 0.08 I S Yes
0.16 R R No 0.1 R I Yes 0.03 R I Yes
176861 12.5 I I No wt wt wt
5 I I No
2.5 I I No n.d. n.d.
1.25 R I Yes n.d. n.d.
0.625 R I Yes n.d. n.d.
0.31 R R No n.d. n.d.
0.16 R R No n.d. n.d.
176747 12.5 S S No wt wt wt
5 I S Yes
2.5 R I Yes
1.25 R I Yes 2.7 S S No 0.66 R I Yes
0.625 R R No 0.9 I I No 0.22 R R No
0.31 R R No 0.3 R R No 0.08 R R No
0.16 R R No 0.1 R R No 0.03 R R No
176587 12.5 I S Yes wt wt wt
5 I I No
2.5 I I No n.d. n.d.
1.25 I I No n.d. n.d.
0.625 R I Yes n.d. n.d.
0.31 R R No n.d. n.d.
0.16 R R No n.d. n.d.
176389 12.5 I S Yes wt wt wt
5 I I No
2.5 I I No n.d. n.d.
1.25 I I No n.d. n.d.
0.625 R I Yes n.d. n.d.
0.31 R R No n.d. n.d.
0.16 R R No n.d. n.d.
ETH ISO TAC Genetic resistance
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2694 12.5 S S No 2.7 S S No 0.66 I S Yes wt C-15T wt
5 R S Yes 0.9 S S No 0.22 I S Yes
2.5 R R No 0.3 R I Yes 0.08 R R No
1.25 R R No 0.1 R R No 0.03 R R No
4269 12.5 R R No 2.7 I I No 0.66 R R No wt C-15T N345K
5 R R No 0.9 R I Yes 0.22 R R No S442S
2.5 R R No 0.3 R R No 0.08 R R No
1.25 R R No 0.1 R R No 0.03 R R No
117 12.5 S S No 2.7 S S No 0.66 R S Yes wt C-15T wt
5 R I Yes 0.9 I S Yes 0.22 R S Yes
2.5 R R No 0.3 R R No 0.08 R R No
1.25 R R No 0.1 R R No 0.03 R R No
179987 12.5 S I No n.d. n.d. wt C-15T wt
5 R R No n.d. n.d.
2.5 R R No n.d. n.d.
1.25 R R No n.d. n.d.
130 12.5 R R No n.d. n.d. S315T1 wt P257P
5 R R No n.d. n.d.
2.5 R R No n.d. n.d.
1.25 R R No n.d. n.d.
186137 12.5 R R No n.d. n.d. S315T1 wt Fs pos. 7
5 R R No n.d. n.d.
2.5 R R No n.d. n.d.
1.25 R R No n.d. n.d.
186038 12.5 S R No n.d. n.d. S315T1 wt W156Stop
5 R R No n.d. n.d.
2.5 R R No n.d. n.d.
1.25 R R No n.d. n.d.
177836 12.5 R R No n.d. n.d. S315T1 wt S266R
5 R R No n.d. n.d.
2.5 R R No n.d. n.d.
1.25 R R No n.d. n.d.
TABLE 1. Synergistic effects of ETH, ISO and TAC with 2-PEB on growth of clinical isolates of M. tuberculosis 
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Addendum 
 
Personal contribution to chapter 6 
In this article it was shown that the licensed food additive 2-phenylethyl-butyrate (2-PEB) 
was able to enhance the efficacy of important second-line drugs such as ethionamide (ETH), 
isoxyl (ISO) and thiacetazone (TAC). These pro-drugs are converted by a common activator, 
EthA. The gene which encodes this Baeyer-Villiger monooxygenase is naturally repressed by 
EthR. By applying 2-PEB, which is able to release EthR from the ethA-promoter, the 
antibacterial effect of ETH, ISO and TAC was enhanced. This synergistic effect was achieved 
when challenging M. tuberculosis strain H37Rv, clinical isolates of M. tuberculosis fully 
susceptible to all common antibiotics and drug-resistant strains with a resistance towards 
ETH. 
 
My contribution as first author to this manuscript was as follows: 
 
• Design of the study 
• MIC-determination 
• Sequencing of the ethR/ethA gene 
• Determination of synergistic effects with the MGIT-system 
• Writing of the manuscript 
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Drug Screening NAD(P) Biosynthesis Pathway 
 
NAD-synthetase Inhibitors 1st generation 
NAD+ is an essential metabolite, and its biosynthetic pathways are of major interest for the 
development of new drugs. In contrast to humans, where an NAD+ synthetase-independent 
recycling pathway exists, M. tuberculosis NAD+ biosynthesis is absolutely dependent on the 
activity of NAD+ synthetase. Therefore 11 candidate compounds with proven inhibition of the 
NAD(P)H biosynthesis pathway in a target based (biochemical) assay (Hegymegi-Barakonyi 
et al., 2008, M. Rizzi, personal communication) have been evaluated in a whole cell assay 
with respect to growth inhibition  of M. tuberculosis laboratory strain H37Rv and a 
multidrug-resistant clinical isolate. The clinical isolate is resistant to the following antibiotics: 
Ethambutol (5 µg/ml), ethionamide (2.5 µg/ml), isoniazid (0.1, 1.0, 3.0, 10.0 µg/ml), 
rifampicin (1.0, 10.0, 50.0 µg/ml) and streptomycin (1.0, 20.0 µg/ml) due to mutations in the 
following genes: rpoB (S531L), katG (S315T1) and inhA (C15T). Possible growth inhibitory 
effects have been tested using the Becton Dickinson BBLTM MGITTM 960 system (MGIT) in 
a BSL3 laboratory. The following 11 candidate compounds have been tested in concentrations 
of 5, 50 and 500 µM: 6026, 6569, 11085, 12507, 12539, 13632, 15108, 16047, 16315, 16581, 
and 17731.  
At a concentration of 5 µM, no compound showed a growth inhibitory effect, neither in the 
drug-sensitive laboratory strain H37Rv, nor in the multidrug-resistant patient isolate 
(Table 1). Compound 15108 is the most effective inhibitor in terms of growth inhibition 
effect. It inhibited growth of both strains by >99% at a concentration of 50 µM, while none of 
the other 10 compounds did show any effect at this concentration. The following 6 
compounds showed a growth inhibitory effect at a concentration of 500 µM in all three 
experiments: 12507, 12539, 13632, 15108, 16315 and 17731. Compound 16581 showed a 
growth inhibition effect of >99% in experiments with the laboratory strain H37Rv and the 
clinical isolate. Several compounds inhibited growth completely while 4 compounds did not 
show any effect on growth of either H37Rv or the clinical isolate (Table 1). 
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Table 1: Drug susceptibility testing of potential NAD-synthetase inhibitors. # indicates concentrations of 
compounds with >99% growth inhibition (in comparison to 1:100 growth control). § First line drug for H37Rv; 
INH (low 0.1 µg/ml; high: 1.0 µg/ml). For MDR: AK (low: 1.0 µg/ml; high: 4.0 µg/ml). 
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NAD-synthetase Inhibitors 2nd generation 
As a follow-up of the 1st generation compounds, 2nd generation compounds have been 
synthesized and tested in a target based (biochemical) assay (M. Rizzi, personal 
communication). Six of these compounds (12601, 12974, 13256, 13268 and 16103) have been 
tested with respect to growth inhibitory effect using the BBLTM MGITTM 960 system. As 
these compounds did not show any growth inhibitory effect at a concentration of 100 µM 
(data not shown), they have been tested at a concentration of 500 µM (Table 2) 
 
 
Table 2: Results drug screening NAD(P) biosynthesis pathway, second generation compounds (500 µM) 
 
At a concentration of 500 µM, 3  out of 5 compounds (12974, 13256, 16103) showed a 
complete growth inhibition, 1 compound (13268), reduced growth by >99%. One compound 
(12601) did not reduce growth at all. 
 
 
 
NAD-synthetase MIC determination of compound 15108 
The most effective NAD-synthetase inhibitor 15108 of the first generation compounds has 
been tested in 6 different concentrations, reaching from 5 up to 80 µM in the BBLTM MGITTM 
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960 system. Compound 15108 reduced growth by >99% starting at a concentration between 
40 µM and 60 µM (Table 3). 
 
 
Table 3: MIC-determination of NAD-synthetase inhibitor 15108 
 
 
Synergistic effects of compound 15108 with different classes of antibiotics 
According to a recent publication (Kohanski et al., 2007), bactericidal but not bacteriostatic 
antibiotics induce hydroxyl radical formation, which causes serious damage in Gram-positive 
as well as in Gram-negative bacteria, leading to cell death. The augmented hydroxyl radical 
formation is based on a rapid depletion of NADH upon administration of bactericidal drugs. 
As the effect of 15108 as an NAD-synthetase inhibitor leads to a lower level of NADH, the 
synergistic effect of 15108 together with different antibiotics has been tested. The following 
antibiotics as representatives of their classes have been tested in the BBLTM MGITTM 960 
system: Ofloxacin (quinolone, bactericidal, 0.25 µg/ml), amikacin (aminoglycoside, 
bactericidal, 0.25 µg/ml), rifampicin (bacteriostatic 0.25 µg/ml) and isoniazid (bacteriostatic 
0.025 µg/ml). All antibiotics have been applied in sub-inhibitory concentrations. The NAD-
synthetase inhibitor 15108 was tested in two different concentrations, 3.0 and 15.0 µM, both 
below the MIC of 60 µM evaluated in section 4.4.3. As controls, 15108 has been tested at 
concentrations of 3.0 and 15.0 µM without adding an antibiotic and all antibiotics have been 
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tested without the addition of 15108 at the above mentioned concentrations. Table 4.4 shows 
the results of the synergism-testing. 
 
15108 [µM] without
antibiotics
Ofloxacin
(0.25 µg/ml)
Amikacin
(0.25 µg/ml)
Rifampicin
(0.25 µg/ml)
Isoniazid
(0.025 µg/ml)
0.0 R R R R R
3.0 R R R R R
15.0 R R R R R
60.0 S n.d. n.d. n.d. n.d.
Synergistic effect of NAD-synthetase inhibitor 15108 and
several different antibiotics on growth of M. tuberculosis  H37Rv
 
Table 4: Synergistic effects of NAD-synthetase inhibitor 15108 and several antibiotics on growth of 
M. tuberculosis H37Rv 
 
The first-line antibiotics RIF and INH did not show a synergistic effect when applied in 
combination with 15108. Likewise, the second-line drugs OFL and AMK did not exert a 
synergistic effect on growth of M. tuberculosis H37Rv in combination with 15108 as well, 
indicated with R in table 4. 
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